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Designing a vaccine that can elicit a strong cytotoxic T-lymphocytes (CTL) 
response will be an important component of vaccines against many viruses, but in 
particular against HIV.  CTL stimulation occurs through the recognition of epitopes 
presented in the context of the class-I major histocompatibility complex (MHC-I).  As a 
way to achieve this, the physical coupling of a viral epitope to the N-terminus of β2-
microglobulin (β2m) via a flexible linker has been explored.  With the stimulation of 
CTLs against the Sendai virus as a model, both the effect of linker size on the vaccine 
and the ability of the β2m-viral epitope fusion vaccine to trigger a primary immune 
response, as either a recombinant protein expressed in E. coli or as part of a mammalian 
expression vector are presented in this work.  Here we show that as a DNA vaccine, β2m-
linked to the immunodominant Sendai NP(324-332) epitope, administered intramuscularly 
(IM) with or without a plasmid encoding for the cytokine IL-12, can cause the 
 vii
proliferation of viral specific splenocytes.  However, when the vaccine was administered 
IM or subcutaneously as recombinant protein, no response was observed.  We also show 
that a construct with a 21 amino acid (AA) linker stimulates more viral specific 
splenocytes than constructs with either a 10 AA or a 15 AA linker.  Further, DNA 
vaccine dosages of 100 µg and 200 µg generate more viral specific splenocytes than 
dosages of 400 µg or 800 µg.  We suggest that the reason for this might be high-localized 
concentrations of β2m.  Finally, we show that in response to a sub-lethal challenge with 
the Sendai virus, mice primed with both the β2m-Sendai epitope DNA vaccine and the 
IL-12 plasmid can trigger the early arrival of viral specific CD8+ memory cells in the 
lungs.   
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Introduction to HIV 
In 1981 M. S. Gottlieb et al., published in the New England Journal of Medicine 
the discovery of an immunodeficiency in highly sexually active gay men (Gottlieb, 
Schroff et al. 1981). This immune disorder would eventually be classified as the acquired 
immune deficiency syndrome, more commonly called AIDS.  At the time the immune 
disorder was only seen in gay men and therefore it picked up a stigma as being a 
homosexual male disease.  In 1983, the cause of AIDS was identified as the newly 
discovered lymphadenopathy-associated virus (LAV), which was later renamed the 
human immunodeficiency virus (HIV).  Robert Gallo at the US National Institute of 
Health and Luc Montagnier at the Pasteur Institute along with their respective lab 
colleagues share this scientific feat (Prusiner 2002).  In western Africa in 1986 a virus 
similar to HIV was isolated that was less pathogenic and immunologically distinct from 
HIV (Clavel, Guetard et al. 1986).  The new virus was termed HIV-2 and the original 
HIV virus was given the new notation of HIV-1.  
 
CURRENT STATE OF HIV IN THE WORLD 
It has been shown that HIV can be found in blood, semen, vaginal fluids and 
breast milk, and can be transferred through contact with these fluids.  HIV infection is 
indiscriminant of race, gender, or sexual orientation and generally AIDS is no longer seen 
as just a homosexual disease.  According to the World Health Organization (WHO), since 
the discovery that HIV caused AIDS, more than 60 million people have been identified as 
being infected with the virus and the most common mode of transmission is heterosexual 
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exposure (Table 1.1) (WHO 2001).  AIDS has become the fourth biggest killer in the 
world and the number one reason for death in sub-Saharan Africa.  Here in the United 
States, AIDS has become the second leading killer of people between the ages of 25-44 
years old.  Worldwide over 20 million people have died of AIDS related diseases and 
with no vaccine or cure currently available the number of deaths is only expected to 
increase because of the other 40 million people currently living with the virus (WHO 
2001).  Furthermore, based on 2001 numbers this pandemic increased at a rate of 5 
million people newly infected each year, which equates to approximately 14,000 HIV 























 6.1 million 
35% 
 Hetero, IDU 
Eastern Europe & 
Central Asia Early '90s 1 million 
20% 
 IDU 
North America Late '70s Early '80s 940,000 20% 
MSM, IDU, 
Hetero 
Total  40 million 48%  
Table 1.1 Total number of people living with HIV in 2001.   
The main mode of transmission whether it is via heterosexual contact (Hetero), 










Figure 1.1 Estimated number o
2001) 
 
Total: 5 millionf people newly infected with HIV during 2001. (WHO 
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The majority of those infected with HIV lived in developing areas such as sub-
Saharan Africa and South-East Asia.  The average life expectancy in sub-Saharan Africa 
has plunged by 15 years, from 62 years if AIDS was not a factor to 47 years with AIDS 
as a factor (WHO 2001). In addition to the loss of lives associated with HIV, the gross 
national product (GNP) for countries in this region has dropped by 0.5-1.2% and it is 
believed that by 2020 the GNP of the hardest hit countries (Botswana, Malawi, 
Mozambique, and Swaziland) may drop by more than 20% (WHO 2001).  The influence 
of HIV on the GNP results from both the death of young adult wage earners and the 
financial strain of treating adults who have become infected and are eventually unable to 
work.  HIV deaths have also played a toll in the education of young children.  In 1999 it 
was estimated that 860,000 children lost teachers due to an AIDS related death (WHO 
2001).  In addition, the education of young women is expected to decrease further as 
more females are asked to provide care for HIV infected relatives.   
To this point HIV infection in the world’s most populated area of East Asia 
remains only at a very low prevalence rate.  However, since HIV was not introduced to 
this area until the late 1980’s and the area has yet to adopt an aggressive prevention 
program, countries like China and India sit primed for a major HIV pandemic.  
According to an update on the HIV epidemic in China published by WHO in June 2002, 
China lacks sufficient political commitment, has few effective policies, insufficient 
financial resources, and is deficient of healthcare personnel that possess the necessary 
medical training and education to prevent a major outbreak of HIV.   Furthermore, HIV 
awareness in the general public remains low and a commitment to prevent transmission 
via sexual encounters or intravenous drug use appears small.  China’s Ministry of Health 
estimates that the number of HIV infections will exceeded 10 million by 2010 (China 
2002). 
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How the HIV pandemic got started is not well known.  The first reported case of 
HIV was found in a plasma sample of a Bantu man from Leopoldville, Belgian Congo 
(current day Kinshasa, Democratic Republic of Congo) who died in 1959 (Nahmias, 
Weiss et al. 1986).  It is believed that he contracted the disease at some point in the late 
1940’s. Analysis of the amplified viral sequences places this sample of HIV near the 
ancestral node for HIV-1 subtypes B, D, and F (Zhu, Korber et al. 1998).  This suggests 
that the beginning of the HIV pandemic may have evolved from the introduction of a 




As mentioned earlier, sexual contact, or more specifically heterosexual contact, 
has become the leading mode of transmission of HIV.  When HIV enters at a mucosal 
site, such as the vagina or anal tract, the virus is believed to first infect or associate with 
Langerhans’ cells (Lc).  Lc cells are derived from macrophages and are located 
intertwined with the epithelial cells at the mucosal barriers.  Lc cells express low levels of 
CD4+ and the HIV co-receptor CCR5 (Dittmar, Simmons et al. 1997) and therefore can 
be infected by HIV.  Lc cells also express a surface molecule known as DC-SIGN, which 
has a high affinity for the HIV surface protein, SU (also known as gp120) (Geijtenbeek, 
Kwon et al. 2000; Geijtenbeek, van Vliet et al. 2001).   It is believed that instead of 
infecting the Lc, HIV bound to DC-SIGN is transported across the mucosal membrane.  
Once across the membrane the virus is released from DC-SIGN and infects nearby 
CD4+/CCR5 T-cells.  The infected T-cells, or Lc cells with HIV still attached, migrate to 
lymph nodes where the virus is given a chance to take hold (Figure 1.2). After about 2-6 
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weeks a burst of virus levels in the blood can be seen.  This burst is known as the primary 
HIV infection, (PHI).  The course of an HIV infection can be divided into two distinct 
phases the PHI and the secondary HIV infection (SHI) (Figure 1.3). 
 
 
Figure 1.2 HIV Transmission via DC-SIGN on Langerhans’ cells.  




Figure 1.3 Course of an HIV Infection taken from McMichael, 2001 (McMichael and 
Rowland-Jones 2001). 
The PHI is associated with the infections of CD4+/CCR5 cells.  PHI is 
characterized by an initial spike in the viral loads peaking at about 109 copies of HIV 
RNA per milliliter of blood.  Following the initial increase of HIV RNA, there is a steady 
decrease, which coincides with an increase in HIV specific CD8+ cytotoxic 
T-lymphocytes (CTLs) (McMichael and Rowland-Jones 2001). During the first few 
weeks of infection there is a rapid decrease in the overall number of CD4+ lymphocytes, 
from 800-1200 cells/µl seen in uninfected individuals to as low as 200 cells/µl during 
PHI, but generally it is not that severe (Weber 2001).  The loss of CD4+ cells is most 
likely due to a combination of direct virus lysis and CD8+ CTL lysis of the infected CD4+ 
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cell. Patients in the PHI phase of infection may experience the development of rashes or 
the reoccurrence of previous infections but often they are asymptomatic.  
After about several months the CD4+ levels increase and levels out at a point 
below the pre-infection level.  Viral RNA levels will remain low but a gradual linear 
decrease in CD4+ cell counts will occur.  The production of HIV virus particles has been 
estimated between 107 and 108 virions per day (Ho, Neumann et al. 1995; Wei, Ghosh et 
al. 1995).  While the average life expectancy for an HIV infected CD4+ cell during this 
time is 24-48 hours as compared to an uninfected CD4+ cell expected lifetime of 100 
days (Ho, Neumann et al. 1995; Wei, Ghosh et al. 1995; Perelson, Neumann et al. 1996). 
The infection will remain this way for 1-10 years without treatment depending on the 
host’s genetics, characterizing the stage known as SHI.   
Once the CD4+ cell count has dropped below 200 cells/µl, the individual is 
classified as having AIDS.  A switch in the HIV co-receptor from CCR5 to CXCR4 
characterizes this last stage of HIV infection.  The occurrence of this switch can be traced 
to the V3 loop of the SU (gp120) protein, where a 2 amino acid substitution directs the 
change.  The CCR5 co-receptor is expressed in activated T-cells but is generally not 
expressed in the resting T-cell population.  The CXCR4, on the other hand, is expressed 
on both resting and active T-cells.  (Weber 2001)  This switch gives HIV a greater pool 
of T-cells to infect and as a result one begins to see a more rapid decrease in the number 
of CD4+ cells.  The most life threatening opportunistic infections generally occur in 
greater frequency in persons with CD4+ cell counts at less than 100 cells/µl (Carr, Chuah 




Persons infected with HIV experience a gradual deterioration of immune function 
over a period of 1-10 years if left untreated (Rutherford, Lifson et al. 1990; Cao and 
Walker 2000). If treated with the highly active antiretroviral therapy called HAART the 
patient can experience a higher quality of life and a longer survival time (Carr, Chuah et 
al. 2000; Van Vaerenbergh 2001; Fumaz, Tuldra et al. 2002; Gallant 2002).  HAART was 
introduced in 1996 as a drug cocktail treatment consisting of two nucleoside analogues 
and a powerful protease inhibitor (Figure 1.4).  Examples of these cocktails are 
zidovudine-lamivudine-indinavir (ZDV-3TC-IDV), stavudine-lamivudine-indinavir 
(d4T-3TC-IDV) or stavudine-didanosine-indinavir (d4T-ddI-IDV) (Carr, Chuah et al. 
2000).  Generally these drugs need to be taken twice a day at set time points.  For 
effective reduction in viral load, as measured by viral RNA in the blood, recipients must 
have an overall adherence to the regime of greater than 95%, which corresponds to only 
missing one dose every 3 weeks (Paterson, Swindells et al. 2000; DeMasi, Graham et al. 
2001). Along with stringent adherence requirements most HAART patients experience 
some adverse side-effects and as many as 70% experience potentially serious side effects 
(Harrington and Carpenter 2000). 
Economic arguments based on the cost effectiveness analysis of prevention verse 
treatment with HAART in developing countries with limited resources inevitably point 
towards efforts centered around prevention (Creese, Floyd et al. 2002; Marseille, 
Hofmann et al. 2002).  Even though the cost of HAART per year per patient in 
developing countries is $350 compared to the US where the cost is $10,000 (Perez-Casas, 
Herranz et al. 2001; Boelaert, Van Damme et al. 2002), on a strictly economical 
argument money spent on the education of the population about the cause of AIDS and 
how to protect themselves from HIV infection still shows to be more effective.  In the  
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Nucleoside Analogues Designed to Inhibit the HIV Reverse Transcriptase 
 
  
Zidovudine or AZT Lamivudine 
 
  
       Stavudine    Didanosine 
 
HIV Protease Inhibitor 
 
Indinavir 
Figure 1.4 Chemical structure of drugs used in highly active antiviral therapy 
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2003 State of the Union Address, President G.W. Bush made history with the 
unprecedented announcement that the US would contribute 15 billion dollars over the 
next five years towards HIV efforts in Africa.  If the sum of the money was ear marked 
for antiviral drugs, a very conservative estimate, performed by the author, based on the 
number of people living with HIV (28.1 million) (WHO 2001) multiplied by the cost of 
HAART for patients in developing countries ($350) gives a total cost of HAART 
treatment per year of 10 billion dollars per year.  At 10 billion/year the US donation 
would be depleted in 1.5 years of HAART. The U.N. has made it known that the 
availability of HAART should increase in developing African countries because not all 
policy decisions are based solely on cost effective analysis (Boelaert, Van Damme et al. 
2002). However, the cost of HAART certainly points strongly towards the need for an 
inexpensive vaccine.  
 
HIV VACCINES 
Vaccines in the past have functioned by reducing the viral load, during the acute 
phase of the infections, to a level at which the immune system is able to keep the 
infection clinically silent.  It is unknown whether this strategy will work for an HIV 
vaccine because the virus infects the T-lymphocytes responsible for keeping the virus in 
check.  This author has an optimistic point of view that believes sterilizing immunity, 
where the virus is completely eradicated from the host, will not be a necessity. 
“The possibility for natural immunity to efficiently control virus infection makes 
it possible to believe that, if the mechanisms of survival are known, we will be able to 
generate a successful HIV vaccine” (Bojak, Deml et al. 2002).  There is comfort in the 
knowledge that there are individuals who have been highly-exposed but persistently 
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seronegative (HEPS) (Devito, Hinkula et al. 2000; Dorrell, Hessell et al. 2000; Kaul, 
Rowland-Jones et al. 2001; Rowland-Jones, Pinheiro et al. 2001; Makedonas, Bruneau et 
al. 2002) and there are also infected individuals who have been classified as long term 
non-progressors (LTNPs) (Clerici and Shearer 1996; Candotti, Costagliola et al. 1999; 
Paroli, Propato et al. 2001).  LTNPs are persons who maintain a stable CD4+ cell count 
around 500 cells/µl and a viral load consistently below 500 HIV RNA copies/ml for 10 
years or more.  These people have demonstrated that the human immune system is able to 
keep the virus in check over a long period of time.   
During the search for an effective vaccine we have learned many important 
contributors for successful control.  A successful HIV vaccine must meet the 
requirements of any vaccine in that it must be safe, easily administered, generate a 
memory response and have long-lasting effects.  The vaccine should be easily 
manufactured, stable for delivery, and economically feasible to produce in mass 
quantities.  More specific requirements for an HIV vaccine are that it generates broadly 
cross-clade reactivity through both a robust neutralizing antibody response and a 
vigorous CTL response at both systemic and mucosal points of entry (McMichael, Mwau 
et al. 2002).  The systemic immune response is needed to protect individuals from 
infection via blood transfusions or the sharing of needles by intravenous drug users.  
Although infection via blood transfusion has virtually been eliminated in this country it 
still remains a problem elsewhere in the world (Rosenthal 2002).  The mucosal immune 
response is needed to protect individuals from sexually transmitted infection.  
Early HIV vaccine designs attempted to trigger a neutralizing antibody response 
against HIV envelope proteins gp120 and its precursor gp160 (Arthur, Bess et al. 1989; 
Belshe, Graham et al. 1994; el-Amad, Murthy et al. 1995; Girard, Yue et al. 1996; Xie, 
Pestano et al. 1996).  These vaccines showed promise because they provide protection 
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against laboratory strains of HIV, however they had trouble providing protection against 
primary HIV infection, (reviewed in (Moore 1995)).  The reason for the failure of these 
vaccines was elucidated by Sullivan et al, 1995, when they showed that the antibodies 
generated against the monomeric form of the HIV envelope proteins could not recognize 
the trimeric form presented on the surface of HIV virion (Sullivan, Sun et al. 1995).   
Recent evidence has pointed to the need to generate a cytotoxic T-lymphocyte 
response to control HIV and thus more current HIV vaccine designs have attempted to 
trigger this side of the immune response (reviewed in ((Letvin 1998)).  CTLs are the 
cytotoxic arm of the cellular immune response.  They can exert substantial pressure on 
HIV replication during both the primary and chronic stages of infections, which results in 
the development of viral escape mutants generated by the error prone HIV reverse 
transcriptase.  It is postulated however, that if the CTL response is great enough, infected 
cells can be killed before they allow the virus to mutate (McMichael and Rowland-Jones 
2001).  This hypothesis is supported by the consistent presence of a cellular immune 
response specific to HIV in highly exposed persistently seronegative (HEPS) cohorts 
(Miyahira, Murata et al. 1995; Rowland-Jones, Dong et al. 1999; Kaul, Rowland-Jones et 
al. 2001; Rowland-Jones, Pinheiro et al. 2001; Li, Promadej et al. 2002).  Also, HIV 
specific CTL responses have been detected in uninfected exposed health care workers 
and uninfected babies born to infected mothers (Pollack, Zhan et al. 1997; Buseyne, 
Burgard et al. 1998; Buseyne, Chaix et al. 1998; Riviere and Buseyne 1998; Wasik, 
Wierzbicki et al. 2000). 
No HIV vaccine has successfully complete phase III studies.  However there is 
one candidate that has finished phase III trials and two others who will start phase III 
trials later this year.  VaxGen, a small pharmaceutical company based in Brisbane, CA, 
leaded the way with its recombinant HIV gp120 envelope protein, which completed 
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phase III trials in both the United States and Thailand, in February 2003.  Unfortunately 
the vaccine failed to offer general protection to the population (McCarthy 2003).  It has 
been shown that the rgp120 vaccine can stimulate an antibody response that reaches a 
maximal serum titer after three or four doses (Graham, Matthews et al. 1993).  The 
rgp120 vaccine was unable to generate an infective class I major histocompatibility 
complex (MHC-I) CTL response, which will be required in order to provide protection 
against the virus.  Therefore, it is believed that this vaccine will be most effective when 
combined with another approach that can induce the CTL response.  With that in mine 
VaxGen combined with the US military, the Royal Thai government, Mahidol and 
Aventis has put forth another vaccine candidate that incorporates a Canarypox vector, 
which delivers the gag, protease, and env and is administered in conjunction with the 
rgp120 protein.  This vaccine is able to generate the required broad CTL response along 
with antibodies against the glycoproteins and should start phase III trials in Thailand later 
this year.   The third vaccine candidate, sponsored by a large contingent that includes the 
NIH, Aventis, Pasteur, and VaxGen, also utilizes Canarypox as the vector.  This vaccine, 
in addition to the gag, protease, env, also codes for the pol and nef proteins, and like the 
other vaccine is administered in combinations with the rgp120 protein.  This vaccine will 
also start phase III trials this year. 
 
ANIMAL MODELS 
Unfortunately, from a treatment standpoint, HIV-1 is a virus specific for humans 
and chimpanzees.  Therefore, few options exist for experimental models that can help 
answer questions concerning the differences observed in the progression to AIDS in 
HIV-1 infected people.  When chimpanzees are infected with HIV-1 isolated from 
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patients who have developed AIDS, the chimpanzee experiences an infection similar to 
the primary infection in humans (Arthur, Bess et al. 1989). However after several weeks 
the chimpanzee is generally asymptomatic, virus cannot be isolated from the blood, and 
the animal fails to progress to the clinical state of AIDS (Novembre, Saucier et al. 1997).  
The endangered species status of chimpanzees coupled with their failure to develop AIDS 
makes the chimpanzees a flawed choice for an animal model.  
Once it became apparent that the chimpanzee model would not suffice, two 
options were explored: genetically created animals susceptible to HIV or the use of other 
animal viruses that are similar to HIV.  Both pathways have been pursued.  In the case of 
altered animals, scientists have created many mice models using transgenic mice and 
severe combined immunodeficient (SCID) mice. Transgenic mice are mice that have 
been altered so their genome contains one or all of the HIV genes.  These types of mice 
have been used to examine select aspects of HIV infections.   However the common 
problem with this model is an inability to mimic the entire HIV life cycle, especially the 
process involved during viral entry, reverse transcription, and integration  (Freed and 
Martin 2001).  Furthermore, transgenic mice show either very little or no productive 
infection.  SCID mice are mice that are depleted of their own immune response and 
engrafted with human immune response components.  These mice have also been useful 
for examining isolated aspects of HIV infection. Yet, like transgenic mice, this model is 
limited by an inability to present the entire HIV life cycle.  They falter in modeling the 
types of tissues affected and in displaying the response generated by an intact immune 
system (Bieniasz and Cullen 2000). 
Some recent work conducted in rats appears promising.  It has been shown that 
rats engineered to express human CD4 and human CCR5 allow for cellular entry, 
replication and the production of infectious HIV virion (Keppler, Yonemoto et al. 2001). 
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Furthermore, these rats have shown the ability to develop AIDS-like complications (Reid, 
Sadowska et al. 2001). Because HIV is a human specific virus and the work in rats is 
relatively new the encouraging preliminary data should be taken with caution. 
The second method of exploring HIV is to look at the effect other lenti 
retroviruses have on their respective host.  Both the simian immunodeficiency virus 
(SIV) and the feline immunodeficiency virus (FIV) have been examined as potential 
models.   There are six known SIV viruses that have been identified based on the host 
from which the virus was isolated, they are:  SIVmac from macaques, SIVsmm from sooty 
mangabey, SIVcpz from chimpanzees, SIVmnd from mandrill, SIVagm from African green 
monkeys and SIVsyk from Syke’s monkeys (Lewis and Johnson 1995).  SIVmac in 
macaques is the only one of the six viruses that has similar characteristics to HIV 
infections.  This model exhibits an initial high viral load, followed by a strong host 
immune response and a latent period of 1-3 years where CD4 counts steadily decrease, 
and an end of life due to the animal eventually succumbing to opportunistic infections 
(Lewis and Johnson 1995; Joag 2000).  Like chimpanzees, macaques are an endangered 
species and are expensive to house, therefore only small scale studies are possible.   
Although cats are relatively inexpensive and not on any endangered species list, 
there are some inherent problems with FIV.  In the lab cats generally show the first signs 
of infection but rarely develop into an immuno-deficient state. Furthermore, it appears as 
though lymphocyte infection is independent of the CD4+ molecule.  The lack of animal 
models has been and unfortunately looks like it will continue to be a problem for HIV 




The HIV Pathogen 
This chapter is provided to give a brief explanation of the structure of the HIV 
virion and the function of each of the HIV viral proteins.  It will also provide a general 
overview of the viral life cycle.  For more details please refer to a recently published 
graduate level virology book such as Fundamental Virology, 4th edition edited by Knipe 
and Howley (Knipe and Howley 2001) or two recent reviews; one by Frankel and Young 
published in the Annual Review of Biochemistry (Frankel and Young 1998) and the other 
by Freed published in Virology (Freed 1998).  
 
SUBTYPES 
The human immunodeficiency virus (HIV) is a member of the lentivirus genus in 
the Retroviridae family.  Phylogenetic analyses of HIV-1 isolates from various parts of 
the world have identified many different clades, or subtypes, which can be divided into 
three main groups: M (major), O (outlier) and N (non-M or O) (Figure 2.1). When the 
genome sequences from the M group are compared with sequences from the O group, 
they share less than 50% identity.  Additionally the M group, which contains over 95% of 
HIV-1 sequences, includes 8 distinct clades, A, B, C, D, F, G, H and J.  Genetic 
variations between clades may differ up to 30-40%, depending on the isolated genomes 
compared (Freed and Martin 2001). Not only do different isolates from around the globe 
vary from one another, different isolates from the same individual can vary in nucleotide 
sequence by as much as 10% (Freed and Martin 2001). The enormous variety of HIV-1 




Figure 2.1 An HIV-1 Phylogenetic Tree for the HIV Pol DNA sequence.   
This tree was created on 5/1/03 from files in the HIV Sequence Database, which 
can be found at http://hiv-web.lanl.gov/content/index. 
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HIV ORGANIZATION 
HIV, like other retroviruses, has an enveloped virion with a diameter between 
100-120 µm.  A mature particle has a cone-shaped core that contains duplicate copies of 
the viral genome (Figure 2.2).  The HIV genome is a single RNA strand that is 
approximately 9 kilo-bases in size and encodes 15 proteins.  The genome encodes for 3 
groups of structural proteins, 2 regulatory proteins, and 4 accessory proteins.  The 3 
groups of structural proteins, the group-specific antigen (Gag), the polymerase (Pol), and 
envelope (Env), are synthesized as three precursor poly-proteins.  The precursor proteins 
Gag, Gag-Pro-Pol, and Env, are then post-translationally modified into the matrix protein 
(MA), the capsid protein (CA), the nucleocapsid protein (NC), the p6 protein, the 
protease (PR), the reverse transcriptase (RT), the integrase (IN), the surface protein (SU), 
and the transmembrane protein (TM).  The two regulator proteins Tat and Rev are the 
first two proteins translated from spliced mRNA.  The final four proteins, Vif, Vpr, Vpu, 
and Nef are also translated from spliced mRNA.  These last four proteins are termed 
accessory proteins and were originally considered unnecessary because open reading 
frame (ORF) disruptions to these genes showed no effect on the virus’s capacity to 
replicate and infect cells in vitro.   Since in vitro experiments seldom have the ability to 
mimic all aspects of the in vivo environment, it was not surprising to find later that these 
proteins play vital roles in vivo.  
In addition to the genes that code for viral proteins, the HIV genome also contains 
short terminal repeats.  During reverse transcriptions (discussed later) these short terminal 
repeats increase in length and are then aptly termed long terminal repeats (LTR).  The 
similar LTRs on the ends of the viral DNA are comprised of three functional regions 
known as: the unique 5′ region (U5), the unique 3′ (U3), and the repeat region (R).  These 





Figure 2.2 Schematic depiction of the HIV Genome and Virion,  
Adapted from Figure 1 Frankel and Young, 1998, (Frankel and Young 1998) 
TRANSCRIPTION AND REPLICATION 
Starting from the inserted viral DNA, the life cycle of HIV begins with the 
initiation of transcription (Figure 2.3).  The transcriptional promoters, enhancers, and 
TATA box necessary to bring RNA polymerase II to the start site are located in the U3 
region of the LTR.  Of particular interest are the two binding sites for the NF-κB 
transcription factor, which is turned on in active T-cells.  With the help of the cellular 
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transcription factors the RNA polymerase engages at the HIV start site located at the 
interface between the U3 region and the R region of the 5’ LTR.  The polymerase then 
proceeds to transcribe the viral gene products.   
There are three classes of viral RNA that leave the nucleus. The first class 
consists of full-length transcripts that serve both as the genome for progeny virus and the 
mRNA for the Gag and Gag-Pro-Pol precursors.  The second is incompletely spliced 
RNA that provides the message for Vif, Vpr, Vpu and Env proteins.  The final type is 
fully processed mRNA that codes for the Tat, Rev, and Nef proteins. 
Only very low levels of viral transcription are seen until the viral gene product Tat 
is recruited back to the nucleus.  The Tat protein of HIV is responsible for increasing 
production of viral RNA by over 100 fold when compared to the steady-state levels of 
viral RNA.  In Tat deficient mutants transcription often does not proceed more than a few 
hundred nucleotides and viral progeny are not produced (Frankel and Young 1998).  The 
86 amino acid protein, Tat, consists of two distinct regions known as the activation 
domain, amino acids 1 through 48, and an arginine rich RNA binding region, amino acids 
49-57.  Tat’s activation domain recruits the cellular cofactors cyclin T1 and CDK9 to 
RNA hairpin regions known as TAR (trans-activating response elements) that form at the 
start of viral transcription (Freed and Martin 2001).  Tat’s RNA binding domain allows 
Tat to bind to TAR.  The recruited cofactors phosphorylate the C-terminal domain of 
RNA polymerase II (Freed and Martin 2001). The phosphorylated RNA polymerase II 
then proceeds to transcribe the remaining viral RNA. 
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Figure 2.3 Schematic depiction of the HIV life cycle.   
The cycle is more fully described in text. 
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HIV’s 116 amino acid Rev protein, which stands for regulator of expression of 
viral protein, is responsible for transporting unspliced and incompletely spliced viral 
mRNA out of the nucleus (Vaishnav and Wong-Staal 1991).  Generally before leaving 
the nucleus introns in mRNA are removed to prevent the translation of non-functional 
proteins.  However a method must exist to get the unmodified RNA out of the nucleus 
since the HIV RNA genome as well as the partially spliced RNA must get into the 
cytoplasm.  The Rev protein is responsible for accomplishing this task.  Rev deletion 
mutants show no accumulation in the cytoplasm of the unspliced RNA or the partially 
spliced mRNA for Vif, Vpr, and Vpu/Env. (Freed and Martin 2001) 
The Rev protein has two functional domains.  The first domain has a binding site 
for a 60 nt portion of the Rev response element (RRE).  RRE is a cis-acting target on all 
unspliced and partially spliced viral mRNA  (Freed and Martin 2001).  This domain of 
Rev also contains a nuclear localization signal that calls translated protein back to the 
nucleus.  The second Rev domain contains a leucine-rich nuclear export signal (NES), 
which gives it the ability to re-cross the nuclear membrane (Frankel and Young 1998). 
Through a complicated sequence of events Rev binds to the RRE on viral RNA and 
transports the RNA through a nuclear pore across the nuclear membrane (For more 
details see Freed and Martin 2001). 
 
TRANSLATION 
After the RNAs have escaped the nucleus, the host cell’s machinery translates the 
viral gene products and poly-protein precursors: Gag, Gag-Pro-Pol, and Env.  The Gag 
precursor, which accounts for over 90% of the viral structural proteins (Ott 2002), has an 
approximate molecular weight of 55 kilo-daltons and therefore is also sometimes referred 
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to as Pr55Gag.  As mentioned earlier, the unspliced viral RNA serves as the mRNA for 
Gag.  This unspliced viral RNA also acts as the mRNA for the 160 amino acid Gag-Pro-
Pol precursor, which is also known as Pr160Gag-Pro-Pol or just Gag-Pol.  The Gag-Pro-Pol 
precursor forms after a stop codon is ignored during the translation of Gag.  Gag and Pro-
Pol lie in different open reading frames (ORF) and about 10% of the time, at a highly-
uridine rich region between the Gag and Pro-Pol genes, the translating ribosome slips 
back one nucleotide (Parkin, Chamorro et al. 1992). This frame shift allows the ribosome 
to continue translating through the stop codon.   
The mRNA that codes the Env precursor (gp160) is partially spliced to remove 
the majority of the Gag and Pro-Pol genes before leaving the nucleus.  The first part of 
the Env precursor translated is a signal peptide that directs the majority of the remaining 
protein to be translated directly into the ER.  A hydrophobic region near the 3′ end 
anchors the protein in the ER membrane.  The leader sequence is removed from the 
protein on the lumen side and the protein is then heavily glycosylated and folded.  The 
folded Env protein is transported to the Golgi complex where it is cleaved into the SU, 
(gp120) and TM (gp41) proteins by a cellular protease.  These proteins are then 
transported to the surface of the host cell. 
 
ASSEMBLY AND BUDDING 
 While the Env proteins are being transported to the surface of the cell, a 
membrane signal tells the Gag and Gag-Pro-Pol to gather near the plasma membrane.  
The myristic acid moiety attached to the N-terminus of the MA along with another 
N-terminal domain of the MA protein, known as the M domain, act as the signal for both 
precursors (Freed 1998).   The MA portion of these precursors is also believed to interact 
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with the cytoplasmic tail of the TM protein to ensure the incorporation of TM and SU 
into the budding virus.   
To ensure that the RNA genome is also packaged before budding, HIV utilizes the 
NC region of the poly-proteins.  The NC protein contains a short sequence consisting 
primarily of cystine residues and a histidine residue that form a motif similar to a zinc-
finger.  This motif allows the NC protein to bind to various RNA packaging regions on 
the viral genome.  The primary packaging region is generally found in between the LTR 
and Gag.  RNA is found in mature virions as a dimer, however whether it is packaged as 
a dimer or forms a dimer during the maturation process is still not clear.  Also, at some 
point during the RNA packaging and viral assembly processes, host cell tRNAs, in 
particular tRNALys3, are integrated into the virion.  Interactions between the tRNA and 
the RT portion of the Gag-Pro-Pol precursor are believed to be important. 
After the assembly of the necessary viral components at the plasma membrane, 
the soon-to-be progeny virus enters the last stage of budding.  As of now this stage is still 
not well known.  But what is known is that mutations to the highly conserved Pro-Thr-
Ala-Pro motif of the p6 portion of the Gag poly-protein prevent the virion from releasing 
effectively.  The p6 portion is also responsible for making sure that the accessory proteins 
Vpr and Vpx are incorporated into the virion before budding. 
 
MATURATION AND THE GAG PROTEINS 
After budding the HIV virion is still not considered a mature virus particle, 
because at this point if it infects a new cell it is unable to reverse transcribe the viral 
genome.  But that will not remain the case once the PR region of the Gag-Pro-Pol 
precursors is able to cleave itself out.  PR acts as a homodimer that forms either because 
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of conformational changes to the precursor or because of the high concentration of 
precursor proteins in the virion compared to the host cytoplasm.   Once dimerized the PR 
protein is able to cleave itself.  After cutting itself out it then makes several cleavages in 
both the Gag and Gag-Pro-Pol precursors.  The processing of these poly-proteins causes a 
conformational change that triggers the formation of a cone-shaped core around the viral 
genome.  At this point the virus particle is able to infect new cells and is thus considered 
mature. 
PR cleaves the Gag precursor into the MA, CA, NC and p6 proteins.  The major 
role of the MA protein, which is also known as the matrix protein or p17, during viral 
assembly has been discussed earlier.  But there is evidence that suggests the MA protein 
also plays a post infection role.  MA mutants demonstrated impaired RT activity that lead 
to a decrease in viral DNA synthesis (Kiernan, Ono et al. 1998).   MA has also been 
found in low amounts in the viral preintegration complex that transports viral DNA into 
the nucleus. 
The 231 amino acid CA proteins form HIV’s cone-shaped core that holds the viral 
genome. CA has two functional domains: one near its C-terminus and the other at its 
N-terminus.  The mutations to the C-terminal domain inhibit the ability of CA to form 
dimers, which lead to assembly defects, whereas mutations to the N-terminal domain 
drastically impair the ability of the virus to infect host cells.  The C-terminal region of the 
CA protein, along with the NC protein, is believed to help the 1,200-1,800 Gag 
precursors properly pack into a spherical shape during assembly. The N-terminal domain 
is believed to play a role in HIV core formation and is known to recruit the cellular 
protein cyclophilin A into the nucleus.  Cyclophilin A is believed to destabilize CA-CA 
interactions post infection allowing the uncoating of the viral genome (Gamble, Vajdos et 
al. 1996). 
 26
The role played in RNA packaging, Gag assembly and tRNA incorporation by the 
72 amino acid NC protein, while part of the Gag precursor, was mentioned earlier.  In the 
mature detached virion NC can be found coupled with the viral genome in the cone-
shaped core. NC has been shown to act as a nucleic acid chaperone binding to RNA at a 
ratio of one molecule per seven nucleotides (Rein, Henderson et al. 1998).  NC mutants 
demonstrate decreased infectivity, which is believed to be associated with a 
destabilization of newly reverse transcribed viral DNA, which in turn leads to 
degradation (Tanchou, Decimo et al. 1998).  
Outside of what was mentioned about viral budding, not much more is known 
about the role of the Gag protein p6.  Cleavage of the other precursor Gag-Pro-Pol gives 
the additional proteins PR, RT, and IN.  The role of the RT and IN proteins will be 
described in context with HIV’s life cycle. As mentioned earlier, the role of the PR 
protein is as a protease making the necessary cleavages to the precursor proteins to give a 
mature viral particle.  The active sites for the PR dimer are known but what makes a good 
cleavage site for the protease seems to follow a fairly relaxed set of governances that are 
not well understood.   What is known is that the PR binding site can hold approximately 
seven amino acids and that PR has the affinity for a cleavage site between CA and NC. 
 
BINDING AND ENTRY  
After precursor processing has occurred the progeny virion is ready to infect a 
new cell.  The heavily glycosylated SU molecule (gp120) interacts non-covalently with 
the smaller transmembrane protein, TM (gp41), to form a heterodimer.  This heterodimer 
is then believed to form a trimer, which then serves as the binding complex for HIV (Lu, 
Blacklow et al. 1995).  The SU portion of this complex binds to HIV’s primary receptor, 
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the surface molecule CD4.  CD4 is expressed primarily on T-helper (TH) cells but is also 
seen to a lesser extent on dendritic cells and macrophages.  The binding of CD4 alone 
does not facilitate infection; HIV must still interact with a co-receptor from the 
transmembrane proteins of the chemokine receptor family (Berger, Murphy et al. 1999).  
The binding to CD4, however, does cause a conformational change in the SU protein that 
either exposes or forms the binding site for the co-receptor molecule (Burton 1997).   As 
mentioned earlier the two major co-receptors for HIV are CCR5 during PHI and CXCR4 
during the transition to AIDS.   
 Once the co-receptor has become bound, the SU molecule experiences another 
conformational change that activates the TM protein.  The activated TM protein is 
believed to insert itself into the host cell thus facilitating closer virion-cell contact 
(Poignard, Saphire et al. 2001).  At this point, in a process that is not understood, the 
virus is able to penetrate the host cell and insert its viral core.  
 
REVERSE TRANSCRIPTION 
After the insertion of the viral core into the cell, HIV begins the process of reverse 
transcribing its RNA into DNA.  This complicated process has been well studied and can 
be broken down into six steps (Figure 2.4) (Gotte, Li et al. 1999). Reverse transcription 
takes place in a large complex similar to the viral core. Most of the reaction is mediated 
by the activity of RT, however, it has been shown that NC may play a role in the 
stabilization of viral DNA ends.  After analysis of viral DNA from NC mutants it was 







Figure 2.4 Schematic depiction of the Reverse Transcription of Viral RNA into Proviral 
DNA 
Modified from (Gotte, Li et al. 1999) and described in text. 
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The active form of RT is a heterodimer consisting of a 66 kd and a 51 kd subunit 
to form a holoenzyme.  The 66 kd subunit is considered the full length RT protein, while 
the 51 kd subunit comes about after a cleavage by PR of RT that cuts out the RNase H 
domain near its C-terminus. The holoenzyme possesses RNA polymerase activity, DNA 
polymerase activity, and RNase H activity.   
During the first step, the tRNA from the previous host cell anneals to the primer 
binding site (PBS) on the viral RNA template.  The PBS is located in the U5′ region of 
the RNA genome.  This site is complimentary to 18 nucleotides at the 3′ end of the 
tRNALys3.  RT recognizes this RNA/tRNA complex and begins to extend the 3′ end of the 
tRNA using the viral RNA as the template to create a new RNA/DNA hybrid.  Along 
with the ability to transcribe DNA from RNA, RT has RNase H activity, which allows it 
to degrade the RNA portion of the hybrid.  This leaves only a DNA portion that is 
complementary to the viral U5′ and R regions of the genome. 
 The second step in the process of generating a full length DNA copy of the 
genome utilizes the fact that the HIV genome has similar R regions on both the 5′ and 3′ 
ends.  The complimentary R region on the newly created piece of DNA binds the R 
region on the 3′ end of the viral genome.  Since the viral genome is an RNA dimer it is 
not clear if the DNA binds the RNA strand it used earlier for a template or if it simply 
binds the other RNA genome.  
 During step three in the process RT begins transcribing a new full length piece of 
negative DNA.  As before, but with one small exception, the RNase H activity of RT 
degrades the RNA from the newly formed RNA/DNA hybrid.  The exception is that the 
full length RNA genome contains two purine rich regions that are resistant to RNA 
degradation.  One region is located near the 3′ terminus and is termed the 3′ polypurine 
tract (3′PPT), while the other can be found in the center of the genome and is aptly 
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termed the central polypurine tract (cPPT).  These regions will serve as the primer for the 
creation of a positive DNA strand. 
 Before the negative strand of DNA is complete the creation of a positive strand of 
DNA has begun at both the 3′PPT and cPPT.  The DNA created from these starting 
points are termed upstream positive (U+) and downstream positive (D+), respectively.  
When RT on the U+ reaches the annealing point of the short negative DNA strand it 
continues transcribing to include the 18 nucleotides of the tRNA it used as a primer.  The 
19th nucleotide of the tRNA acts as a stop signal and is known as the plus-strand-strong-
stop DNA.  At this point RT uses its RNase H activity to chop up the tRNA as well as to 
go back and get rid of the previously un-digestible PPTs. 
 The fourth step in the process involves another strand transfer.  This time the 
positive DNA strands U+ and D+ bind the negative full length DNA.  RT then continues 
the transcription of the positive DNA strand using the negative strand as the template.   
 The fifth step of the process highlights another activity of RT.  During the 
transcription of the positive strand RT is inevitably going to run into the point where the 
U+ or D+ bind.  When this happens RT must have a way to disrupt the DNA/DNA 
interaction to allow the transcription to continue.  RT continues transcribing the D+ 
strand until it reaches the PBS region.  This continuation creates the 3′ LTR on the 
positive DNA. 
The sixth step involves the continuation of the U+ strand transcription until it 
reaches a termination sequence in the center of the genome.  This sequence is 
approximately 100 nucleotides downstream of the D+ 5′ binding site and is known as the 
central termination sequence (CTS).  Because of CTS’s location the positive DNA strand 
will have an overlap in the middle.  The negative and positive DNA strands interact to 
give the proviral DNA.    
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INTEGRATION 
After the conversion of RNA to proviral DNA, by the reverse transcriptase 
complex, the viral core proteins are shed to give the pre-integration complex (PIC) 
(Figure 2.5) (Sherman and Greene 2002).  PIC is comprised of the proviral DNA, IN, 
MA, Vpr and RT.   PIC gives the newly created proviral DNA the ability to cross the 
membrane of dividing and non-dividing cells.  PIC utilizes host cell macromolecules 
(known as nuclear pore complexes (NPCs)) that span the nuclear membrane.  The NPC is 
made up of 50-100 host cell proteins.    
The IN protein of PIC contains a nuclear localization signal (NLS) somewhere 
between amino acids 152-184 (Bouyac-Bertoia, Dvorin et al. 2001).  A yet-to-be 
determined host cell protein, which is most likely from the family of proteins known as 
importins, binds NLS and facilitates the passage of PIC through the nuclear membrane.  
Mutations in the NLS sequence of IN prevent the integration of proviral DNA in both 
dividing and non-dividing cells (Bouyac-Bertoia, Dvorin et al. 2001). 
NPC allows passive transport of molecules with a radius of up to 9nm and active 
transport of molecules with a radius of up to 25 nm (reviewed in (Mattaj and Englmeier 
1998)).  The radius of PIC prior to import is estimated at 56 nm (Miller, Farnet et al. 
1997). Therefore a method must exist that allows PIC to condense to a smaller size.  The 
linear proviral DNA is 9.4 kilo nucleotides in length which when linear would equate to a 
length of  ~ 3.3 µm.  In order for the PIC to have an average radius of 56 nm, the proviral 
DNA is most likely coiled in some fashion.  It is also known that IN binds the ends of the 
proviral DNA, which might provide protection from exonuclease activity (Miller, Farnet 
et al. 1997). After binding the INs then come together to form a multimer, causing the 
proviral DNA to fold (reviewed in (Cullen 2001)).  The DNA overlap in the positive 
proviral DNA is also believed to provide additional flexibility to allow the PIC complex 
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to condense even further.  It is known that HIV mutants that were engineered to be 






Figure 2.5 Schematic depiction of the Preintegration Complex with the Nuclear Pore 
Complex 
Adapted from (Sherman and Greene 2002) 
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In addition to IN and the proviral DNA, the PIC also contains Vpr, MA, and RT.  
Vpr is believed to give HIV the ability to infect non-dividing macrophages.  In culture 
Vpr deletion mutants show decreased viral replication in non-dividing macrophages but 
have little effect on replication in proliferating PBMC or T-cells (de Noronha, Sherman et 
al. 2001).  The role of MA and RT in nuclear import is not understood.   
After transversing the nuclear membrane, the proviral DNA must still be inserted 
into the host genome.  This involves a 3-step process.  During the first step the 32 kd IN 
removes 2-3 nucleotides from the 3′ ends of the proviral DNA to create overhangs.  In the 
next step IN uses the 3′ OH to break the phosphodiester backbone of the host DNA and 
attach the 3′ end of the proviral DNA to the 5′ end of the cut in the host DNA.  The 
location is sequence independent and results in the 3′ ends of the viral DNA attached to 
the host DNA and the 5′ end protruding.    NC may also be involved in this step, because 
during in vitro integration assays without NC, the major product was only a single end of 
the proviral DNA attached to the host genome (Carteau, Gorelick et al. 1999).  The final 
step of integration employs host cell machinery to remove the 5′ overhang and repair the 
DNA.   
 
THE ACCESSORY PROTEINS 
 Vif stands for virus infectivity factor and this 192 amino acid protein is important 
for productive infection in vivo (Frankel and Young 1998; Potash, Bentsman et al. 1998; 
Blumenzweig, Baraz et al. 2002; Pomerantz 2002; Yang, Gao et al. 2003).  Vif defective 
mutants in vitro have been shown to infect the cell lines 293T, COS, HeLa, SupT1, 
CEM-SS and Jurkat.  These cells have been termed Vif-permissive.  Other cells such as 
primary lymphocytes, some T-cell lines and monocyte-derived macrophages are not 
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infected in vitro by Vif defective mutants and are thus termed Vif-non-permissive (Freed 
and Martin 2001).    
A much debated question is whether Vif is inhibiting a host cell factor found in 
non-permissive cells or is filling the role of a host cell factor absent in these cells.  That 
debate has recently swung towards the argument that Vif is inhibiting a cell factor found 
in non-permissive cells.   Sheehy et al. published in 2002 that a host cell factor from a 
non-permissive cell, when expressed in permissive cells, causes these cells to become 
non-permissive (Sheehy, Gaddis et al. 2002). They termed the host cell factor CEM15 
after the cell line from which it was isolated. 
Also, recently, an activity of Vif most likely unrelated to the inhibition of CEM15 
has been reported.  The N-terminal portion of Vif has been shown in vitro to inhibit the 
activity of PR, the HIV protease (Potash, Bentsman et al. 1998; Yang, Gao et al. 2003).  
The inhibition is believed to ensure that the PR refrains from cleaving itself out 
prematurely, thus allowing for proper assembly of the Gag and Gag-Pro-Pol precursor.  
 Vpr, for viral protein R, is a 96 amino acid protein believed to serve three 
functions. First, as mentioned earlier, Vpr is part of the PIC and is important during the 
infection of non-dividing macrophages. Second, it has been shown that T-cells infected 
with HIV-1 containing an intact Vpr gene product do not replicate and eventually die 
(reviewed in (Emerman 1996)).  Vpr locks the T-cell in the G2 phase preventing it from 
entering mitosis.  The highest rate of HIV expression is seen in the G2 phase, which 
might explain why Vpr locks infected cells into this phase (Goh, Rogel et al. 1998).  
Since, as mentioned earlier, the average life span of HIV infected CD4+ cells is about 24-
48 hours, locking the cell in the G2 phase might be the way HIV has developed to 
maximize its reproductive efforts.  
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 The final function of Vpr may be related to its first.  It has been shown that Vpr 
faintly induces an increase in viral transcription.  This observation would be consistent 
with the increased viral transcription seen during the G2 phase.  However, it has been 
suggested that Vpr may directly interact with host cell transcription factors (Freed and 
Martin 2001). 
 The 17kd, 81 amino acid, integral membrane protein, Vpu, participates in two 
main activities.  First the C-terminal cytoplasmic region of Vpu interacts with CD4 
downregulating it on the surface of the cell (Chen, Gandhi et al. 1996).  Degradation of 
CD4 is believed to follow a ubiquitin-dependent-proteasome pathway because after 
binding CD4, Vpu recruits TrCP, a member of a E3 ubiquitin ligase complex. (Bour, 
Perrin et al. 2001)  Down regulation of CD4 serves two purposes.  First, by reducing the 
primary receptor for HIV, infected cells are less likely to get infected again, thus 
increasing the number of cells that will become infected.  Second, the chances that SU 
will interact with CD4 on its own envelope are decreased.   
A side effect of Vpu binding TrCP is that there is a decrease in the activity of 
NF-κB. (Bour, Perrin et al. 2001)  The Vpu interacts with TrCP without being degraded 
itself, which is unusual.  This unusual interaction is believed to keep TrCP-dependent 
degradation of phosphorylated IκB-α during tumor necrosis factor (TNF)-α stimulation.  
Degradation of IκB-α releases NF-κB allowing it to act as a transcription factor.  The 
lack of NF-κB transcription factor activity results in a decrease in transcription of the 
HIV-1 genes (Bour, Perrin et al. 2001).  There are many immune response elements that 
are upregulated by NF-κB such as chemokines and cytokines, which HIV may be 
targeting instead. 
 The second activity associated with Vpu involves the stimulation of virion 
release.  Vpu defective mutants show significant increases in the number of particles 
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remaining attached to the host cell membrane. (Lamb and Pinto 1997)  Furthermore, it 
has been shown that Vpu is not required for efficient particle release in dividing cells but 
is essential for release in non-dividing cells, such as those locked in the G2 phase. (Deora 
and Ratner 2001)  
 The final accessory protein is the one I find most fascinating:  Nef, which stands 
for negative effect. The 27 kd, 206 amino acid, Nef protein is expressed early in the HIV 
life cycle and accounts for 80% of early RNA transcription (reviewed in (Marsh 1999)).   
Scientists originally believed Nef might play a role in the clinical latency seen in HIV 
infected patients.  They believed this because in some cell lines it was shown that cells 
infected with Nef mutants replicated the virus faster than cells infected with wild type 
HIV. Others quickly refuted that observation and now experiments show that Nef has no 
effect or only offers a very moderate increase in replication in vitro. 
Several activities have been credited to Nef.  First like Vpu Nef can down 
regulate the expression of CD4 on the surface of cells.  Nef accomplishes this task by 
increasing the endocytosis of CD4 in clathrin-coated pits.  Nef has been shown to interact 
with both CD4 and the AP-2 adapter complex, which is responsible for recruiting 
membrane proteins to these pits for endocytosis (reviewed in (Arora, Fredericksen et al. 
2002)). 
Second Nef can also down regulate the expression of major histocompatibility 
complex class I (MHC I) on the surface of cells up to 300 fold (Collins, Chen et al. 
1998).  The MHC-I molecule, which will be discussed in detail in the next chapter, is 
responsible for presenting viral epitopes to the T-cell receptor on CD8 positive cells.  
Down regulation of MHC-I would decrease the immune system’s ability to identify 
infected cells.  The exact mechanism for MHC-I down regulation is still not fully 
deduced; what is known is that Nef interacts with PACS-1 (phosphofurin acidic cluster 
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sorting protein-1) and proceeds to endocytose MHC-1 through a PI3K-Regulated ARF6 
Endocytic Pathway (Blagoveshchenskaya, Thomas et al. 2002). 
Nef has also been shown to upregulate FasL. This is accomplished through a 
cascade of events that is triggered by Nef interacting with the T cell receptor ζ chain 
(reviewed in (Fackler and Baur 2002)).  The up regulation of FasL may lead to the 
apoptosis of CTLs specific for HIV.  This apoptotic event is triggered when Fas on CTLs 
bind the FasL on the infected CD4 cell.  Nef is also responsible for minimizing apoptosis 
by cis acting Fas/FasL binding on the same infected cell by inhibiting the activation of 
apoptosis signaling kinases 1 (ASK1).  
The HIV genome encodes for only 15 proteins that have evolved to ensure the 
reproduction of the virus.  These proteins display complicated characteristics that allow 
for the reverse transcription of the RNA genome, the nuclear import and integration of 
the proviral DNA and the export of unprocessed RNA.  The virus has evolved methods to 
increase infectivity while decreasing exposure to the immune system.  The HIV pathogen 




Overview of the Immune Response 
Our body’s defensives can be divided into two general areas, innate immunity and 
specific immunity.  The innate immunity is fairly non-specific and includes barriers such 
as your skin, the acidic environment of your stomach, tears, saliva and mucous 
membranes lining your respiratory and gastrointestinal tract.  When pathogens get past 
the innate immune system they encounter your specific immune system, which must first 
identify the intruder before unleashing a counter attack consisting primarily of antibodies, 
which bind to pathogens outside cells, and cytotoxic T-lymphocytes (CTL), which 
destroy cells that have been infected by the pathogen.   
The innate immune system response is effective against most pathogens the body 
comes across.  However, since it is non-specific, there is little need to elaborate more on 
it because the goal of this work was the creation of specific vaccines.  The specific 
immune system can be subdivided into two types of responses; the humoral and the cell-
mediated.  Furthermore, the specific immune system can be looked at in terms of the 
location of the response; whether it is systemic or mucosal. 
Aside from the location and type of response, the immune system functions 
differently if it is responding to a primary infection or secondary infection.  The primary 
response, which results from the initial exposure to an antigen, is mediated by naïve 
lymphocytes (B and/or T). In mice a primary response peaks 10-17 days post infection 
and is of relatively low magnitude and short duration.  For humans the peak response can 
take longer.  Furthermore, the primary immune response is characterized by the 
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production of antibodies from the immunoglobulin M class.  (Antibody classes are 
discussed later.) 
The second time the immune system sees the antigen, or after chronic infection, 
the immune system responds principally with memory lymphocytes.  In mice the 
secondary response peaks after 2-7 days and has a much higher magnitude and longer 
duration compared to the primary response. The production of antibody from the 
immunoglobulin G class is the overwhelming antibody response observed.  The goal of a 
vaccine is to ensure that when the actual antigen is seen the immune system treats it like a 
second encounter.  In other words, the body has been prepared to more quickly counter 
the effects of the infection. 
 
B-CELL MATURATION 
Humoral immunity refers to the interaction of B-cells with pathogens, which leads 
to their proliferation and differentiation into plasma cells that secrete antibodies and form 
memory B-cells.  B-cells begin in the bone marrow as lymphoid stem cells, and when 
given the right environment, which includes the cytokine IL-7 and direct interaction with 
stromal cells, they can differentiate into mature B-cells that express on their membrane a 
unique antigen-binding receptor.  During maturation the B-cells go through a process of 
negative selection to insure that the antigen-binding receptor does not recognize self-
antigens. This phase of maturation is designated as the antigen-independent phase.  
After maturation, the mature B-cell, now termed naïve, is released into the 
periphery to circulate in the blood and lymphatic fluids. The naïve B-cell has yet to be 
exposed to its particular antigen and if it does not encounter it within a few weeks it will 
die by apoptosis.  However, if the B-cell comes in contact with the antigen in the 





Figure 3.1 Schematic depiction of the B-cell maturation and differentiation process. 
Adapted from Kuby Immunology, page 270 (Goldsby, Kindt et al. 2000). 
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B-cells go through a process of class switching and differentiation that results in plasma 
cells that can secrete antibodies and memory B-cells that can respond to future infections.  
This stage of B-cell differentiation has been appropriately referred to as the antigen-
dependent phase (Figure 3.1). 
 
TYPES OF ANTIGEN 
The antigen recognized by naïve B-cells can be of protein, polysaccharide or lipid 
origin.  The antigen can be a sequence of amino acids or a non-sequential motif.  B-cell 
antigens can be categorized by their need for TH cell contact.  As seen in mice, there are 
two types of antigen; a few antigens fall into the category of thymus-independent (TI) 
antigens, while the majority of antigens are classified as thymus-dependent (TD) 
antigens.  The TI antigens can further be divided into type 1 (TI-1) antigens and type 2 
(TI-2) antigens.   
As the name suggests TI antigens do not require direct contact with TH cells.  TI-1 
antigens, such as the bacterial wall components lipopolysaccharide (LPS), peptido-
glycan, and porin, are mitogens that cause the polyclonal activation of B-cells into 
differentiated antibody-secreting plasma cells regardless of their antigenic specificity.  
Not only are TI-1 antigens not bound by TH-cell contact but they also do not require any 
cytokines secreted by the TH-cells.  TI-2 antigens recognized by B-cells, on the other 
hand, do require the B-cell to be in proximity to cytokines secreted by TH-cells to trigger 
class switching.  These types of antigen are not polyclonal activators and can only 
activate mature B-cells.  TI-2 antigens are generally repeating polymers that are also 
found as part of the bacterial wall. 
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TD antigens are antigens that have been internalized by the B-cell receptor 
(BCR), processed through the endocytic pathway, and presented in the class II  major 
histocompatibility complex (MHC-II).  Cross-linking of the membrane bound 
immunoglobulin (IgM) by the antigen results in the phosphorylation of the Igα/β 
immunoreceptor tyrosine-based activation motif (ITAM).  This initiates an effective 
intracellular signal, which provides the first signal for activation.  This signal leads to an 
increase in both MHC-II expression and the expression of the co-stimulatory molecule 
B7.  The T-cell receptor (TCR) on CD4+ T cells recognizes the antigen, which triggers 
the activation of the TH-cell.  The activation of TH-cell results in the secretion of 
cytokines, such as interleukin 2 (IL-2), IL-4, IL-5, and others, and in the expression of 
CD40L, which is a member of the tumor necrosis factor receptor family.  CD40L 
interacts with a member of the tumor necrosis factor surface protein family known as 
CD40 on the B-cell.  The CD40L/CD40 cross-linking triggers a second signal in the 
B-cell.  This signal is amplified when the co-stimulatory molecule B7 interacts with 
CD28 on the TH-cell.  The amplified signal drives the naïve B-cell from the G0 phase into 
the G1 phase of the cell cycle pathway resulting in an activated B-cell. 
Activation of the B-cells causes the upregulation of cytokine receptors on the 
surface of the cells.  The cytokines released by bound TH-cells, or released by other 
cytokine producing cells in the area, interact with the cytokine receptors on the B-cell.  
This event directs the B-cell to proliferate and differentiate into plasma cells and memory 
B-cells (Figure 3.2). 
 There are several differentiations to plasma cells possible depending on the type 
of cytokines present. A differentiating B-cell in the presence of interferon gamma (INF-γ) 
gives rise to plasma cells secreting immunoglobulin G2a (IgG2a) or IgG3.  
Differentiation in the presence of transforming growth factor-β (TGF-β) triggers the 
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Figure 3.2 Schematic depiction of the activation and differentiation of B-cells by a TD 
antigen. 
 Adapted from Kuby Immunology, page 282 (Goldsby, Kindt et al. 2000). 
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creation of plasma cells releasing IgG2b or IgA.  Plasma cells secreting antibodies IgE 
and IgG1 result from proliferation of B-cells in the presence of IL-4.  The cytokines IL-2, 





Figure 3.3 Schematic depiction of the cytokine driven B-cell differentiation. 
B-cells differentiate into plasma cells secreting different immunoglobulins.  




Immunoglobulins, or antibodies, are present on the surface of B-cells or are 
secreted by the plasma cells.  Ig has a basic structure of two homogeneous light chains of 
about 220 amino acids attached by disulfide bonds to two homogeneous heavy chains of 
about 440 amino acids.  Each light and heavy chain contains two domains, one 
C-terminal constant domain known as CL or CH, respectively, and one N-terminal 
variable domain termed VL and VH respectively.   Both VL and VH include regions of 
concentrated sequence differences that have been termed hypervariable regions.  These 
hypervariable regions form two antigen-binding sites on the N-terminals of the Ig 
molecule (Figure 3.4). 
Antibodies interact with antigens in a non-covalent manner triggering several 
outcomes.  First after binding the antigen, the CH regions of the antibody can interact 
with receptors on phagocytic cells, causing receptor mediated phagocytosis of the 
antigen, also known as opsonization.  Second, after binding the antigen, the CH regions of 
the antibody can trigger the complement pathway; which results in the formation of a 
membrane attack complex that can lysis invading cells.  Third, when an antibody binds 
an antigen on the surface of an infected cell, for example the antigen can be part of a 
budding virus particle, the CH regions can call in natural killer cells to lyse the infected 
cell.  This process is known as antibody-dependent cell-mediated cytotoxicity. Finally, 
the actual binding of the antibody to the antigen could neutralize an important activity of 
the invader.  
As alluded to above there are several classes of Igs. The classes are distinguished 
from one another by differences in their CH domain.  The Igs are divided into the classes, 




Figure 3.4 Schematic depiction of the immunoglobulin structure. 
The structure consists of two homogeneous light chains attached by disulfide 
bounds to two homogeneous heavy chains.  Each light and heavy chain contains 
two domains, one C-terminal constant domain known as CL or CH, respectively, 
and one N-terminal variable domain termed VL and VH respectively.  The coming 
together of the VL and VH domains forms the antigen binding site.  Adapted from 
Kuby Immunology, page 84 (Goldsby, Kindt et al. 2000). 
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IgA allow them to be categorized further into subclasses.  In humans the subclasses for 
IgG are IgG1, IgG2, IgG3, and IgG4, while in mice they are termed IgG1, IgG2a, IgG2b,  
and IgG3.  IgA in humans can be broken down into IgA1 and IgA2, while in mice no 
subdivision of IgA is observed. Because the distinguishing characteristic of an Ig class is 
the variations in the CH regions, class effector functions may differ. 
IgG is secreted from plasma cells as a monomer.  It is the most abundant Ig class 
found in the serum, accounting for about 80% of the total.  As for the isotypes, the 
concentration in serum has this relative intensity: IgG1 > IgG2 > IgG3 > IgG4.  IgG1, 
IgG2 and IgG4 have half-lives of close to 23 days while IgG3 has a half life of only 8 
days.  The antibody effector functions also differ between subclasses. In decreasing 
efficiency IgG3, IgG1 and IgG2 activate the complement pathway. IgG1 and IgG3 have a 
high affinity for receptors on phagocytic cells and thus effectively initiate opsonization.  
Furthermore, IgG1, IgG3 and IgG4 play a role in the protection of the fetus because of 
their unique ability to cross the placenta.  
The immunoglobulin produced first in a primary response is IgM.  IgM accounts 
for somewhere between 5-10% of total serum antibodies in humans under normal 
conditions.  It is seen in the monomeric form attached to the membrane of immature and 
mature B-cells.  IgM secreted by plasma cells forms a pentamer that has a half life of 5 
days.  The pentamer results from disulfide bonds between CH and the incorporation of an 
additional polypeptide, known as the J chain.  The J chain gives the secreted IgM the 
ability to cross the epithelial lining between the systemic and mucosal areas of the body.  
Thus the pentamer form of IgM can be found in external fluids, such as saliva, tears, 
breast milk and mucus.  IgM is most noted for its abilities to trigger the complement 
pathway and facilitate the opsonization of large molecules. 
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Although IgM can be secreted, the most abundant immunoglobulin class found in 
the external fluids mentioned above is IgA.  In serum IgA accounts for 10%-15% of the 
total antibodies and is generally found as a monomer, but it can also form multimers.  In 
external fluids IgA is most often found as a dimer bound also to a J chain and an 
additional molecule known as the secretory component.  The secretory component is 
incorporated during the transport of IgA across the epithelial cell layer.  IgA activates the 
complement via an alternative pathway compared to the classical pathway used by IgG 
and IgM.  IgA has been shown to be effective in preventing the attachment of some 
antigens to mucosal cells. 
The immunoglobulin class, IgE has a half-life of 2.5 days and accounts for less 
than 0.002% of serum antibodies.  IgE is believed to be important in the removal of 
parasites from the gut and respiratory tract, but is most known for its ability to trigger 
hypersensitivity reactions.  The CH domain of IgE can bind a receptor on mast cells and 
basophils known as FcεRI.  Binding prompts degranulation and cytokine production 
resulting in allergic reactions with symptoms such as hives, asthma, hay fever, and in the 
worst-case scenario anaphylactic shock.  
IgD, the final class of immunoglobulins, has a half-life of 3 days and accounts for 
less than 0.2% of serum antibodies.  IgD can be found bound to the membrane of mature 
B-cells, but not immature ones. To date, no antibody effector function has been 
established for this class of immunoglobulin.  Since it is one of the only two antibodies 




 While B-cell maturation occurs in the bone marrow, T-cell maturation transpires 
in the thymus.   When progenitor T-cells arrive in the thymus they do not carry the 
characteristic T-cell markers such as the TCR and accessory molecules CD4 or CD8, the 
most important of which is the TCR.  Over a three-week period, the progenitor T-cell 
creates a TCR and verifies its functionality.  
 The TCR is a transmembrane heterodimer that is held together by disulfide 
bridges and consists of either an α and β chain or a δ and γ chain.  The two types of TCR 
are aptly termed αβ TCR and γδ TCR.  The αβ TCR accounts for over 95% of the T-cell 
receptor molecules in adults.  Like antibodies the TCR chains contain both a variable 
domain and a constant domain. Through a random process of gene rearrangement, which 
is beyond the scope of this writing, the T-cells create a pool of TCRs with an antigenic 
diversity potentially exceeding 1015 for αβ TCR and 1018 for δγ TCR.  Also like the 
membrane bound antibodies, the cytoplasmic tail of the TCR is small and thus it 
associates with other proteins, CD3, forming the TCR-CD3 complex.  CD3 are a group of 
proteins that have longer cytoplasmic tails that contain the ITAM motif and are necessary 
for intracellular signaling (Figure 3.5). Unlike antibodies the TCR is confined to 
recognizing antigens presented in one of the two classes of MHC molecules, MHC-I and 
MHC-II.   
Since the gene rearrangement is a fairly random process (for review see chapter 9 
in (Goldsby, Kindt et al. 2000)), not all TCR created will have the ability to recognize the 
MHC and some might recognize self antigens.  To ensure that the TCR recognizes 
antigen presented in the MHC molecules the T-cell undergoes a process known as 
positive selection.  This takes place in the cortical region of the thymus and involves the 




Figure 3.5  Schematic depiction of the T-cell Receptor (TCR) and CD3 complex. 
Adapted from Kuby Immunology, page 227 (Goldsby, Kindt et al. 2000). 
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Figure 3.6 Schematic depiction of positive and negative selection. 
T-cell selection process ensuring TCRs that recognize self MHC molecules but 
not self antigens.  Adapted from Kuby Immunology, page 244 (Goldsby, Kindt et 
al. 2000).  
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cells are believed to receive a signal that prevents apoptosis.  T-cells that do not receive 
this signal initiate programmed cell death.   Next, to prevent the destruction of cells 
presenting normal cell antigens, the T-cell goes through a procedure known as negative 
selection.  Negative selection involves interactions with the antigen presenting cells in the 
medulla region of the thymus.  It is believed that T-cells that bind antigen presented in 
the MHC molecules on the dendritic cells and macrophages in this region of the thymus 
receive a signal triggering programmed cell death.  It is estimated that less that 5% of 
T-cells pass the selection process and are allowed to leave the thymus (Figure 3.6).  
 After leaving the thymus the T-cell is considered mature because it has a 
functional TCR; however, it is still referred to as naïve because it has not yet encountered 
antigen.  The naïve T-cell continually circulates through the bloodstream, spleen and 
lympathic vessels, such as lymph nodes and Peyer’s patches.  Any given naïve T-cell is 
believed to circulate through these areas every 12-24 hours.  The circulation of the T-cell 
increases the chances that it will encounter a cell presenting an antigen it recognizes. If 
the T-cell does not encounter antigen it is believed to trigger apoptosis after 5-7 weeks of 
circulation. However, if the naïve T-cell detects an antigen it becomes active and 
proliferates into effector T-cells and memory T-cells. 
 
CD4+ T-CELL CO-STIMULATION REQUIREMENTS 
The activation process differs if the naïve T-cell is CD4+ or CD8+ and if the TCR 
is αβ or γδ.  Since the majority of TCR are αβ, that will be the pathway described here.  
As mentioned earlier CD4+ cells exclusively identify antigen presented in the MHC-II 
molecule and are almost exclusively TH-cells.  The initial interaction of the TCR with the 
antigen in the MHC-II molecule ‘results in the upregulation of cell surface molecules 
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such as CD28, IL-2 receptor (IL-2R) β and IL-2Rγ, and in the induction of surface 
expression of CD40 ligand (CD40L), Ox40, 41BB, IL-2Rα and other’ molecules 
(Whitmire and Ahmed 2000).  In addition to the interaction with the MHC-II molecule, 
the activation of TH-cells requires one or more co-stimulation signals.   
Potential co-stimulation signals result from the interaction of CD40 with CD40L, 
the interaction of CD28 with B7, or the interaction of Ox40 with the Ox40L.  Using 
CD40L-deficient mice infected with lymphocytic choriomeningitis virus (LCMV), 
recombinant adenovirus, or murine γ-herpesvirus 68 (MHV-68) it has been shown that 
the CD4+ response is reduced by greater than 5-10 fold (reviewed in (Whitmire and 
Ahmed 2000)).  A similar reduced CD4+ response is seen in Ox40-deficient mice infected 
with LCMV and influenza virus (reviewed in (Whitmire and Ahmed 2000)).  Also when 
mice treated with anti-B7 molecules to block the CD28/B7 interaction, the mice 
demonstrated impaired CD4+ responses when infected with LCMV (reviewed in 
(Whitmire and Ahmed 2000)).  However, mice unable to create the 41BB-41BBL 
(ligand) interaction, which were infected with LCMV or influenza virus mounted a CD4+ 
response similar to the wild type mice (reviewed in (Whitmire and Ahmed 2000)).  This 
implies that not all molecules upregulated during the initial interaction with antigen 
presented in the MHC-II molecule are important in activation.  
 
CD8+ T-CELL CO-STIMULATION REQUIREMENTS 
The activation of naïve CD8+ T cells (or TC-cell) differs from the CD4+ T-cells.  
As mentioned earlier the CD8+ T cells recognize antigen presented in the MHC-I 
molecule.  TC- cells can be distinguished by their requirement for TH-cell responses.  In 
mice it has been shown that infections with acute LCMV, Sendai virus, vaccinia virus, 
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influenza virus, Ectromelia virus, or MHV-68 can induce TC-cell responses in the 
absence of CD4+ cells, whereas mice infected with Adenovirus, Japanese encephalitis 
virus, or Herpes simplex virus require CD4+ cells to become active (reviewed in 
(Whitmire and Ahmed 2000)). 
Like CD4+ cells the recognition of antigen triggers ‘the upregulation of cell 
surface molecules such as CD28, IL-2 receptor (IL-2R) β and IL-2Rγ, and in the 
induction of surface expression of CD40 ligand (CD40L), Ox40, 41BB, IL-2Rα and 
others (Whitmire and Ahmed 2000).  However, unlike the CD4+ T-cells a co-simulation 
signal requirement depends on the antigen recognized.  It has been shown that TH-cell 
independent activation does not require CD40/CD40L interaction or Ox40/Ox40L 
interaction.  The requirement for the CD28-B7 interaction depends on the virus.  TH-cell 
independent activation requires CD28/B7 interaction when mice are infected with 
vaccinia virus, VSV, and influenza (subtype H1N1), but is not required during acute 
LCMV infection or infection with influenza (subtype H2N2). Whereas in CD4+ T cell 
activation the 41BB/41BBL interaction was not required, it appears to be necessary in 
both TH-cell independent and TH-cell dependent activation of CD8+ T-cells. TH-cell 
dependent activation also showed a requirement for the CD40/CD40L and the CD28/B7 
interactions (reviewed in  (Whitmire and Ahmed 2000)).    
Although the CD40/CD40L interaction was not necessary for the activation of 
TC-cells during T-cell independent infections, it has been demonstrated that CD40 
deficient mice generated 10 fold fewer memory cells after LCMV infection compared to 
the wild type.  If these mice are reinfected with LCMV they are able to mount a memory 
cell response, which implies that, although there were less memory cells, they were still 
functional.  Thus the CD40/CD40L response is probably involved in inhibiting portions 




Another signal unrelated to intercellular interactions is necessary to activate both 
the TH-cells and TC-cells.  As mentioned above, the expression of a high affinity IL-2R is 
induced when the TCR first recognizes the antigen.   Also upon antigen recognition, both 
the TH-cells, especially TH-1, and to a lesser extent the TC-cells begin secreting IL-2.  The 
IL-2 secreted by these cells can then attach to the IL-2R on their own surface or the 
IL-2R on T-cells in the area.  This interaction provides the final signal necessary to 




After the initial signal and, when necessary, the co-stimulation signal are 
produced, the now active TH-cell or TC-cell proliferates and differentiates into effector 
and memory cells.  There are two subsets of effector TH-cells that are termed TH1 and 
TH2, and there is only one type of effector TC-cells, known as CTL.  In both cases the 
initial interaction of an effector cell with professional antigen presenting cells (discussed 
later) or potential target cells is weak.  This weak interaction gives the TCR time to 
distinguish the antigen presented.  If the TCR is not specific for the antigen, then the 
effector cell disengages from the other cell.  If, however, the TCR is specific, then the 
cellular interactions increase due to an increase in the affinity of the leukocyte function-
associated molecule 1 (LFA-1) on the effector cell for the intracellular adhesion 
molecule-1 (ICAM-1) on the target cell.  Without a co-stimulation signal the effector 






Figure 3.7  Schematic depiction of the activity of cytokines released by T helper cells. 
Adapted from Kuby Immunology, page 320 (Goldsby, Kindt et al. 2000). 
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Both subsets of TH-cells secrete the cytokine IL-3 and granulocyte-macrophage 
colony-stimulating factor (GM-CSF).  The TH1 effector cells specifically secrete 
cytokines IL-2, interferon (INF)-γ, and TNF-β.  TH1 effector cell cytokines increase the 
B-cell production of IgG isotypes that initiate complement, most notably IgG2a in mice.  
They also activate macrophages, activate TC-cells, participate in the delayed-type 
hypersensitivity and promote the inflammatory response. The TH2 effector cells 
specifically release cytokines IL-4, IL-5, IL-10, and IL-13.  These cytokines prompt 
B-cells to secrete IgM, IgE and IgG1.  A ratio of IgG2a/IgG1 in mice is a common way 
of determining the relative strengths of the TH1/TH2 response.  TH2 cytokines also 
activate eosinophils and mast cells (Figure 3.7).  
Effector CTLs secrete cytokines, in particular IFN-γ and TNF-β, but they serve a 
lytic function as well.  These cells have two mechanisms for inducing the destruction of 
the target cells.  One mechanism involves the Fas/Fas ligand (FASL) interaction, and the 
other involves the release of perforin and granzymes. Upon recognition of the antigen, 
CTLs upregulate the expression the membrane bound molecule FasL.  When the FASL 
binds the Fas expressed on the target cell it triggers an apoptosis pathway through the 
activation of the FAS-associated death domain protein and caspase proteins (Krammer 
2000). 
A noticeable difference between naïve TC-cells and CTLs is the increase in the 
number of granules in CTLs.  These granules contain perforin and granzymes, which are 
then released, upon antigen detection, into the extracellular space between the CTL and 
target cell.  The perforin molecules are exclusively found in the granules of CTLs and not 
in other granule containing cells such as basophils, eosinophils and neutrophils.   These 
molecules insert themselves into the target cells’ membrane, creating a perforin channel.  
The formation of the channel in itself does not cause lysis of the cell but instead allows 
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the entry of granzymes.  Granzymes can also enter the cell via receptor-mediated 
endocytosis but require the perforin molecule to exit the endosome.  There are four types 
of granzymes that have been identified in humans and nine types in mice.   Inside the cell 
these granzymes are proteases that can trigger the caspase apoptosis pathway used by the 
Fas/FasL binding method and can cause mitochondria malfunctions that lead to necrosis 
(reviewed in (Krammer 2000)). 
 
ANTIGEN PRESENTATION IN THE MHC-II MOLECULE 
Presentation of peptides to CD4+ cells in the MHC-II molecule follows a pathway 
known as the endocytic pathway.  First the antigen is taken up by APC either through 
receptor-mediated endocytosis, pinocytosis, or phagocytosis.   The antigen moves 
through several compartments with decreasing pHs and is finally degraded in the low pH 
(4.5-5.0) compartment known as the lysosome, which also contains hydrolytic enzymes.  
While the antigen is being processed, class II MHC molecules in association with the 
invariant chain (Ii) are transported from the ER to the Golgi complex.  The class II MHC 
is translated directly into the ER.  There it associates with the Ii to prevent it from binding 
peptides proceeding through the cytosolic pathway (described later).  The MHC-II 
molecule and Ii leave the Golgi and enter the endocytic pathway.  As the pH decreases, 
from compartment to compartment, the Ii is degraded leaving only a small portion of 
itself left in the antigen binding cleft.  This portion is known as the class II-associated 
invariant chain peptide (CLIP) and is believed to prevent immature association of peptide 
with the binding site.  At some point the compartment containing the degraded antigen 







Figure 3.8 Schematic depiction of the endocytic pathway.   
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exogenous peptide takes its place.  The MHC-II molecule is then exocytosed allowing it 
to present its peptide to the CD4+ cells (Figure 3.8). 
The MHC-II molecule is a heterodimer consisting of an α and β chain, which is 
expressed primarily on antigen-presenting cells (APC) such as macrophages, dendritic 
cells, and B-cells, but can also be found on the epithelial cells in the cortical region of the 
thymus.  The α and β chain are both transmembrane proteins and associate via non-
covalent interactions.  Both proteins have two domains with the N-terminal membrane-
distal domain referred to as 1, (α1 and β1) and the C-terminal membrane-proximal 
domain as 2, (α2 and β2).  Interaction between α1 and β1 form the antigen-binding cleft, 
which holds the exogenous peptide for presentation to the TH-cells. 
The peptides found in MHC-II molecules are generally 13-18 amino acid residues 
in length.  The MHC-II antigen binding cleft only interacts with 13 of the residues in the 
peptide.  The cleft formed by the α1 and β1 domains is open and allows excess amino 
acid residues to hang over the sides.  Peptides that bind are diverse in sequence but they 
often times have a hydrophobic or aromatic residue at the N-terminus and three 
hydrophobic residues in the middle.  A proline has been found at the 2nd residue in 30% 
of MHC-II peptides analyzed.    
 
ANTIGEN PRESENTATION IN THE MHC-I MOLECULE 
 The peptide/antigen presented in MHC-I goes through a process known as the 
cytosolic pathway to get there. Proteins are tagged with ubiquitin and are sent to the 
proteasomes. The proteasome is a large multifunctional protease complex that chops the 
protein into smaller peptides.  Peptides between the lengths of 8-12 amino acids that 
possess the appropriate residues are shuttled into the ER by the transporters associated 
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with antigen processing (TAP). TAP along with chaperones, like calnexin and tapasin, 
are responsible for loading the peptide into the groove on the MHC heavy chain. The 
assembled MHC I complex (MHC heavy chain, β2-microglobulin (β2M), and the peptide) 
leave the ER in a vesicle, which travels to the Golgi complex before being exocytosed 
into the extracellular environment.  If CTL receptors recognize the peptide on the MHC it 
triggers the lytic functions of the CTL (Figure 3.9). 
Unlike the MHC-II molecule the MHC-I molecule is ubiquitous and thus any cell 
the CTL comes in contact with is a potential target cell. The MHC-I molecule consists of 
the MHC heavy chain, β2-microglobulin (β2m), and the peptide (Figure 3.10).  The MHC 
heavy chain is a transmembrane protein that contains three external domains known as 
α1, α2, and α3.  Domains α1 and α2 come together in a manner that creates a groove 
that acts as the peptide-binding cleft.   
The peptide binding cleft of MHC-I preferentially binds peptides with lengths of 
8-10 amino acids; however, larger class I peptides are known (Jiang, Borthwick et al. 
2002).  The peptide binding cleft generally interacts with particular residues of the 
peptide at the N-terminal and C-terminal.  These residues are designated as anchor 
residues and they are generally hydrophobic in nature.  It has been shown that a given 
MHC-I allele can bind more than 2000 distinct peptides. There are an estimated 105 
MHC allele molecules per cell.  It has been suggested that a particular peptide needs to 
occupy as few as 100 MHC molecules to cause a peptide specific CTL response 






















Figure 3.10 The structure of the MHC-I complex published by Fremont.   
The MHC heavy chain is in light blue, the β2-microglobulin (β2m) in green and 
the Sendai peptide from the nucleoprotein amino acids 324-332 is in dark blue 
(Fremont, Mutsamura et al. 1992). 
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Unlike the MHC-I heavy chain, which has hundreds of alleles, as discussed 
above, β2M is located on a different chromosome from the rest of the MHC molecules 
and is not considered polymorphic. This will be an important consideration as discussed 
in chapter 5 on Project Approach. β2m contains no transmembrane anchor residues and 
associates with the heavy chain through non-covalent interactions.  β2m makes contact 
with all three external domains of the MHC heavy chain and provides structural support 
to the MHC-I complex as a whole.  A type of tumor cell known as Daudi cells do not 
contain β2m and are unable to present peptides in the class I molecule, illustrating the 
importance of β2m molecule in the MHC-I complex. 
 
MHC MOLECULE NOMENCLATURE  
The molecules involved in the formation of both the MHC-I and MHC-II 
molecule are located on chromosome 6 in humans and chromosome 17 in mice.  The 
MHC molecule in humans is known as HLA for human leukocyte antigen and in mice it 
is termed H-2.  The molecules are then classified further based on the locus from which 
the gene was located.  For humans the MHC-I molecules are designated as HLA-A, 
HLA-B, and HLA-C and in mice they are labeled H-2K and H-2D.  The MHC-II 
molecule is termed HLA-DP, HLA-DQ, and HLA-DR in humans and in mice it is called 
H-2IA and H-2IE.    
The loci that encode for the MHC molecule are highly polymorphic and thus 
many MHC gene forms exist.  These different forms are known as alleles and in the 
population as a whole there are hundreds of different allelic variations of these MHC 
molecules. These MHC alleles can differ in DNA sequence up to 5%-10%, which results 
in gene products with similar yet unique structures. Any given individual is only likely to 
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express up to 6 variations of the MHC-I molecule and 12 variations of the MHC-II 
molecule.  Most individuals inherit two sets of alleles, one set from each parent.  A set of 
alleles is known as a haplotype.  With mice there is a potential for inbreeding and thus 
haplotypes are often designated along with the loci region coding for the MHC molecule.  
A superscript in the MHC designation such as H-2a, H-2b, H-2Kk, or H-IAd denotes the 
haplotype. 
 
To obtain more information about the immune system functions covered in this 
chapter and those aspects that were not covered please refer to Kuby Immunology, from 




Immune Response to HIV 
In the last chapter, I presented an overview of the immune system; in this chapter 
I hope to provide a picture of the immune response specific for HIV.  Understanding how 
the immune system naturally counteracts this viral infection will provide insight in to the 
development of an HIV vaccine.  Also in this chapter I intend to highlight the 
mechanisms HIV uses to evade the immune response. 
The first response to any viral infection comes from the cells in the innate 
immune system and the response to HIV is no different.   ‘The innate system includes 
macrophages, natural killer cells (NK cells), natural killer T cells (NK T), peripheral 
blood mononuclear cells, soluble factors produced by each of these cell types, and the 
complement system’ (Redpath, Angulo et al. 2001).  The relative contribution of these 
cells to HIV control is not fully understood.  What is known is that activation of the 
innate immune system results in the production of type 1 INF by immature dendritic cells 
(DC) (Levy 2001).  A loss of cells able to secrete INF has been associated with an 
increase in viral loads and a correlation between loss of INF secreting cells in individuals 
that proceed to AIDS compared to LTNP has been observed (Soumelis, Scott et al. 2001).  
The INF increases the expression of MHC-I and B7 on professional APC and is 
important for priming the humoral and cellular response (reviewed in (Levy 2001)).   
During a primary HIV infection (PHI) the host is able to generate an HIV specific 
humoral response.  The detection of antibodies provided the first diagnostic tests for HIV 
infection.  Unfortunately the antibodies generated during the PHI have little ability to 
control the virus.  As mentioned in the HIV pathogen chapter, the envelope proteins SU 
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and TM interact in a non-covalent manner to form an oligomer, most likely a trimer, 
which acts as the binding complex for HIV (Lu, Blacklow et al. 1995).  The non-covalent 
interaction fails to hold all the envelope proteins in this trimeric form and thus HIV SU 
proteins can disassociate from the virion.  It is believed that the antibodies generated 
during the primary infection are directed against free monomeric SU proteins and TM 
proteins left anchored to the cell or viral membrane.  When the SU and TM proteins are 
in their trimer the antibody-binding sites are not exposed and thus the antibodies are 
unable to neutralize the virus (Figure 4.1) ((Moore, Cao et al. 1995) and reviewed in 
(Burton 1997)).   
Another problem facing the development of neutralizing antibodies is that the SU 
protein is highly glycosylated.  It has been reported that this glycoprotein is by weight 
40-50% carbohydrates (reviewed in (Poignard, Saphire et al. 2001)).  Since glycosylation 
of the SU protein occurs in the exogenous pathway of the host cell, similar to host cell 
proteins, the carbohydrates mask the HIV SU protein in a shield of self-antigens.  This 
self-shield is believed to make it more difficult to develop neutralizing antibodies (Nab).  
Antibodies able to neutralize the virus take longer to appear, sometimes months or even 
years (reviewed in (Morris 2002)).  Currently there are three broadly acting Nab targets 
that have been identified, two on the SU protein, b12 and 2G12, and one on the TM 
protein, 2F5.  The antibodies that recognize these antigens are from the antibody class 
IgG.  The b12 antibody-binding site is in the region that forms the CD4 binding site.  The 
2G12 antibody-binding site has been shown to be primarily composed of carbohydrates 
particularly mannose.  The 2G12 is believed to interfere with the co-receptor binding.  
The 2F5 binding site is a linear amino acid sequence, ELDKWA.  Since these 
neutralizing antibodies are not present during the PHI they are believed to participate in 




Figure 4.1 Schematic depiction of the HIV binding complex trimer. 
The trimer is composed of three SU (gp120) and three TM (gp41) proteins.  The 
three known neutralizing antibody sites are b12, 2G12, and 2F5.  (Modified from 
(Burton 1997)) 
 
Since the antibody response is ineffective, it would presumably be the cellular 
response that causes the drastic down slope in the peak viral load. The graph below, 
Figure 4.2, was taken from Andrew McMichael’s article in Nature 2001, but Dr. 
Wilson’s group out of Sydney conducted the original work (Wilson, Ogg et al. 2000; 
McMichael and Rowland-Jones 2001). I have included this graph to demonstrate the 
host’s ability to generate a strong CTL response against HIV during PHI.  On the X axis    
are days after HIV infection and the Y-axis represents two variables, on the left is the % 
of CTL’s from peripheral blood monocytes that recognize the HLA-B27 Gag263-272 
epitope as determined by MHC tetrameric studies and the right is the viral load based on 
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Figure 4.2 The CTL response compared to the viral load. 
The CTL response as shown by HIV Gag263-272 antigen specific tetramer staining 
compared to the viral load over time.   The blue bars at the top indicate when 
HAART was employed.  Taken from (McMichael and Rowland-Jones 2001) with 
the original work being conducted by (Wilson, Ogg et al. 2000). 
 
the copies of RNA per ml.   The blue bars at the top of the graph indicate treatment with 
HAART.  At the start of the infections there is a sharp increase in the viral load (red line) 
peaking around week 5 at over 2 million copies/ml.  But after the peak there is an equally 
sharp decrease in the viral load beginning prior to the start of HAART.  This decrease 
appears to correspond with the appearance and peak of HIV specific CTLs (maroon line).  
These effector CTLs begin to show around the third week of infection and peak during 
the seventh week.  Shortly after the viral load decreases, due to the lytic activity of the 
CTL there is a decrease in the HIV specific CTLs.  The CTL count further decreases 
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when HAART is started in the 9th week. When HAART is interrupted from about the 
200-250 day there is a minor increase in the viral load.  More importantly, however, there 
is a sharp increase in the HIV specific CTLs, demonstrating a strong CTL memory 
response that is able to keep the viral replication in check.  Thus, the memory CTL 
response is important during the SHI.     
Over time the pressure exerted by the CTL response and later by the antibody 
response begins to waver as escape mutants start to appear.  The development of these 
mutants can be traced back to two fundamental aspects about HIV, first, that HIV’s RT 
protein does not possess proofreading capabilities and second that the primary receptor 
for HIV is the CD4 molecule.  It is estimated that RT’s failure to proofread causes 1 
mutation in the HIV genome every cycle (reviewed in (Johnson and Desrosiers 2002)).  
This may not seem like much, but given that an infected individual produces HIV 
particles at a rate estimated between 107 and 108 virions per day, this would lead to 
enormous diversity (Ho, Neumann et al. 1995; Wei, Ghosh et al. 1995).  Furthermore, it 
has been shown that within an infected individual the DNA coding for the Env 
polyprotein can vary in sequence up to 10%. This diversity becomes a problem as the 
CD4+ cell count decreases.  Since HIV primarily infects the CD4+ TH-cells, as the host 
cell’s CTL response destroys these cells, they slowly become depleted (Figure 1.2).  
Without the CD4+ TH-cells, naïve B-cells and T-cells fail to receive the co-stimulatory 
signals they need to properly differentiate and proliferate (Champagne, Ogg et al. 2001). 
Not only does HIV evade the immune response by generating mutations in 
potentially antigenic areas, but they also have evolved a way to evade detection.  As 
mentioned in the HIV pathogen chapter, HIV’s Nef protein down-regulates the surface 
expression of MHC-I and CD4 molecules and up-regulates the expression of the FASL 
(Xu, Screaton et al. 1997; Collins, Chen et al. 1998; Fackler and Baur 2002).  These 
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functions both hide the HIV infected cell from the CTL response and destroy CTLs that 
recognize HIV infected cells.  Most interesting is that Nef specifically down-regulates 
classical MHC-I molecules, HLA-A and HLA-B, but not HLA-C and non-classical 
HLA-E.  Not discussed in the immune system review was the activation of natural killer 
cells (NK), which have been shown to lyse cells not expressing HLA-C and HLA-E, 
(reviewed in (Biassoni, Cantoni et al. 2000)). Thus, by not down-regulating HLA-C and 
HLA-E the HIV infected cell avoids the effect of the NK cells.  
The Tat protein also participates in the evasion process by down-regulating the 
MHC-II molecule (Kanazawa, Okamoto et al. 2000) Down-regulation of MHC-II 
molecules is not a concern in TH-cells but presents a problem for macrophages. The 
macrophage, one of the antigen presenting cells, expresses low levels of CD4 and is 
therefore susceptible to HIV infection.  Down-regulation of the MHC-II molecule should 
result in a decrease in antigen presentation to TH-cells.  
 Perhaps HIV’s most effective way of avoid the immune system is its ability to 
infect resting memory TH-cells.  After HIV has inserted its proviral DNA into the host 
genome it remains silent until the cell becomes active.  During this silent phase, HIV 
does not produce proteins and thus remains completely undetectable.  The only difference 
between an infected memory cell and an uninfected memory cell is the addition of 10 Kd 
to the total genomic mass, due to the proviral DNA.  This makes it a very hard target for 
anti-viral drugs.  Resting memory T-cells in uninfected persons have a mean survival of 5 
months but HIV infected memory T-cells are believed to have a half-life of 44 months 
(reviewed in (Blankson, Persaud et al. 2002)).  When these cells do become active it is 
likely that they will be lysed but not before infecting a new set of resting T-cells, thus 





Since there is an obvious need for a vaccine against HIV that can prime the 
cellular arm of the immune system, our lab has looked at various ways to accomplish this 
goal.  (Pollack, Zhan et al. 1997; Buseyne, Chaix et al. 1998; Riviere and Buseyne 1998; 
Rowland-Jones, Dong et al. 1999; Wasik, Wierzbicki et al. 2000; Buseyne, Le Gall et al. 
2001; Kaul, Rowland-Jones et al. 2001; Rowland-Jones, Pinheiro et al. 2001)  One of the 
more promising methods we have developed involves the tethering of a viral epitope to 
the N-terminus of the β2-microglobulin (β2m) via a small flexible linker.  Recall that β2m 
is the highly conserved structural protein in the MHC-I complex and that the MHC-I 
complex has the task of presenting epitopes to the cytotoxic T lymphocytes.  Upon 
looking at the structure of the MHC-I complex, Figure 3.9, it became apparent that the 
C-terminus of the viral epitope was in line with the N-terminus of β2m.  From this 
observation it was postulated that by linking the two, one could present viral specific 
epitopes to the cellular immune system in the context of the MHC-I complex (Figure 
5.1).   
   A detailed description of the rationale behind the idea can be found in Dr. James 
Caras’s dissertation (Caras 1999).  Briefly, it had been known for years that exogenous 
peptides could exchange with native peptides associated with the MHC-I molecule (Chen 
and Parham 1989).   Also it had been shown that mice previously vaccinated with 
synthetic exogenous viral specific peptides could protect the mice from a lethal viral 
challenge (Kast, Roux et al. 1991).  The peptide used was defined as an immunodominant 







Figure 5.1 Depiction of the presumed β2m-viral epitope exchange processes. 
Presumably the β2m linked to a viral peptide could exchange with native peptide 
and β2m.  Once exchange occurs the viral peptide present in the context of the 
MHC-I complex would stimulate CTLs to proliferate. 
 
as potential vaccines had also been examined to protect sheep from bovine leukemia 
virus, a retrovirus (Hislop, Good et al. 1998).  Four of the eight sheep immunized showed 
the desired CTL response even in the absence of a detectable antibody or CD4+ TH-cell 
response. Presence of proviral DNA was used as a measure of protection; sheep showing 
the desired CTL response were void of proviral DNA, whereas both sheep that displayed 
no CTL response and unvaccinated sheep showed detectable amounts.  It should be 
noted, however, that peptides are very rapidly cleared from the bloodstream, greatly 
limiting their potential as effective vaccines. 
There was also literature available showing that β2m in serum readily exchanged 
with β2m bound to the side of the MHC-I molecule (Bernabeu, van de Rijn et al. 1984).   
“The separate evidence demonstrating both peptide and β2m exchange, as well as the 
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perceived spatially proximal and complementary ends of the displayed peptide and bound 
β2m, led to the postulation of a novel vaccine comprised of a viral CTL epitope linked by 
a short peptide linker to β2m.  This construct could therefore present a viral antigen to 
cytotoxic T-lymphocytes by exchanging with native β2m and peptide bound to cell-
surface MHC I, thereby directly priming the cytotoxic immune response for subsequent 
protection against the virus” (Caras 1999). 
 The model system chosen to test the vaccine efficacy was the protection of mice 
from a lethal Sendai virus challenge.  The Sendai virus is an enveloped negative-stranded 
RNA virus that belongs to the Paramyyxoviridae family and Paramyxovirus genus.  
Other members of this genus included the human parainfluenza virus type 1 and type 3 as 
well as the bovine parainfluenza virus type 3.  The approximate 15,500 nucleotide 
genomic RNA of the Sendai virus encodes for 6 unique genes: nucleocapsid protein (NP), 
phosphorylated nucleocapsid-associated protein (P), large nucleocapsid-associated 
protein (L), nonglycosylated matrix protein (M), hemagglutinin-neuramindase 
glycoprotein (HN), and the fusion glycoprotein (F).  In addition to these 6 genes, 6 other 
variations of the P protein exist and are referred to as C, C′, Y1, Y2, V, and W. (Lamb 
1996) The first four variations C, C′, Y1 and Y2 are generated when alternative 
translational start codons slightly up stream or down stream of the P protein start site are 
utilized.  The use of these start codons results in mRNA in the +1 open reading frame in 
relationship to the P protein mRNA.  The remaining two variations of the P protein come 
about when one or two additional G nucleotides are inserted due to as a result of the RNA 
polymerase “stuttering” in a short repeat of C nucleotides.   These additional P gene 
products can be found in an infected cell but not in the Sendai virion. (Lamb 1996) 
 The Sendai virion is spherical in shape with a diameter of approximately 150 to 
350 nm.  The virion consists of two sections, the other envelope and the helical 
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nucleocapsid.  Separating the two sections is a layer of the M protein. The other envelope 
is made up of the previous host’s lipid bilayer, the HN protein and the F protein.  HN and 
F are responsible of adhesion and cell entry.  The helical core is composed of the 
negative stranded RNA genome and approximately 2600 copies of NP, 300 copies of P 
and 50 copies of L (Lamb 1996).   After the virus has infected a cell the NP, P, and L 
proteins come together to former the RNA transcriptase, which is responsible for 
transcribing and replicating the negative stranded RNA. 
Although the Sendai virus is a negative stranded RNA virus and not a retrovirus 
similar to HIV, there are some features of this virus that make it a good model to test out 
the vaccine.  First like HIV, protection from the Sendai virus requires a strong CTL 
response.  Second, a well-characterized immunodominant CTL epitope from the NP 
protein is known (Kast, Roux et al. 1991).  Third, a lethal dose of Sendai virus could kill 
unprotected mice within 2-3 weeks.  Finally, the virus is non-transferable to humans. 
Dr. Caras performed the initial work towards this goal.  He tethered the 
immunodominant CTL epitope (NP324-332) from the Sendai virus nucleocapsid protein 
(Kast, Roux et al. 1991) to the N-terminus of β2m via a flexible 21 amino acid (AA) 
linker using extension PCR.  He then cloned and expressed the construct in E. coli.  After 
purifying the protein, he demonstrated that the recombinant protein was able to exchange 
with native β2m on the surface of EL-4 cells in vitro (Figure 5.2).  He showed that the 
construct was able to stabilize the MHC-I complex on the surface of RMA-S cells (Figure 
5.3).  Finally, Caras showed that the construct could stimulate viral specific T-cell 




















Figure 5.2  Cell surface binding/exchange of β2mS. 
Taken from Dr. Caras' Dissertation (Figure 33). RMA (H-2Kb) cells were 
incubated with 125I-radiolabeled β2mL21SE (β2mS) in a serum free media. Cells 
were washed and the radioactivity was measured in a gamma counter.  A half 
saturating concentration of ~1 µg/ml and a maximum binding concentration of ~2 

































Figure 5.3  Upregulation of MHC Expression. 
Taken from Dr. Caras' Dissertation. RMA-S cell were incubated with 100 µM 
β2mL21SE (β2mS), the Sendai NP peptide, or mouse β2m.  Cells were then 
labeled with anti-mouse MHC heavy chain and the mean fluorescence was 



























Figure 5.4  T-cell hybridoma stimulation assay. 
Taken from Dr. Caras' dissertation (Caras 1999).  EL-4 cells were first incubated 
with equal molar amounts of either β2mL21SE (B2mS) or the Sendai NP peptide 
to allow for the exchange with native β2m and peptide or just the peptide alone.  
These target cells were then incubated with T-cell hybridomas (M3 and B3) 
reactive to the Sendai epitope.  The ability to stimulate the hybridomas was 
determined by monitoring the release of IL-2 in the supernatant by a standard 
sandwich ELISA. 
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The overall conclusion from Caras’ work was that the β2m- 21 AA linker- Sendai 
epitope fusion protein could exchange with native β2m and peptide and trigger the release 
of IL-2 from viral specific T-cell hybridomas, in vitro.  Since the vaccine was less 
efficient at stimulating the hybridomas than the peptide alone it was speculated that the 
linker might be interfering with the TCR binding to the MHC-I molecule.  Caras chose 
the length of the linker by adding a few amino acids to the minimum length that was 
needed to fuse the C-terminus of Sendai epitope to the N-terminus of β2m, based on 
molecular modeling he performed using the published crystal structure data (Fremont, 
Mutsamura et al. 1992).  
At about the same time that Caras was performing the initial work on the β2m 
peptide vaccine, Dr. Barber’s lab at the University of Toronto published an article in 
1998 in the Journal of Immunology that showed that both cells pulsed with a recombinant 
fusion protein of human β2m tethered via 12 AA to a H-2Db-restricted immunodominant 
epitope from influenza virus NP and cells transfected with a plasmid encoding β2m 
linked via 8 AA to a H-2Kd-restricted influenza NP epitope could function as target cells 
in a chromium release assay with splenocytes from influenza infected mice (Uger and 
Barber 1998). However, neither Caras nor Uger examined the effect of linker sizes on 
TCR recognition.  But more importantly neither group assayed the ability of the β2m 
fusion vaccine to trigger an immune response in vivo or its ability to provide protection 
from a viral challenge.  Both the effect of linker size and the vaccine's protective qualities 
as either a recombinant protein expressed in E. coli or as part of a mammalian expression 







Figure 5.5 The presumed effect linker size has on T-cell receptor recognition of the 
MHC-I molecule. 
 
One can imagine that the linker could interfere with the TCR’s interaction with 
the MHC-I molecule in the following manner (Figure 5.5).  If the linker was too large one 
might expect that a bulge could develop near the C-terminus of the Sendai epitope thus 
causing interference with viral specific T-cell hybridoma recognition.  If the linker was 
too small one might expect that the Sendai epitope would be unable to set appropriately 
in the MHC heavy chain groove.  Given that Caras chose a length that was above his 
predicted length, I was charged with engineering two additional β2m Sendai epitope 
fusion proteins: one with a 15 AA linker and the other with a 10 AA linker. Once the best 
linker size was determined it would be tested in vivo to see if it could elicit a viral 
specific CTL immune response and protect against a lethal viral challenge.  
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 In addition to the potential of peptide vaccines, much work has been published on 
the potential of naked DNA to stimulate the cytotoxic T-lymphocyte portion of the 
cellular immune response in both animals and humans.  Wolff et al., 1990, demonstrated 
that naked DNA encoding standard marker genes such as beta-galactoside or luciferase 
could produce detectable protein up to two months after injection into muscles of mice 
(Wolff, Malone et al. 1990).  Then in 1993, Ulmer, et al, showed that mice vaccinated 
intramuscularly with a plasmid expressing the influenza A nucleocapsid protein was able 
to protect mice against a lethal challenge of influenza A (Ulmer, Donnelly et al. 1993).  
Also that same year, Robinson, et al. showed that a plasmid expressing the influenza 
haemagglutinin protein was able to protect 50% of vaccinated chickens from a lethal 
challenge of influenza (Robinson, Hunt et al. 1993).  Since these initial studies many 
other labs have shown the protective potential of DNA vaccines. (Barouch, Santra et al. 
2000; Johnson, Conway et al. 2000; Shata and Hone 2001; van Rooij, Glansbeek et al. 
2002)   
 A proposed mechanism by Gregersen as to how the DNA vaccine could elicit a 
CTL response is depicted in Figure 5.6 (Gregersen 2001).   In this model, injected naked 
DNA is taken up by the muscle cell, which then expresses the protein encoded by the 
plasmid.  At this point the translated protein could get tagged for degradation, processed 
via the cytosolic pathway, and be presented in the MHC-I complex to CD8+ T-cells.  
Alternatively the protein may be secreted or released in to the extracellular fluids.  There 
professional antigen presenting cells, such as macrophages or dendritic cells, would be 
able to endocytose the protein and present epitopes to CD4+ T-helper cells via the 
endocytic pathway.   Presentation to the T-helper cells would cause the secretion of 









Figure 5.6 A proposed mechanism showing how a DNA vaccine could elicit an immune 
response. 
  Modified from Fig. 1 Gregersen, 2001 (Gregersen 2001) and described in text. 
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 Given the promising results from DNA vaccine studies of others, it was believed 
that the β2m-viral fusion construct with minimal modifications could be ideal as a DNA 
vaccine.  The primary modification to the original design of the plasmid construct used 
for production of the tripartite fusion peptide vaccine in E. coli was adding a eukaryotic 
signal peptide that would direct the translation of the fusion protein directly into the 
endoplasmic reticulum of recipient cells.  This was done because degradation in the 
cytosol was thought to be unwanted and unnecessary for association with the MHC heavy 
chain.  Since the optimal linker size had not been determined, I was given the opportunity 
to develop the DNA vaccine with the β2m-viral epitope-signal peptide fusion construct 
utilizing three different linker sizes: 10 AA, 15 AA, and 21 AA.   Again, once the best 
linker size had been determined in vitro, the vaccine would be assayed in vivo for its 
ability to generate a viral specific CTL response and its capacity to protect against a 





β2m-Sendai Epitope Vaccine as a Recombinant Protein 
PEPTIDE VACCINE CONSTRUCT DESIGN AND CLONING 
The design of the β2-Microglobulin-Sendai Epitope peptide vaccine involved the 
fusion of β2-microglobulin (β2m) to the immunodominant CTL epitope of the Sendai 
virus nucleocapsid protein (NP). The Sendai epitope was taken from NP amino acids 
324-332 (FAPGNYPAL), which had been reported to be the most immunogenic region 
of the virus (Kast, Roux et al. 1991). In order for the Sendai epitope to load correctly into 
the MHC heavy chain, a spacer linking the N-terminal of β2m to the C-terminal of the 
Sendai virus NP epitope was required.  The optimal length of the linker was unknown, so 
three linker sizes were chosen: 10, 15 and 21 amino acids (AA).  Linkers were composed 
of glycines and serines to provide flexibility and low immunogenicity. For ease of 
purification an N-terminal poly-histidine tag was added.  An enterokinase site was also 
included to allow for removal of the poly-histidine tag and to ensure that the N-terminal 
of the fusion protein was the first AA residue of the Sendai epitope. 
 
Cloning of β2-microglobulin-Sendai epitope vaccine with a 21 AA linker and a poly-
histidine tag (β2mL21SEHT) 
The design and cloning of the β2-microglobulin-Sendai vaccine with a 21 AA 
linker (β2mL21SEHT) is described in detail in Dr. Jamie Caras’ Dissertation, 1999;  
therefore, it will not be discussed in detail in this writing (Caras 1999).  The end result 
was a pET-21a plasmid (Novagen) with an insert coding for β2m-L21 amino acid linker-
Sendai epitope (NP324-332) – poly-histidine tag.  In Dr. Caras’s dissertation  β2mL21SEHT 
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                                                    Poly-Histidine Tag   
                              M  G   H  H  H  H   H  H  S   S  E  L 
  1 atctggccca gccggcccag catatgggcc atcatcatca tcatcatagc agcgagctca 
            Sfi I              Nde I                              Sac I 
 
     Enterokinase Site ↓  Sendai NP(324-332) Peptide 
    I  D  D  D   D  K  F   A  P  G   N  Y  P  A   L  G  G   G  G  S   
 61 tcgacgacga cgacaagttc gctccgggta actacccggc tctgggaggt ggcggatccg 
                                                                  Bam HI 
  
                   Flexible Linker                     
    G  G  G  G   S  G  G   G  G  S   G  G  G  G   S  G  I   Q  K  T   





    P  Q  I  Q   V  Y  S   R  H  P   P  E  N  G   K  P  N   I  L  N   





    C  Y  V  T   Q  F  H   P  P  H   I  E  I  Q   M  L  K   N  G  K    





    K  I  P  K   V  E  M   S  D  M   S  F  S  K   D  W  S   F  Y  I   





    L  A  H  T   E  F  T   P  T  E   T  D  T   Y  A  C  R   V  K  H   





    A  S  M  A   E  P  K   T  V  Y   W  D  R  D   M  &  S   A  & 
420 ccagtatggc cgagcccaag accgtctact gggatcgaga catgtgatca gcatcatgat 
 
     
481 gctcggaaga aagcttatcg ataccgtcga cctcgagggg gggcccggta cccaattcgc 
            Hind III         Sal I    Xho I 
 
 
541 cctatagtga gtcgtatta 
          T7 terminator primer 
 
Figure 6.1 The sequence of β2mL21SEHT. 
Taken from Dr. Caras’s dissertation (1999) ‘Figure 26:  Nucleic acid and protein 
sequence of β2mS construct.’ 
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 is referred to as β2mS; however, throughout this presentation it will have the 
abbreviation of β2mL21SEHT to distinguish it from both the peptide vaccine constructs 
with other linker sizes and the DNA vaccine constructs. Figure 6.1 gives the construct 
DNA sequence and protein sequence; and highlights the various segments of the 
construct.  Restriction digestion sites are underlined and an arrow identifies the location 
of the enterokinase cut.  The flexibility to exchange epitopes was integrated into the 
construct by surrounding the region coding for the epitope with a Sac I and a BamH I 
endonuclease site. 
 
Cloning of β2-microglobulin-Sendai epitope vaccine with a 10 or 15 AA linker and a 
poly-histidine tag (β2mL10SEHT, β2mL15SEHT) 
Dr. Caras obtained a pBluescript-SK vector coding for the murine 
β2-microglobulin (pSK-β2m) from Dr. Stanley Nathenson at the Albert Einstein College 
of Medicine of Yeshiva University. (Sakita, örig et al. 1996).  This was also used in the 
current work.  For the generation of β2-microglobulin-Sendai epitope vaccine with a 10 
or 15 amino acid linker and a poly-histidine tag, β2mL10SEHT and β2mL15SEHT, 
respectively, this pSK-β2m acted as the initial template in a two-step extension PCR.  For 
each PCR reaction, the T7 terminator primer was used as the downstream primer.  The 
first extension primer overlapped 18 nucleotides on the N-terminal of β2m in the 
pSK-β2m plasmid and added the linker of 10 or 15 AA. The second primer annealed to 
the linker and added the Sendai epitope and enterokinase site (Figure 6.2).  A byproduct 
of the PCR reactions was the addition of adenosine nucleotides to the 3′ ends of the 
amplified product.  This byproduct allowed for direct ligation of the purified PCR 
product 2 into the pCRT7/NT TOPO vector (Invitrogen).  The vector encodes for its own 






Figure 6.2  Peptide vaccine construct design. 
A) Schematic depiction of the extension PCR used to constructed the 
β2mL10SEHT and β2mL15SEHT peptide vaccines.  The first extension PCR adds 
the linker to the N-terminal of β2m; the second PCR adds the Sendai epitope and 
enterokinase site. B) A color-inverted digital image of a 1% agarose gel showing 
the increase in β2mL15SEHT construct size from PCR1 to PCR2.  The 
downstream primer and upstream primers were at a final concentration of 0.3µM.  
The PCR reaction was set at 94.0°C for 5 min, then cycled for 30 times from 
94.0°C for 45s -> 55.0°c for 45s -> 72.0°C for 60s.  The template for the first 
reaction was the pSK-β2m plasmid, while the templates for the second PCR 
reactions was the gel-purified product from the previous PCRs. 
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site does not cut at the N-terminal of the Sendai epitope, which was why an additional 
enterokinase site was added during PCR 2.  The plasmids were transformed into and 
cloned in TOP10F’ cells (Invitrogen).  The cells were allowed to recover in (SOC) before 
being plated on LB/Agar plates with ampicillin.  Using a PCR reaction, colonies were 
screened for the inserted vector (Figure 6.3). The plasmids were isolated from colonies 
showing the insert and then purified before being sequenced at the University of Texas 
Sequencing Center. Figures 6.4 and 6.5 give the construct DNA and protein sequences 
for β2mL10SEHT and β2mL15SEHT, respectively.  Highlighted are the various segments 
of the construct, such as the poly-histidine tag, the enterokinase sites, the Sendai epitope, 
the linker and the murine β2m.  Restriction digestion sites are underlined and an arrow 
identifies the location of the enterokinase cut.   
 
 
Figure 6.3 Colony PCR screen for β2mL10SEHT. 
A color-inverted digital image of a 1% agarose gel with the products of a colony 
PCR screen for β2ML10SESP.  β2ML10SEHT was transformed into TOP10F’ 
cells by heat shock at 42°C for 45 seconds.  Cells were allowed to recover in SOC 
for 1 hour and then plated on LB plates containing 60 µg/ml ampicillin.  With a 
toothpick individual colonies were chosen and then screen by PCR for the insert.   
C1-C10 correspond to the 10 colonies selected.  PCR2 is the purified product 
from the second extension PCR for β2ML10SEHT.  MW is a DNA ladder. 
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 Poly Histidine Tag 
1 11 21 31 41 51 61 
 F  P S R N N F V  # L  # E G D I H M  R G S H H H 
TTT/CCC/TCT/A GA/AAT/AAT/TT T/GTT/TAA/CTT/ TAA/GAA/GGA/G AT/ATA/CAT/AT G/CGG/GGT/TCT/ CAT/CAT/CAT/C 
 Xba I Nde I 
  Enterokinase site from vector 
71 81 91 101 111 121 131 
H H  H G  M A S M T G  G  Q Q M G R  D L  Y D D  D D K 
AT/CAT/CAT/GG T/ATG/GCT/AGC/ ATG/ACT/GGT/G GA/CAG/CAA/AT G/GGT/CGG/GAT/ CTG/TAC/GAC/G AT/GAC/GAT/AA 
 Nhe I 
 Enterokinase site Inserted Sendai Epitope 
141 151 161 171 181 191 201 
 D P T L  S S E L I D D  D D K F A P G  N Y  P A L 
G/GAT/CCA/ACC/ CTT/AGC/AGC/G AG/CTC/ATC/GA C/GAC/GAC/GAC/ AAG/TTC/GCT/C CG/GGT/AAC/TA C/CCG/GCT/CTG/ 
 BamH I Sac I 
 
 10 Amino Acid Linker β2-microglobulin 
211 221 231 241 251 261 271 
G G G G S G  G  G  S G I Q K  T P Q I Q V Y S  R H  
GGA/GGT/GGC/G GA/TCC/GGT/GG C/GGA/AGC/GGA/ ATC/CAG/AAA/A CC/CCT/CAA/AT T/CAA/GTA/TAC/ TCA/CGC/CAC/C 
 BamH I 
β2-microglobulin 
281 291 301 311 321 331 341  
P P  E N  G K P  N I  L N  C Y V T Q  F H  P P H I E I 
CA/CCG/GAG/AA T/GGG/AAG/CCG/ AAC/ATA/CTG/A AC/TGC/TAC/GT A/ACA/CAG/TTC/ CAC/CCG/CCT/C AC/ATT/GAA/AT 
 
β2-microglobulin 
351 361 371 381 391 401 411 
 Q M L K N G K K I P K  V E M S D  M S  F S K D  W  
C/CAA/ATG/CTG/ AAG/AAC/GGG/A AA/AAA/ATT/CC T/AAA/GTA/GAG/ ATG/TCA/GAT/A TG/TCC/TTC/AG C/AAG/GAC/TGG/ 
 
β2-microglobulin 
421 431 441 451 461 471 481   
S F Y I L A H T E F  T P T E T D T Y A C R V K  
TCT/TTC/TAT/A TC/CTG/GCT/CA C/ACT/GAA/TTC/ ACC/CCC/ACT/G AG/ACT/GAT/AC A/TAC/GCC/TGC/ AGA/GTT/AAG/C 
 
 β2-microglobulin 
491 501 511 521 531 541 551 
H  A  S  M   A E P K T  V  Y  W D R D M  & S  A S & C S E   
AT/GCC/AGT/AT G/GCC/GAG/CCC/ AAG/ACC/GTC/T AC/TGG/GAT/CG A/GAC/ATG/TGA/ TCA/GCA/TCA/T GA/TGC/TCT/GA 
 Bcl I  
 
561 571 581 591 
 E S  L S  I P S T S R G G P  V P N S P  Y S  E S Y 
A/GAA/AGC/TTA/ TCG/ATA/CCG/T CG/ACC/TCG/AG G/GGG/GGC/CCG/ GTA/CCC/AAT/T CG/CCC/TAT/AG T/GAG/TCG/TAT 
 Ban III Xho I Apa I 
Figure 6.4 The sequence for pCRT7/NT β2mL10SEHT. 
TOP10F’ cells were transformed by heat shock with pCRT7/NT β2mL10SEHT 
and grown overnight in 5mls of LB with 60 µg/ml ampicillin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
reverse primer. The sequence is reported here in the 5’-3’direction. 
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Enterokinase site from vector Enterokinase site inserted Sendai Epitope 
1 11 21 31 41 51 61 
D D D D K D P T  L S S E L I D  D D  D K F A  P G 
GAC/GAT/GAC/G AT/AAG/GAT/CC A/ACC/CTT/AGC/ AGC/GAG/CTC/A TC/GAC/GAC/GA C/GAC/AAG/TTC/ GCT/CCG/GGT/A 
 BamH I Sac I 
Sendai Epitope 15 Amino Acid Linker 
71 81 91 101 111 121 131 
N Y  P A L G G G G  S  G G G G S G G G G S  I Q K T 
AC/TAC/CCG/GC T/CTG/GGA/GGT/ GGC/GGA/TCC/G GT/GGC/GGA/GG A/AGC/GGC/GGA/ GGT/GGC/AGC/A TC/CAG/AAA/AC 
 BamH I 
β2-microglobulin 
141 151 161 171 181 191 201 
 P Q I Q V Y S R H P P  E N G K P N I L N  C Y V 
C/CCT/CAA/ATT/ CAA/GTA/TAC/T CA/CGC/CAC/CC A/CCG/GAG/AAT/ GGG/AAG/CCG/A AC/ATA/CTG/AA C/TGC/TAC/GTA/ 
 
β2-microglobulin 
211 221 231 241 251 261 271 
 T  Q F H P P H I  E I Q M L  K N G K K I P K V E  
ACA/CAG/TTC/C AC/CCG/CCT/CA C/ATT/GAA/ATC/ CAA/ATG/CTG/A AG/AAC/GGG/AA A/AAA/ATT/CCT/ AAA/GTA/GAG/A 
 
β2-microglobulin 
281 291 301 311 321 331 341 
M S D M  S F S  K  D  W S  F Y I L A  H  T  E F T P T E 
TG/TCA/GAT/AT G/TCC/TTC/AGC/ AAG/GAC/TGG/T CT/TTC/TAT/AT C/CTG/GCT/CAC/ ACT/GAA/TTC/A CC/CCC/ACT/GA  
 
β2-microglobulin 
351 361 371 381 391 401 411 
 T D T Y A C R V K H A S M A E P  K T V Y W D R 
G/ACT/GAT/ACA/ TAC/GCC/TGC/A GA/GTT/AAG/CA T/GCC/AGT/ATG/ GCC/GAG/CCC/A AG/ACC/GTC/TA C/TGG/GAT/CGA/ 
 
 
421 431 441 451 461 471 481  
 D M & S A S & C S E E S L  S I P  S T S R G G P 
GAC/ATG/TGA/T CA/GCA/TCA/TG A/TGC/TCT/GAA/ GAA/AGC/TTA/T CG/ATA/CCG/TC G/ACC/TCG/AGG/ GGG/GGC/CCG/G 
 Bcl I Ban III Xho I Apa I 
 
Figure 6.5 The sequence for pCRT7/NT β2mL15SEHT. 
TOP10F’ cells were transformed by heat shock with pCRT7/NT β2mL15SEHT 
and grown overnight in 5mls of LB with 60 µg/ml ampicillin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
forward primer. The primer bound just before the enterokinase site on the vector, 
thus for the poly-histidine tag sequence and start codon refer to the Invitrogen 
pCRT7/NT manual (Invitogen 2000).  Also additional restriction sites can be 
found there. 
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Cloning of β2-microglobulin-dummy epitope vaccine with a 15 AA linker and a poly-
histidine tag (β2mL15DMHT) 
The original attempts to exchange the epitope coding sequence for Sendai 
NP323-332 with the dummy epitope involved restriction-digesting the β2mL21SEHT with 
Sac I and BamH I, then ligating in complementary oligos, so that when annealed it 
encoded the dummy epitope with Sac I and BamH I overhangs. This method, however, 
failed.  Instead the construct for the dummy epitope was obtained by performing a one-
step extension PCR.  The template used was the pCRT7/NT β2mL15SEHT and the 
downstream primer was the T7 terminator primer.  The upstream primer was similar to 
the primer in the second PCR reaction above, except instead of encoding for the Sendai 
epitope it encoded the dummy epitope.  This PCR product was gel purified and ligated 
into the pCRT7/NT TOPO plasmid.  The plasmid was transformed into and cloned in 
TOP10F′ cells. Cells were plated on LB/Agar plates with ampicillin and were colony 
PCR screened for the insert.  (Data not shown)  The plasmid was isolated from a single 
colony and then purified before being sequenced at the University of Texas Sequencing 
core facility. Figure 6.6 gives the construct DNA sequence and protein sequence for 
β2ML15DMHT.  Highlighted are the various segments of the construct, such as the poly-
histidine tag, the enterokinase sites, the Sendai epitope, the linker and the murine β2m.  
Restriction digestion sites are underlined and an arrow identifies the location of the 





Enterokinase site from vector Enterokinase site inserted Dummy Epitope 
1 11 21 31 41 51 61 
D  D D D K D P T  L I  D D D D K  F A S I R A  L  A 
GAC/GAT/GAC/G AT/AAG/GAT/CC A/ACC/CTT/ATT/ GAC/GAC/GAC/G AT/AAG/TTC/GC A/TCT/ATA/CGT/ GCC/CTT/GCT/C  
 BamH I  
 
 15 Amino Acid Linker β2-microglobulin 
71 81 91 101 111 121 131 
L G G G G S G G G G S G G G G S I Q K T P Q I Q 
TG/GGA/GGT/GG C/GGA/TCC/GGT/ GGC/GGA/GGA/A GC/GGC/GGA/GG T/GGC/AGC/ATC/ CAG/AAA/ACC/C CT/CAA/ATT/CA  
 BamH I 
β2-microglobulin 
141 151 161 171 181 191 201 
 V Y S R H P P E N G K  P N I L N C Y V T Q F H 
A/GTA/TAC/TCA/ CGC/CAC/CCA/C CG/GAG/AAT/GG G/AAG/CCG/AAC/ ATA/CTG/AAC/T GC/TAT/GTA/AC A/CAG/TTC/CAC/  
 
β2-microglobulin 
211 221 231 241 251 261 271 
P  P H I E I Q M  L K N G K K I  P K V E M S  D  M  
CCG/CCT/CAC/A TT/GAA/ATC/CA A/ATG/CTG/AAG/ AAC/GGG/AAA/A AA/ATT/CCT/AA A/GTA/GAG/ATG/ TCA/GAT/ATG/T  
 
β2-microglobulin 
281 291 301 311 321 331 341 
S F S K D W S F Y I L A H T E F T P T E T D T Y 
CC/TTC/AGC/AA G/GAC/TGG/TCT/ TTC/TAT/ATC/C TG/GCT/CAC/AC T/GAA/TTC/ACC/ CCC/ACT/GAG/A CT/GAT/ACA/TA  
 
β2-microglobulin 
351 361 371 381 391 401 411 
 A C R V K H A S M A E  P K T V Y W D R D M & S 
C/GCC/TGC/AGA/ GTT/AAG/CAT/G CC/AGT/ATG/GC C/GAG/CCC/AAG/ ACC/GTC/TAC/T GG/GAT/CGA/GA C/ATG/TGA/TCA/  
 Bcl I 
 
421 431 441 451 461 471 481  
A  S & C S E E S  L S I P S T S  R G G P V P  N  S 
GCA/TCA/TGA/T GC/TCT/GAA/GA A/AGC/TTA/TCG/ ATA/CCG/TCG/A CC/TCG/AGG/GG G/GGC/CCG/GTA/ CCC/AAT/TCG/C  
 Ban III Xho I Apa I 
 
 
Figure 6.6 The sequence for pCRT7/NT β2mL15DMHT. 
TOP10F’ cells were transformed by heat shock with pCRT7/NT β2mL15DMHT 
and grown overnight in 5mls of LB with 60 µg/ml ampicillin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
forward primer. The primer bound just before the enterokinase site on the vector, 
thus for the poly-histidine tag sequence and start codon refer to the Invitrogen 
pCRT7/NT manual (Invitogen 2000).  Additional restriction sites can also be 
found there.  
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EXPRESSION AND PURIFICATION 
The verified plasmids were individually transformed into the BL21(DE3) vector 
and grown in LB with ampicillin. Expression was induced with IPTG for 2-4 hours 
before the cells were pelleted.  The cell pellets were lysed with 8M urea and the cell 
debris was removed by centrifugation.  The protein, containing the poly-histidine tag, 
was bound to a denatured Ni-NTA column and then eluted by lowering the pH.   The 
protein was then refolded in a two-step dialysis in which the urea concentration was 
dropped from 8M to ~ 4M and then to ~ 30 mM.  The poly-histidine tag was cut off the 
protein by digesting it with enterokinase (Novagen).  Samples were then concentrated 
using a YM-3 Centricon or YM-3 Centripep (Millipore Corporation).  The purification 
process (Appendix 1) was analyzed by SDS-PAGE (Figure 6.7).  Uncut proteins were 
referred to as pβ2mL10SEHT, pβ2mL15SEHT, pβ2mL21SEHT, and pβ2mL15DMHT.  
Since the histidine tag was cut off, the final protein products were identified as 
pβ2mL10SE, pβ2mL15SE, pβ2mL21SE, and pβ2mL15DM. 
 
MHC EXPRESSION UPREGULATION / STABILIZATION 
An MHC expression upregulation experiment was performed to determine if the 
β2m-Sendai epitope fusion proteins could stabilize the MHC complex on RMA-S cells 
(Zhou, Glas et al. 1993).  The RMA-S cell line is void of TAP2, thus cytosolic peptide 
processed in the classical cytosolic pathway is unable to be shuttled across the ER 
membrane.  This leads to MHC complexes presented on the outside of the cell, consisting 
of only the MHC heavy chain and β2m.  Without the peptide in the groove of the MHC 
heavy chain, these complexes are unstable and disassociate.  The ‘empty’ MHC 
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1. Lysate supernatant
2. Load flow through
3. Wash flow through












Figure 6.7 A 15% SDS-Page gel on pβ2mL10SE vaccine purification, enterokinase 
digestion, and concentration.  
A 10 ml starter culture of LB with 60 µg/ml ampicillin was inoculated with 
BL21(DE3) cells, which had been transformed with the pCRT7/NT TOPO vector 
coding for the β2mL10SEHT protein, and grown overnight.  The starter culture 
was used to inoculate 2 six-liter flasks containing 1400 ml of LB with 60 µg/ml 
ampicillin.  The cells were grown to an OD600 between 0.7-0.8 Abs at which point 
they were induced with 1 mM IPTG.  Protein expression was allowed to continue 
for 2-3 hrs before the cells were collected by centrifugation at 4500g for 15 min.  
The cell pellet was weighed and the cells lysed with 5 times (ml/g) of Lysis 
Buffer (8M urea, 100 mM NaH2PO4, 10 mM Tris•Cl, pH=8.0).  The cell debris 
was removed from the lysate by spinning at 27000g for 30 min.  The supernatant 
(Lane 1) was loaded on to a Ni-NTA agarose column and the flow through was 
collected (Lane 2).  The column was washed with Lysis Buffer (pH=6.3) and the 
flow through was collected (Lane 3).  The protein was then eluted with Lysis 
Buffer (pH=4.5) (Lane 4).  The pH of the collected protein was raised to 8 and 
then it was refolded in a two step dialysis first with buffer A (50 mM glycine, 
10% (w/v) sucrose, 1 mM EDTA, 4 M urea, 1 mM reduced glutathione, 0.1 mM 
oxidized glutathione, pH 9.6) and then with buffer B (60 mM ethanolamine, pH 
9.6, 10% (w/v) sucrose, 1 mM EDTA, 0.1 mM reduced glutathione, 0.01 mM 
oxidized glutathione) (Lane 5).  After refolding the poly-histidine tag was 
removed by cutting with 50 U of recombinant Enterokinase (Lane 6).  The protein 
was concentrated using a YM-3 Centriprep spun at 3000g (Lane 7 = concentrated 
solution; Lane 8 = filtrate).  The purification examined with a 15% SDS-PAGE 
gel with a molecular weight marker in lane 9.   
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complexes can be stabilized on the surface of the cells if they are pulsed with class I 
peptide.  Thus, this system will allow easy determination if the Sendai peptide, at the 
N-terminal of the vaccine constructs, is properly loaded into the groove. This can be 
demonstrated by increased MHC-I (H-2Kb) staining as measured by flow cytometry. 
RMA-S cells were incubated with 50 µM purified pβ2mL10SE, pβ2mL15SE, 
pβ2mL21SE, or Sendai NP peptide: five samples each.  The cells were then stained for 
MHC upregulation using a R-PE Anti-mouse H-2Kb antibody (BD Pharmingen), which 
can be detected in the FL2 channel of the flow cytometer.  The negative controls for this 
experiment were RMA-S cells pulsed with nothing and stained for MHC-I and RMA-S 
cells pulsed with nothing and not stained with the MHC-I antibody. Samples were gated, 
after data collection, by forward scatter and side scatter measurements to isolate the live 
cells (Figure 6.8).  Notice that there are very few cells in the live cell gate for Sendai 
peptide pulsed RMA-S cell.  This concern will be addressed in the next experiment.  
Figure 6.9 presents representative stains demonstrating the shift in fluorescence 
indicative of the stabilization of the MHC-I molecule. Notice that in stained RMA-S cells 
the peak occurs close to 102, whereas in all fusion protein pulsed cells the peak shifts 
right to approximately 103. Unfortunately, there were not enough live cells in the peptide 
pulsed group to make sense of the data and thus it is not presented.  Figure 6.10 depicts 
the average of the five samples and provides the confidence level, based on Student 
t-Test analysis, at which one can state that the values were distinct from one another.  
 96
 
Figure 6.8 Live cell gate used for an MHC-I upregulation experiment. 
RMA-S cells (3.5x105) were incubate with 50 µM of the given β2m-Sendai 
epitope fusion protein, the Sendai peptide or nothing at all and grown at 30°C and 
5%CO2 for 1hr. The plate was sealed and the cells were then grown for 18-20hrs 
at 26°C.  The cells were then placed at 37°C for 5% CO2 for 2hr.  The cells were 
pelleted and washed with wash buffer (PBS with 0.1% sodium azide). Cells were 
incubated with R-PE Anti-mouse H-2Kb (BD Pharmigen) at 2.0 µg/ml in wash 
buffer for 30 min on ice.  Cells were washed twice and resuspended in 200 µl of 
wash buffer then stored on ice until analyzing the fluorescence via FACS. 
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Figure 6.9  Representative anti-mouse H-2Kb stains for MHC-I upregulation 
For protocol see Figure 6.8.  The M1 gate confines the average mean 























 No Ab RMA-s L10 L15 L21 
No Ab 0.00% - - - - 
RMA-s 98.42% 0.00% - - - 
L10 100.00% 99.99% 0.00% - - 
L15 100.00% 100.00% 93.65% 0.00% - 
L21 100.00% 100.00% 97.47% 64.61% 0.00% 
Figure 6.10 MHC-I upregulation experiment summary. 
For protocol see Figure 6.8.  Each group represents the results of five samples of 
RMA-S cells pulsed over night with 50 µM of the given β2m-Sendai epitope 
fusion protein as designated by the linker size or nothing at all.  A) Presents the 
average mean fluorescence due to PE anti-mouse H-2Kb antibody, with error bars 
designating the standard deviation.  Averages are gated by live cells and by the 
M1 gate shown in Figure 6.9. B) Gives the percent confidence level that the 
results are distinct from one another, based on Student t-Test evaluation. 
 99
Cells pulsed with the pβ2mL21SE showed the greatest mean fluorescence at 1066 
± 116, followed closely by the cells pulsed with pβ2mL15SE at 990 ± 62.  The cells 
pulsed with pβ2mL10SE had a mean fluorescence of only 753 ± 149. But with 99.99% 
confidence one can say that the fusion protein causes an upregulation of the MHC-I 
complex on the surface of the cell as compared to non-pulsed cells, 106 ± 70.  The 
average mean fluorescence of fusion protein pulsed cells was between 7-10 times more 
than unpulsed cells.  Furthermore with close to 95% confidence one can say that the 
linker sizes of 15 AA or 21 AA performed better than the linker size of 10 AA.  At only 
65% confidence, with the 21 AA linker being preferred, can one distinguish between the 
effectiveness of the 15 AA and 21 AA linkers.  
 
MHC EXPRESSION UPREGULATION / STABILIZATION WITH 7AAD 
Because of the concern associated with the lack of live cells in the peptide pulsed 
group from the above MHC-I upregulation experiment, another MHC-I upregulation 
experiment was conducted.  In this experiment 7-Aminoactinomycin D (7AAD) was 
added.  7AAD is a fluorescent dye that stains dying cells, fluoresces at 646 nM and can 
be read in channel FL3 of the flow cytometer.  Also available at the time of this 
experiment was the purified pβ2mL15DM fusion protein with the dummy epitope.  
Therefore, an upregulation experiment similar to that described above was performed 
using 50 µM of purified pβ2mL15DM or 50 µM of Sendai epitope.   To help link the two 
experiments together, a group of cells was pulsed with 50 µM of pβ2mL21SE. The 
negative controls included RMA-S cells pulsed with nothing that were stained with the 
MHC-I antibody and 7AAD, with only the MHC-I antibody or with only the 7AAD dye, 
or nothing at all. 
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From the lower 7AAD staining seen in the population of cells with the high 
forward scatter and lower side scatter (gate 1) it is clear that these cells are alive and that 
the gate used in the previous experiment was correctly around the live cells.  Notice 
increased 7AAD in the cell population with the lower forward scatter and higher side 
scatter (gate 2) (Figure 6.11).  In this experiment there were ample cells in the live cell 
gate of the peptide pulsed cells, (data not shown).  Representative stains demonstrating 
the shift in fluorescence indicative of the stabilization of the MHC-I molecule are offered 
in Figure 6.12.   The average mean fluorescence for each sample group is presented along 
with error bars showing the standard deviation (Figure 6.13).  The number of samples 
analyzed for the RMA-S No Ab, RMA-S w/Ab, Dummy, L21, and Peptide were 3,4,3,7, 
and 8, respectively. 
The cells pulsed with the pβ2mL21SE again showed the highest average mean 
fluorescence at 201 ± 28, which was approximately 10 times greater than the mean 
fluorescence of the RMA-S cells stained with antibody, 22 ± 2.  The actual mean 
fluorescence was lower than the previous experiment, but this was simply due to 
differences in the setting of the voltage or gain used when collecting the data.  Both the 
peptide and the pβ2mL15DM pulsed cells, at 49 ± 14 and 53 ± 3, respectively, showed a 
distinct upregulation of the MHC-I molecule when compared to the RMA-S cells.  
Though the values were less than the pβ2mL21SE pulsed cells, the mean fluorescence 
was still twice that of unpulsed cells. 
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Figure 6.11  RMA-S cell populations stained with 7-Aminoactinomycin D (7AAD). 
RMA-S cells (3.5x105) were grown at 30°C and 5%CO2 for 1hr. The plate was 
sealed and the cells were then grown for 18-20hrs at 26°C.  The cells were 
pelleted and washed with wash buffer (PBS with 0.1% sodium azide). Cells were 
incubated with R-PE Anti-mouse H-2Kb (BD Pharmigen) at 2.0 µg/ml in wash 
buffer for 30 min on ice.  Cells were washed twice and resuspended in 200 µl of 
was buffer then stored on ice.  4 µl of 7AAD was 10 min before analyzing the 
fluorescence via FACS. A) Density plot based on forward and side scatter results 
from un pulsed RMA-S stained with 7AAD.  Two cell population have been 
gated; one cell population, gate 1, has high forward scatter and low side scatter; 
the other population, gate 2, has a low forward scatter and higher side scatter B) 
Histogram for total 7AAD fluorescence C) Histogram for 7AAD fluorescence in 




Figure 6.12 Representative anti-mouse H-2Kb stains for MHC-I upregulation, with 
7-Aminoactinomycin D (7AAD). 
RMA-S after 7-Aminoactinomycin D staining for dead cells.  Cells were pulsed 
with 50 µM pβ2mL15DM,  Sendai peptide, pβ2mL21SE, or nothing at all.  The 
M1 gate confines the average mean fluorescence, presented in Figure 6.13, to the 

























Antibody Dummy  L21 Peptide 
RMA-S no 
Antibody 0.00% - - - - 
RMA-S with 
Antibody 79.90% 0.00% - - - 
Dummy  99.87% 100.00% 0.00% - - 
L21 100.00% 100.00% 100.00% 0.00% - 
Peptide 99.47% 99.54% 38.52% 100.00% 0.00% 
Figure 6.13 MHC-I upregulation experiment summary, with 7-Aminoactinomycin D 
(7AAD).  
For protocol see Figure 6.11  A) Presents the average mean fluorescence due to 
PE anti-mouse H-2Kb antibody, with error bars designating the standard 
deviation.  Averages have been gated by live cells and by the M1 gate shown in 
Figure 6.12. B) Gives the percent confidence level that the results are distinct 
from one another, based on Student t-Test evaluation. 
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T-CELL HYBRIDOMA STIMULATION ASSAY 
To determine which linker size would be the best to use as a vaccine, a T-cell 
hybridoma assay was performed.  Sendai specific T-cell hybridomas were obtained from 
Dr. Woodland’s lab at the Trudeau Institute (Cole, Hogg et al. 1995).  The ability of the 
vaccine to trigger a viral-specific immune response in vitro was determined by the release 
of IL-2.  Individual T-cell hybridoma clones (M2.5D10, M1.1B3, M2.2E9, or M3.4D3) 
or a combination of clones (M1.1B3, M2.2E9, and M3.4D3) were cultured with RMA-S 
cells.  The RMA-S cells had been pulsed with the peptide vaccines pβ2mL10SE, 
pβ2mL15SE, or pβ2mL21SE, or the controls pβ2mL15DM or Sendai NP peptide.  These 
cells served as the target cells in this assay.  There were also two other controls, T-cell 
hybridomas without RMA-S cells and RMA-S cells without T-cell hybridomas.   
The supernatant from these reactions were collected after 24 hours and then 
transferred to ELISA plates coated with anti-mouse IL-2 antibody (BD Pharmingen). 
After 2 hours the plates were washed and the secondary biotinylated anti-mouse IL-2 
antibody (BD Pharmingen) was added.  After 1 hour the plates were again washed and an 
avidin-horseradish peroxidase conjugate (BD Pharmingen) was added.  The reaction was 
allowed to take place for 30-60 min before being stopped.  The absorbance was read at 
450 nm and compared against a recombinant mouse IL-2 standard curve.   
The results of three different experiments are shown below. Figure 6.14 
represents the average of 4 samples of RMA-S cells incubated with M2.5D10, assayed in 
duplicate. Figure 6.15 depicts the average of 4 samples of RMA-S cells incubated with a 
combination of clones M1.1B3, M2.2E9 and M3.4D3, assayed in duplicate.  Finally, 
Figure 6.16 depicts the average of 4 samples of RMA-S cells incubated with M1.1B3, 
M2.2E9 and M3.4D3 individually or as a combination of all three, assayed in duplicate. 
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In the third experiment the M2.2E9 cells appeared unhealthy prior to the incubation with 
RMA-S cell and afterwards they looked dead.  Also the cells incubated with pβ2mL15SE 
and pβ2mL15DM were found dead.  In the third experiment pβ2mL15SE and 





























Figure 6.14 T-cell hybridoma stimulation with M2.5D10 clone. 
RMA-S cells (3x105 cells/well) were incubated with 50µM of the vaccine or 
control at 30°C and 5%CO2 for 1hr. The plate was sealed and the cells were then 
grown for 18-20hrs at 26°C.  Cells were pelleted and 4.5 x105 cells of M2.5D10 
were added to each well. The RMA-S cells and hybridomas were allowed to react 
for 18-24 hours at 37°C and 5%CO2.  The supernatant was then assayed for IL-2 
using the protocol outlined in the OptEIA Mouse IL-2 Set (BD Pharmingen). 
Given is the average of 4 samples of RMA-S cells assayed in duplicate. L21, L15 
and L10 represent the peptide vaccines with the corresponding linker size. T-cell 
only and RMA-S cells are the results from unstimulated M2.5D10 alone and 


















Figure 6.15 T-cell hybridoma stimulation with a mixture of hybridoma clones.  
RMA-S cells (3x105 cells/well) were incubated with 50µM of the vaccine or 
control at 30°C and 5%CO2 for 1hr. The plate was sealed and the cells were then 
grown for 18-20hrs at 26°C.  Cells were pelleted and 4.5 x105 cells consisting of a 
mixture of M1.1B3, M2.2E9 and M3.4D3 was added to each well. The RMA-S 
cells and hybridomas were allowed to react for 18-24 hours at 37°C and 5%CO2.  
The supernatant was then assayed for IL-2 using the protocol outlined in the 
OptEIA Mouse IL-2 Set (BD Pharmingen). Given is the average of 4 samples of 
RMA-S cells assayed in duplicate. L21, L15 and L10 represent the peptide 
vaccines with the corresponding linker size.  DUM signifies the dummy epitope 
control vaccine and PEP is the results from the Sendai epitope.  T-cell and 


























Figure 6.16 T-cell hybridoma stimulation with individual hybridoma clones. 
RMA-S cells (3x105 cells/well) were incubated with 50µM of the vaccine or 
control at 30°C and 5%CO2 for 1hr. The plate was sealed and the cells were then 
grown for 18-20hrs at 26°C.  Cells were pelleted and 4.5 x105 cells of M1.1B3, 
M2.2E9 and M3.4D3 individually or as a combination of all three, were added.  
The RMA-S cells and hybridomas were allowed to react for 18-24 hours at 37°C 
and 5%CO2.  The supernatant was then assayed for IL-2 using the protocol 
outlined in the OptEIA Mouse IL-2 Set (BD Pharmingen). In this experiment the 
M2.2E9 cells appeared unhealthy prior to the incubation with RMA-S cell and 
afterwards they looked dead.  The cells incubated with pβ2mL15SE and 
pβ2mL15DM were also found dead.  In this experiment pβ2mL15SE and 
pβ2mL15DM were not concentrated enough so the cells were unable to survive in 
the diluted media.  The values represent for samples assayed in duplicate. 
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 The positive result obtained from these experiments was that the peptide vaccines 
could stimulate viral specific T-cell hybridomas, in vitro. The obvious negative 
conclusion was that the T-cell hybridoma stimulation assay could not be used to 
determine which linker size to use. The data taken as a whole shows that recognition of 
peptide vaccines depends on the T-cell hybridoma involved.  The M2.5D10 clone, Figure 
6.14, was unable to recognize any of the vaccines.  The M1.1B3 clone preferentially 
recognized the pβ2mL10SE and released 680 pg/ml IL-2 (Figure 6.16).  The M3.4D3 
clone preferred the pβ2mL21SE vaccine and secreted 1770 pg/ml IL-2, Figure 6.16.  The 
difference in each clone's ability to recognize the vaccines can be explained by the 
tolerance they exhibit towards AA substitution in the Sendai epitope sequence.  Table 6.1 
was complied from data published by Cole, 1995 (Cole, Hogg et al. 1995).  The data 
clearly shows that T-cell hybridoma clones have different tolerance for variations in the 
wild type Sendai epitope sequence.  Notice that the M2.5D10 clone, which was unable to 
recognize the vaccines, was stringent in its requirement for an alanine residue at position 
8.  This position is near the C-terminal of the epitope, where the linker attaches in our 
vaccine candidates.  
 
IN VIVO STIMULATION OF SENDAI SPECIFIC IFN-γ CELLS 
Because of the mixed results in distinguishing which linker size was optimal in 
the T-cell hybridoma stimulation experiment it was determined that the best solution 
would be to test all the fusion proteins in vivo.  Therefore, two in vivo trials were 








Sendai Epitope = F A P G N Y P A L  




F1 G4 N5 A8 
M2.5D10 A,D,G,H,I,K,N, 
L,P,Q,R,S,V,Y 
Must be G4 G E,S,Q 
M1.1B3 A,D,Q H,Y Must be N5 D,F,H,I,K,N,L, 
P,Q,R,T,V,Y 
M2.2E9 No Data No Data No Data No Data 
M3.4D3 No Data No Data No Data No Data 
 
 
Table 6.1:  T-cell hybridoma clone tolerance for variations in the wild type Sendai 
epitope.   
The table was complied from data published by Cole, 1995 (Cole, Hogg et al. 
1995).  The wild type Sendai epitope AA sequence is given at the top of the table 
with its corresponding position. Expectable substitution for residues F1, G4, N5 
and A8 are given.  Unfortunately no data was available for hybridoma clones 
M2.2E9 and M3.4D3. 
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Traditional method with peptide vaccines 
Five 7-10 week old C57BL/6 (H-2Kb) mice (Charles River Laboratories) were 
injected intramuscularly (IM) on day 0, 7, and 14 with a solution of TiterMax Gold 
(CytRx) and either 150 µg of the peptide vaccines, control vaccine, the Sendai epitope or 
PBS. TiterMax Gold is an adjuvant that the company reports will help facilitate a TH1 
immune response.  (From conversations with CytRx technical support)  All solutions 
injected on day 0 and 7, except for the PBS, included 10 µg of the plasmid 
pUMVC3-mIL12, expressing both the p35 and p40 components of IL-12 (Aldevron).  
The IL-12 expressing plasmid was not added to any solution on day 14.  Spleens and 
Peyer’s patches were isolated 7 days after the last boost and allowed to culture for two 
days.  Cells were counted and assayed for the number of INF-γ producing cells using an 
ELISPOT assay (BD Pharmingen) (Appendix 1).  The number of INF-γ producing cells 
should be equivalent to the number of cells that recognize the Sendai epitope.  Since the 
epitope is class I MHC restricted the INF-γ producing cells should all be CTLs. The 
splenocyte response is indicative of the systemic immune response, while the Peyer’s 
patch response represents the mucosal response. 
The results show that the peptide vaccines were unable to generate a viral specific 
CTL response in vivo when injected IM along with TiterMax Gold, Table 6.2.  A small 
response was seen in the spleen of mice injected with the Sendai epitope, 11 ± 1.4 IFN-γ 
producing cells per 2x105 splenocytes.  Although, by weight the amount of each injection 
was similar, by moles the Sendai epitope was approximately 15 times more concentrated.  
This might suggest that in order to achieve an immune response with the vaccines, mice 
would have to be injected with over 2 mg per dose.  Purifying this amount of vaccine 
would be difficult.  A possible explanation of the poor result could be the use of 
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TiterMax Gold.  According to Weeratna, et. al. 2000 (Weeratna, McCluskie et al. 2000), 
TiterMax Gold as an adjuvant may have severely shifted the immune system towards a 
TH2 response instead of a TH1.  This is contrary to the information provided by the CytRx 
technical support.  An additional problem may have been the route of administration. 
Since these vaccines require the exchange of the vaccine with native β2m and peptide on 







Number of INF-γ 
producing in 2 x105 
splenocytes 
Number of INF-γ 
producing in 2 x105 
Peyer’s Patch cells 
pβ2mL21SE (150 µg) 0.8 ± 1.3 0 ± 0 
pβ2mL15SE (150 µg) 2.6 ± 2.7 0 ± 0 
pβ2mL10SE (150 µg) 4.3 ± 4.0 0 ± 0 
pβ2mL15DM (150 µg) 0 ± 0 0 ± 0 
Sendai Epitope (150 µg) 11 ± 1.4 0 ± 0 
PBS 0 ± 0 0 ± 0 
 
Table 6.2 Average number of INF-γ producing cells ± σ in 2x105 splenocytes or Peyer’s 
patches 
There were five mice in each group, assayed in duplicate.  Mice were vaccinated 
on day 0, 7, and 14 with 150 µg of vaccine or control in a 1:1 solution with 
TiterMax Gold.  All solutions injected on day 0 and 7, except for the PBS, 
included 10 µg of the plasmid pUMVC3-mIL12.  Spleens and Peyer’s patches 
were isolated and assayed for IFN-γ producing cells using the procedure outlined 
in the Mouse IFN-γ ELISPOT Set (BD Pharmingen). 
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‘Designed’ experiment method with peptide vaccines 
The concerns mentioned above were addressed in this experiment.  All vaccines 
were given as a molar amount equivalent to 150 µg of pβ2mL21SE.  The TiterMax Gold 
was removed and injections were performed subcutaneously (SQ) under the arm.  The 
injection site was chosen with hopes that the vaccine would enter the lymph ducts and be 
taken to either the auxiliary lymph node or brachial lymph node.  
The use of designed experiments allows an investigator to determine the effect of 
multiple variables on the response in the fewest number of experiments. In this 
experiment the peptide vaccines pβ2mL10SE, pβ2mL15SE, and pβ2mL21SE, and the 
controls pβ2mL15DM and the Sendai NP peptide, served as the variables.  The response 
measured was the number of INF-γ producing cells determined by an ELISPOT assay. 
The orthogonal matrix of variables and the average response seen is given in Table 6.3.  
7-10 week old C57BL/6 (H-2Kb) (Charles River Laboratories) mice were injected twice- 
on day 0 and day 14.  All injections included 25 µg of the plasmid pUMVC3-mIL12. 
Spleens and Peyer’s patches were isolated 5 days after the boost.  Cells were counted and 
immediately assayed for the number of INF-γ producing cells using an ELISPOT assay 
(BD Pharmingen).  The doses Low (-), Medium (0), and High (+) corresponds to 0 
nmoles, 5.4 nmoles, and 10.8 nmoles, respectively.  The response represents the average 
response ± standard deviation (σ) found in two mice assayed twice for the number INF-γ 
producing cells in 2 x105 splenocytes or 2 x105 Peyer’s patch cells.    
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1 ----+ Low Low Low Low High 0 ± 0.6  0 ± 1.2 
2 --++- Low Low High High Low 0 ± 1.3 0 ± 1.3 
3 -+-+- Low High Low High Low 0.25 ± 1.2 0 ± 1.3 
4 -++-+ Low High High Low High 0.75 ± 1.0 0 ± 1.3 
5 00000 Medium Medium Medium Medium Medium 1.0 ± 2.6 0 ± 0.8 
6 +--++ High Low Low High High 0 ± 0.6 0 ± 1.0 
7 +-+-- High Low High Low Low 0 ± 1.2 0 ± 1.7 
8 ++--- High High Low Low Low 0 ± 0.8 0 ± 1.0  
9 +++++ High High High High High 4.0 ± 3.0 0 ± 1.0  
Table 6.3 Peptide vaccine ‘designed’ experiment matrix 
 The vaccines and controls served as the variables and the response was the 
number of IFN-γ producing cells/ 2 x105 cells assayed via a standard ELISPOT.  
Samples were prepared based on a low dose, medium dose, and high dose 
corresponding to 0 nmoles, 5.4 nmoles, and 10.8 nmoles, respectively.  All 
sample volumes were equalized with PBS.  Samples were injected SQ along with 
25 µg of pUMVC3-mIL12 on day 0 and 14.  Spleens and Peyer’s patches were 
isolated on day 19 and assayed for IFN-γ producing cells using the procedure 
outlined in the Mouse IFN-γ ELISPOT Set (BD Pharmingen). 
 
The highest number of IFN-γ producing cells, 4.0 ± 3.0 was seen in the 9th set of 
mice which were injected with a high dose of all the vaccines and controls. This number 
was very close to the detection limit for this assay, which is advertised at 1/300,000 
(Helms, Boehm et al. 2000).  This experiment clearly showed that the peptide vaccines, 
when administered in a matrix format S.C. on day 0 and boosted on day 14, were unable 
to generate an immune response in vivo.  The failure to generate IFN-γ producing cells 
using this mode of administration triggered the termination of the peptide version as a 
primary vaccine.  The use of the pβ2mL21SE version as a boost after DNA vaccination 
was explored below. 
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β2m-Sendai Epitope Vaccine as a Mammalian Expression Vector 
DNA VACCINE CONSTRUCT DESIGN AND CLONING 
The design of the β2-microglobulin-Sendai epitope DNA vaccine involved fusion 
of β2m to the same Sendai epitope (NP324-332) and then to an endoplasmic reticulum 
signal peptide.  In order for the Sendai epitope to load correctly into the MHC heavy 
chain a spacer linking the N-terminal of β2-microglobulin to the C-terminal of the Sendai 
epitope was required.  The optimal length of the linker was unknown so three linker sizes 
were chosen: 10, 15 and 21 amino acids. As before the linker was composed of glycines 
and serines, which should be non-immunogenic and provide steric flexibility. The signal 
peptide sequence (MARSVTLVFLVLVSLTGLYA, Swiss-protein P01887) was the 
normal signal sequence for mouse β2m and should guide the translating protein to the 
endoplasmic reticulum.  DNA constructs with 10 and 15 AA linkers were constructed 
with one method while the cloning of the DNA construct with the 21 AA linker 
proceeded in a slightly different fashion.  Negative control vaccines with a dummy 
epitope or no epitope were engineered in the same method as the 21 AA linker DNA 
vaccine. 
 
Construct design and cloning of β2-microglobulin-sendai epitope- signal peptide 
DNA vaccine (β2mSESP) with a 10 or 15 amino acid linker 
 The same pBluescript-SK vector coding for the murine β2-microglobulin, 
mentioned above, acted as the initial template in a three-step extension PCR.  To clone 
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Figure 6.17 DNA vaccine construct.  
A) Schematic depiction of the extension PCR use
and β2mL15SESP DNA vaccines.  The first exte
N-terminal of β2m; the second PCR adds the Sen
type mouse signal peptide for β2m; the final PCR
peptide. B) A color-inverted digital image of 
increase in the β2mL10SESP construct size from
PCR3.   The downstream primer and upstr
concentration of 0.3µM.  The PCR reaction wa
cycled for 30 times from 94.0°C for 45s -> 55.0°
template for the first reaction was the pSK-β2m 












500 BP to constructed the β2mL10SEP 
sion PCR adds the linker to the 
ai epitope and part of the wild 
dds the remainder of the signal 
 1% agarose gel showing the 
 PCR1 to PCR2 then again in 
am primers were at a final 
 set at 94.0°C for 5 min, then 
 for 45s -> 72.0°C for 60s.  The 
lasmid, while the templates for 
gel-purified product from the 
three sequential PCR reactions to add the necessary sequences to the β2m gene.  For each 
PCR reaction, the T7 terminator primer was used as the downstream primer.  The first  
extension PCR primer added either the 10 AA or 15 AA linker to the β2m gene.  The 
second primer added the Sendai epitope and a portion of the signal peptide.  The final 
PCR primer, added the remainder of the signal peptide and a Kozak initialization signal 
(Figure 6.17). 
Endonuclease restriction sites were also added at both ends of the PCR product 
during the extension PCR reactions:  Nhe I and AFL II were added just upstream of the 
signal peptide and sites for Xho I, Apa I, and Kpn I were already downstream of the 
transcription stop site.  The flexibility to add new pathogenic epitopes to the vaccine was 
integrated into the construct by surrounding the region coding for the Sendai epitope with 
Age I and BamH I restriction sites.   
The final PCR products and the plasmid pVAX1 (Novagen) were cut with the 
restriction enzymes Nhe I and Xho I.  The digested pVAX1 vector was treated with 1 unit 
of shrimp alkaline phosphatase to remove terminal phosphates.  The PCR product was 
then ligated into the pVAX1 plasmid and the resulting ligation was transformed into 
TOP10F′ cells.  The cells were plated on LB/Agar plates contain kanamycin.  Colonies 
were chosen and then screened for the insert using PCR (Figure 6.18).  The plasmid was 
isolated from the appropriate colonies and the sequence verified at the University of 
Texas Sequence Center.  Figures 6.19 and 6.20 give the construct DNA sequence and 
protein sequence for β2ML10SESP and β2ML15SESP, respectively.  Highlighted are the 
various segments of the construct, such as the signal peptide,  the Sendai epitope, the 
linker and the murine β2m.  Restriction digestion sites are underlined.   
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Figure 6.18 Colony PCR screen for β2ML10SESP. 
A color-inverted digital image of a 1% agarose gel with the products of a colony 
PCR screen for β2ML10SESP.  β2ML10SESP was transformed into TOP10F’ 
cells by heat shock at 42°C for 45 seconds.  Cells were allowed to recover in SOC 
for 1 hour and then plated on LB plates containing 50 µg/ml kanamycin.  With a 
toothpick individual colonies were chosen and then screen by PCR for the insert.   
C1-C10 correspond to the 10 colonies selected.  P3 is the purified product from 
the third extension PCR for β2ML10SESP.  L is a DNA ladder. 
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 Signal Peptide 
1 11 21 31 41 
S W L A N M A R S V T L V F L V L   
AGC/TGG/CTA/G CT/AAC/ATG/GC G/AGA/TCA/GTA/ ACT/CTT/GTA/T TT/CTA/GTT/TT 
 Nhe I 
 
 Signal Peptide Sendai Epitope 
51 61 71 81 91 
   V S L T G L Y A F A P G N Y P A   
A/GTA/AGT/TTA/ ACC/GGT/TTA/T AT/GCT/TTT/GC T/CCT/GGT/AAT/ TAT/CCA/GCT/T 
 Age I 
 
 10 Amino Acid Linker β2-microglobulin 
101 111 121 131 141 
L G G G G S G G G S G I Q K T P Q 
TA/GGA/GGT/GG C/GGA/TCC/GGT/ GGC/GGA/AGC/G GA/ATC/CAG/AA A/ACC/CCT/CAA/ 
 BamH I 
β2-microglobulin 
151 161 171 181 191 
I Q V Y S R H P P E N G K P N I L 
ATT/CAA/GTA/T AC/TCA/CGC/CA C/CCA/CCG/GAG/ AAT/GGG/AAG/C CG/AAC/ATA/CT 
 
β2-microglobulin 
201 211 221 231 241 
   N C Y V T Q F H P P H I E I Q M 
G/AAC/TGC/TAC GTA/ACA/CAG/T TC/CAC/CCG/CC T/CAC/ATT/GAA/ ATC/CAA/ATG/C 
 
β2-microglobulin 
251 261 271 281 291 
L K N G K K I P K V E M S D M S F 
TG/AAG/AAC/GG G/AAA/AAA/ATT/ CCT/AAA/GTA/G AG/ATG/TCA/GA T/ATG/TCC/TTC 
 
β2-microglobulin 
301 311 321 331 341  
 S K D W S F Y I L A H T E F T P T 
AGC/AAG/GAC/T GG/TCT/TTC/TA T/ATC/CTG/GCT/ CAC/ACT/GAA/T TC/ACC/CCC/AC 
 
β2-microglobulin 
351 361 371 381 391 
   E T D T Y A C R V K H A S M A E  
T/GAG/ACT/GAT/ ACA/TAC/GCC/T GC/AGA/GTT/AA G/CAT/GCC/AGT/ ATG/GCC/GAG/C 
 
 β2-microglobulin 
401 411 421 431 441  
P  K T V Y W D R D M & S A S & C S  
CC/AAG/ACC/GT C/TAC/TGG/GAT/ CGA/GAC/ATG/T GA/TCA/GCA/TC A/TGA/TGC/TCT/ 
 
451 461 471 481 491 
E  E S L S I P S T R V @ R A R # 
GAA/GAA/AGC/T TA/TCG/ATA/CC G/TCG/ACC/CGA/ GTC/TAG/AGG/G CC/CGT/TAA/AC 
 Hind III Ban III Sal I XbaI Apa I 
 
 
Figure 6.19 The sequence for β2mL10SESP. 
TOP10F’ cells were transformed by heat shock with pVAX1 β2mL10SESP and 
grown overnight in 5mls of LB with 50 µg/ml kanamycin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 





1 11 21 31 41 
L I E I N T T H Y R ? T Q S W L A 
CTT/ATC/GAA/A TT/AAT/ACG/AC T/CAC/TAT/AGG/ NAG/ACC/CAA/A GC/TGG/CTA/GC 
 Nhe I 
 Signal Peptide 
51 61 71 81 91 
 N M A R S V T L V F L V L V S L 
T/AAC/ATG/GCG/ AGA/TCA/GTA/A CT/CTT/GTA/TT T/CTA/GTT/TTA/ GTA/AGT/TTA/A 
 
 Signal Peptide Sendai Epitope 
101 111 121 131 141 
T G L Y A F A P G N Y P A L G G G  
CC/GGT/TTA/TA T/GCT/TTT/GCT/ CCT/GGT/AAT/T AT/CCA/GCT/TT A/GGA/GGT/GGC/  
Age I 
 
 15 Amino Acid Linker β2-microglobulin 
151 161 171 181 191 
G S G G G G S G G G G S I Q K T P 
GGA/TCC/GGT/G GC/GGA/GGA/AG C/GGC/GGA/GGT/ GGC/AGC/ATC/C AG/AAA/ACC/CC  
BamH I 
β2-microglobulin 
201 211 221 231 241 
 Q I Q V Y S R H P P E N G K P N 
T/CAA/ATT/CAA/ GTA/TAC/TCA/C GC/CAC/CCA/CC G/GAG/AAT/GGG/ AAG/CCG/AAC/A  
 
β2-microglobulin 
251 261 271 281 291 
I L N C Y V T Q F H P P H I E I Q 
TA/CTG/AAC/TG C/TAC/GTA/ACA/ CAG/TTC/CAC/C CG/CCT/CAC/AT T/GAA/ATC/CAA/  
 
β2-microglobulin 
301 311 321 331 341  
M L K N G K K I P K V E M S D M S 
ATG/CTG/AAG/A AC/GGG/AAA/AA A/ATT/CCT/AAA/ GTA/GAG/ATG/T CA/GAT/ATG/TC  
 
β2-microglobulin 
351 361 371 381 391 
 F S K D W S F Y I L A H T E F T 
C/TTC/AGC/AAG/ GAC/TGG/TCT/T TC/TAT/ATC/CT G/GCT/CAC/ACT/ GAA/TTC/ACC/C  
 
β2-microglobulin 
401 411 421 431 441  
P T E T D T Y A C R V K H A S M A 
CC/ACT/GAG/AC T/GAT/ACA/TAC/ GCC/TGC/AGA/G TT/AAG/CAT/GC T/AGT/ATG/GCC/  
 
 β2-microglobulin 
451 461 471 481 491 
E P K T V Y W D R D M & S A S & C 
GAG/CCC/AAG/A CC/GTC/TAC/TG G/GAT/CGA/GAC/ ATG/TGA/TCA/G CA/TCA/TGA/TG  
 
501 511 521 531 541 
 S E E S L S I P S T S S L E G P 
C/TCT/GAA/GAA/ AGC/TTA/TCG/A TA/CCG/TCG/AC C/TCG/AGT/CTA/ GAG/GGC/CCG 
 Hind III Ban III Sal I Xho I XbaI Apa I 
Figure 6.20 The sequence for β2mL15SESP. 
TOP10F’ cells were transformed by heat shock with pVAX1 β2mL15SESP and 
grown overnight in 5mls of LB with 50 µg/ml kanamycin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
reverse primer.  The sequence is reported in the 5’-3’direction. 
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Construct design and cloning of β2-microglobulin-sendai epitope- signal peptide 
DNA vaccine with a 21 amino acid linker (β2mL21SESP) and the control vaccines 
with a dummy epitope (β2mL21DMSP) or no epitope (β2mL21NOSP). 
The β2mL21SESP vaccine and the control vaccines with a dummy epitope 
(β2mL21DMSP) or no epitope (β2mL21NOSP) were created in the same manner.  The 
process began by digesting pVAX1 β2mL15SESP first with the endonucleases Age I and 
then with BamH I. This digestion cut out a small portion of the signal peptide, the Sendai 
epitope, and a small portion of the linker.  
Next, complementary oligonucleotides (Sigma Genosys) that encoded for the lost 
portion of the signal peptide, the Sendai epitope, and the lost portion of the linker plus 6 
additional amino acids were annealed together.  When annealed the oligonucleotides 
formed overhangs corresponding to the overhangs of Age I and BamH I.   The annealed 
oligonucleotides were then ligated into the cut pVAX1 β2mL15SESP.  The ligation 
product was transformed into TOP10F′ cells and then plated on LB/Agar plates 
containing kanamycin.  Isolated colonies were picked and then screened for the insert 
using PCR.  (Data not shown)  The plasmid was isolated from the appropriate colonies 
and the sequence verified at the University of Texas Sequence Center.  Figure 6.21 gives 
the construct DNA and protein sequences for β2ML21SESP.   
The only difference between the creation of β2mL21SESP and β2mL21DMSP or 
β2mL21NOSP was the sequence of the complementary oligonucleotides used.  The 
oligonucleotides for β2mL21DMSP encoded for the dummy epitope (FASIRALAL) 
instead of the Sendai epitope (Figure 6.22). The oligonucleotides for β2mL21NOSP 
completely left the Sendai epitope out (Figure 6.23).  The creation of these vaccines 




1 11 21 31 41 
D S L @ G D P S W L A N M A R S V 
GAC/TCA/CTA/T AG/GGA/GAC/CC A/AGC/TGG/CTA/ GCT/AAC/ATG/G CG/AGA/TCA/GT  
 Nhe I 
 
 Signal Peptide 
51 61 71 81 91 
 T L V F L V L V S L T G L Y A F 
A/ACT/CTT/GTA/ TTT/CTA/GTT/T TA/GTA/AGT/TT A/ACC/GGT/TTA/ TAT/GCT/TTT/G  
 Age I 
 
 Sendai Epitope 21 Amino Acid Linker 
101 111 121 131 141 
A P G N Y P A L G G G G G S G G G 
CG/CCA/GGA/AA T/TAT/CCC/GCT/ TTA/GGA/GGT/G GT/GGA/GGT/AG T/GGT/GGA/GGA/  
 
 21 Amino Acid Linker β2-microglobulin 
151 161 171 181 191 
G S G G G G S G G G G S I Q K T P 
GGA/TCC/GGT/G GC/GGA/GGA/AG C/GGC/GGA/GGT/ GGC/AGC/ATC/C AG/AAA/ACC/CC  
BamH I 
β2-microglobulin 
201 211 221 231 241 
 Q I Q V Y S R H P P E N G K P N 
T/CAA/ATT/CAA/ GTA/TAC/TCA/C GC/CAC/CCA/CC G/GAG/AAT/GGG/ AAG/CCG/AAC/A  
 
β2-microglobulin 
251 261 271 281 291 
I L N C Y V T Q F H P P H I E I Q 
TA/CTG/AAC/TG C/TAC/GTA/ACA/ CAG/TTC/CAC/C CG/CCT/CAC/AT T/GAA/ATC/CAA/  
 
β2-microglobulin 
301 311 321 331 341  
M L K N G K K I P K V E M S D M S 
ATG/CTG/AAG/A AC/GGG/AAA/AA A/ATT/CCT/AAA/ GTA/GAG/ATG/T CA/GAT/ATG/TC  
 
β2-microglobulin 
351 361 371 381 391 
 F S K D W S F Y I L A H T E F T 
C/TTC/AGC/AAG/ GAC/TGG/TCT/T TC/TAT/ATC/CT G/GCT/CAC/ACT/ GAA/TTC/ACC/C  
 
β2-microglobulin 
401 411 421 431 441  
P T E T D T Y A C R V K H A S M A 
CC/ACT/GAG/AC T/GAT/ACA/TAC/ GCC/TGC/AGA/G TT/AAG/CAT/GC T/AGT/ATG/GCC/  
 
 β2-microglobulin 
451 461 471 481 491 
E P K T V Y W D R D M & S A S & C 
GAG/CCC/AAG/A CC/GTC/TAC/TG G/GAT/CGA/GAC/ ATG/TGA/TCA/G CA/TCA/TGA/TG  
 
501 511 521 531 541 
 S E E S L S I P S T S S L E G P 
C/TCT/GAA/GAA/ AGC/TTA/TCG/A TA/CCG/TCG/AC C/TCG/AGT/CTA/ GAG/GGC/CCG/ 
 Hind III Ban III Sal I Xho I  XbaI Apa I 
 
Figure 6.21 The sequence for β2mL21SESP. 
TOP10F’ cells were transformed by heat shock with pVAX1 β2mL21SESP and 
grown overnight in 5mls of LB with 50 µg/ml kanamycin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
reverse primer.  The sequence is reported in the 5’-3’direction. 
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1 11 21 31 41 
D S L @ G D P S W L A N M A R S V 
GAC/TCA/CTA/T AG/GGA/GAC/CC A/AGC/TGG/CTA/ GCT/AAC/ATG/G CG/AGA/TCA/GT  
 Nhe I 
 
 Signal Peptide 
51 61 71 81 91 
 T L V F L V L V S L T G L Y A F 
A/ACT/CTT/GTA/ TTT/CTA/GTT/T TA/GTA/AGT/TT A/ACC/GGT/TTA/ TAT/GCT/TTT/G  
 Age I 
 
 Dummy Epitope 21 Amino Acid Linker 
101 111 121 131 141 
A S I R A L A L G G G G G S G G G 
CG/TCT/ATA/CG A/GCC/CTT/GCT/ TTA/GGA/GGT/G GT/GGA/GGT/AG T/GGT/GGA/GGA/  
 
 21 Amino Acid Linker β2-microglobulin 
151 161 171 181 191 
G S G G G G S G G G G S I Q K T P 
GGA/TCC/GGT/G GC/GGA/GGA/AG C/GGC/GGA/GGT/ GGC/AGC/ATC/C AG/AAA/ACC/CC  
BamH I 
β2-microglobulin 
201 211 221 231 241 
 Q I Q V Y S R H P P E N G K P N 
T/CAA/ATT/CAA/ GTA/TAC/TCA/C GC/CAC/CCA/CC G/GAG/AAT/GGG/ AAG/CCG/AAC/A  
 
β2-microglobulin 
251 261 271 281 291 
I L N C Y V T Q F H P P H I E I Q 
TA/CTG/AAC/TG C/TAC/GTA/ACA/ CAG/TTC/CAC/C CG/CCT/CAC/AT T/GAA/ATC/CAA/  
 
β2-microglobulin 
301 311 321 331 341  
M L K N G K K I P K V E M S D M S 
ATG/CTG/AAG/A AC/GGG/AAA/AA A/ATT/CCT/AAA/ GTA/GAG/ATG/T CA/GAT/ATG/TC  
 
β2-microglobulin 
351 361 371 381 391 
 F S K D W S F Y I L A H T E F T 
C/TTC/AGC/AAG/ GAC/TGG/TCT/T TC/TAT/ATC/CT G/GCT/CAC/ACT/ GAA/TTC/ACC/C  
 
β2-microglobulin 
401 411 421 431 441  
P T E T D T Y A C R V K H A S M A 
CC/ACT/GAG/AC T/GAT/ACA/TAC/ GCC/TGC/AGA/G TT/AAG/CAT/GC T/AGT/ATG/GCC/  
 
 β2-microglobulin 
451 461 471 481 491 
E P K T V Y W D R D M & S A S & C 
GAG/CCC/AAG/A CC/GTC/TAC/TG G/GAT/CGA/GAC/ ATG/TGA/TCA/G CA/TCA/TGA/TG  
 
501 511 521 531 541 
 S E E S L S I P S T S S L E G P 
C/TCT/GAA/GAA/ AGC/TTA/TCG/A TA/CCG/TCG/AC C/TCG/AGT/CTA/ GAG/GGC/CCG/ 
 Hind III Ban III Sal I Xho I  XbaI Apa I 
Figure 6.22 The sequence for β2mL21DMSP. 
TOP10F’ cells were transformed by heat shock with pVAX1 β2mL21DMSP and 
grown overnight in 5mls of LB with 50 µg/ml kanamycin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
reverse primer.  The sequence is reported in the 5’-3’direction. 
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1 11 21 31 41 
C L L A Y R N # Y D S L @ G D P S 
TGC/TTA/CTG/G CT/TAT/CGA/AA T/TAA/TAC/GAC/ TCA/CTA/TAG/G GA/GAC/CCA/AG  
  
 Signal Peptide 
51 61 71 81 91 
 W L A N M A R S V T L V F L V L 
C/TGG/CTA/GCT/ AAC/ATG/GCG/A GA/TCA/GTA/AC T/CTT/GTA/TTT/ CTA/GTT/TTA/G  
 Nhe I 
 
 Signal Peptide 21 Amino Acid Linker 
101 111 121 131 141 
V S L T G L Y A G G G G G S G G G 
TA/AGT/TTA/AC C/GGT/TTA/TAT/ GCT/GGA/GGT/G GT/GGA/GGT/AG T/GGT/GGA/GGA/  
 Age I 
 21 Amino Acid Linker β2-microglobulin 
151 161 171 181 191 
G S G G G G S G G G G S I Q K T P 
GGA/TCC/GGT/G GC/GGA/GGA/AG C/GGC/GGA/GGT/ GGC/AGC/ATC/C AG/AAA/ACC/CC  
BamH I  
β2-microglobulin 
201 211 221 231 241 
 Q I Q V Y S R H P P E N G K P N 
T/CAA/ATT/CAA/ GTA/TAC/TCA/C GC/CAC/CCA/CC G/GAG/AAT/GGG/ AAG/CCG/AAC/A  
 
β2-microglobulin 
251 261 271 281 291 
I L N C Y V T Q F H P P H I E I Q 
TA/CTG/AAC/TG C/TAC/GTA/ACA/ CAG/TTC/CAC/C CG/CCT/CAC/AT T/GAA/ATC/CAA/  
 
β2-microglobulin 
301 311 321 331 341  
M L K N G K K I P K V E M S D M S 
ATG/CTG/AAG/A AC/GGG/AAA/AA A/ATT/CCT/AAA/ GTA/GAG/ATG/T CA/GAT/ATG/TC  
 
β2-microglobulin 
351 361 371 381 391 
 F S K D W S F Y I L A H T E F T 
C/TTC/AGC/AAG/ GAC/TGG/TCT/T TC/TAT/ATC/CT G/GCT/CAC/ACT/ GAA/TTC/ACC/C  
 
β2-microglobulin 
401 411 421 431 441  
P T E T D T Y A C R V K H A S M A 
CC/ACT/GAG/AC T/GAT/ACA/TAC/ GCC/TGC/AGA/G TT/AAG/CAT/GC T/AGT/ATG/GCC/  
 
 β2-microglobulin 
451 461 471 481 491 
E P K T V Y W D R D M & S A S & C 
GAG/CCC/AAG/A CC/GTC/TAC/TG G/GAT/CGA/GAC/ ATG/TGA/TCA/G CA/TCA/TGA/TG  
 
501 511 521 531 541 
 ? E E S L S I P S T ? S ? E G P 
C/TNT/GAA/GAA/ AGC/TTA/TCG/A TA/CCG/TCG/AC C/TNG/AGT/NTA/ GAG/GGC/CCG/ 
 Hind III Ban III Sal I  Apa I 
Figure 6.23 The sequence for β2mL21NOSP. 
TOP10F’ cells were transformed by heat shock with pVAX1 β2mL21NOSP and 
grown overnight in 5mls of LB with 50 µg/ml kanamycin.  The plasmid was 
isolated using the Mini Prep kit from Qiagen.  The plasmid was then sent to the 
University of Texas Sequence Center and the sequence was verified using the 
reverse primer.  The sequence is reported in the 5’-3’direction. 
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 T-CELL HYBRIDOMA STIMULATION ASSAY 
 The T-cell hybridoma stimulation assay was first attempted with RMA-S cells 
acting as the target.  Attempts to transect this cell line with a green fluorescence protein 
expressing plasmid, peGFP-N2 (CLONTECH) failed.  Thus, the RMA-S cell line was 
abandoned for the NOR-10 cell line (ATCC, CCL-197).  The NOR-10 cell line is derived 
from the abdominal wall muscle of C57BL/10 mice.  Transfection of the NOR-10 cell 
line proved possible using the SuperFect transfection reagent (Invitrogen).  Using a flow 
cytometer to determine GFP expression, these cells demonstrated transfection efficiencies 
between 6-9%.  (Data not shown)    
 NOR-10 cells were then transfected using the SuperFect transfection protocol 
(Appendix 1) with peGFP-N2 and either the DNA vaccines β2mL10SESP, β2mL15SESP, 
or β2mL21SESP or the controls β2mL21DMSP, β2mL21NOSP, or pVAX1.  The 
peGFP-N2 plasmid was used in this experiment to verify transfection and to normalize 
the results.  The transfected NOR-10 cells then served as the target cells in the hybridoma 
assay. 
 Individual T-cell hybridomas clones M1.1B3 and M3.4D3 or a combination of the 
two were cultured with transfected NOR-10 cells.  The supernatant from these reactions 
was collected after 24 hours and then transferred to ELISA plates coated with anti-mouse 
IL-2 antibody (BD Pharmingen). After 2 hours the plates were washed and the secondary 
biotinylated anti-mouse IL-2 antibody (BD Pharmingen) was added.  After 1 hour the 
plates were again washed and an avidin-horseradish peroxidase conjugate (BD 
Pharmingen) was added.  The reaction was allowed to take place for 30-60 minutes 
before being stopped.  The absorbance was read at 450 nm and compared against a 
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recombinant mouse IL-2 standard curve.  Figure 6.24 presents the average of four 



















Figure 6.24  T-cell hybridoma stimulation assay results for the DNA vaccines.  
L10, L15 and L21 correspond to the linker size of the vaccine used. The 
controls Dummy, No epitope and pVAX1 correspond to β2mL21DMSP, 
β2mL21NESP and the pVAX1 vector, respectively.  NOR-10 cells (2x106) 
were plated the night before they were transfected with 9 µg of DNA vaccine 
and 3 µg of peGFP-N2 using the SuperFect transient transfection protocol 
(Invitrogen) at a 1 µg of DNA to 5 µl of SuperFect ratio.  Cells were grown 
overnight and then passed into a 12 well plate at 3.5x105 cells per well.  These 
cells were allowed to adhere overnight and then incubated with 1x106 T-cell 
hybridomas for 18-24 hours.  The release of IL-2 was measured by ELISA.  
These results have not been normalized for transfection efficiency.  The error 
bars represent the standard deviation. 
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The results presented in Figure 6.24 were similar to results observed on two other 
attempts to stimulate the hybridomas with transfected NOR-10 cells.  The greatest release 
of IL-2 observed came from M1.1B3 cells incubated with NOR-10 cells that had been 
transfected with β2mL21DMSP at 9.1 pg/ml and the next highest response was given by 
those transfected with β2mL10SESP at 7.9 pg/ml.  For the M3.4D3 hybridoma, the 
greatest release of IL-2 was seen by cells incubated with NOR-10 cells that had been 
transfected with β2mL21SESP at 7.7 pg/ml.  Given the generally low values, high σ, and 
the high value for pVAX1, it is questionable whether any of data were far enough above 
the signal to noise ratio to be considered real values.  These data were disappointing, 
however an inability to stimulate hybridoma cells with a transfected cell line in vitro, 
should only be taken as that and not viewed as a strong indicator of what would be 
expected in vivo. 
 
IN VIVO DNA STUDIES 
‘Designed’ experiment method with DNA vaccines 
The use of designed experiments allows an investigator to determine the effect of 
multiple variables on the response in the fewest number of experiments.  In this 
experiment the DNA vaccines β2mL10SESP, β2mL15SESP, and β2mL21SESP and the 
controls β2mL21DMSP, β2mL21NOSP and the pVAX vector served as the variables.  
The response measured was the number of INF-γ producing cells that recognize the 
Sendai epitope as determined by an ELISPOT assay. The orthogonal matrix of variables 
and the average response seen is given in Table 6.4.  7-10 week old C57BL/6 (H-2Kb) 
mice (Charles River Laboratories) were injected twice - on day 0 and day 14.  All 
injections included 25 µg of pUMVC3-mIL12 and were done IM, splitting the sample 
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equally between both hind legs. The dose Low (-), Medium (0), and High (+) corresponds 
to 0 pmoles,  26.1 pmoles, and 52.4 pmoles, respectively.  Spleens and Peyer’s patches 
were isolated 5 days after the second injection. Cells were counted and immediately 
assayed for the number of INF-γ producing cells using an ELISPOT assay (BD 
Pharmingen).  The response represents the average number of spots ± σ found in two 
mice assayed twice for number INF-γ producing cells in 2x105 splenocytes.  Similar to 
the results achieved with the peptide vaccine there was no measurable INF-γ producing 
















1 ----++ Low Low Low Low High High 0.3 ± 0.5 
2 --++-- Low Low High High Low Low 1.3 ± 1.5 
3 -+-+-+ Low High Low High Low High 1.3 ± 1.9 
4 -++-+- Low High High Low High Low 17.8 ± 7.5 
5 000000 Medium Medium Medium Medium Medium Medium 10.5 ± 1.7 
6 +--++- High Low Low High High Low 14.5 ± 16.6 
7 +-+--+ High Low High Low Low High 32.0 ± 2.6 
8 ++---- High High Low Low Low Low 16.0 ± 9.6 
9 ++++++ High High High High High High 46.0 ± 43.0 
 
Table 6.4 DNA vaccine ‘designed’ experiment matrix  
The vaccines and controls served as the variables and the response was the 
number of IFN-γ producing cells/ 2x105 cells assayed via a standard ELISPOT.  
Samples were prepared based on a low dose, medium dose, and high dose 
corresponding to 0 pmoles,  26.1 pmoles, and 52.4 pmoles, respectively.  All 
sample volumes were equalized with PBS.  Samples were injected IM along with 
25 µg of pUMVC3-mIL12 on day 0 and 14.  Spleens and Peyer’s patches were 
isolated on day 19.  No response was observed in the Peyer’s patches and 
therefore the data was not presented. 
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According to the central limit theorem, the averages from sample sets of any 
population will be distributed approximately normally around the population average.  
The experiment was designed so that four groups of mice were given each variable and 
another four groups of mice were not injected with that variable.  Thus an easy way to get 
an idea of the effect of each variable is to subtract the average response of mice without 
the variable from the average response of mice that received the variable, Table 6.5.  
Conservatively the two variables with the greatest effect were β2mL21SESP and 
β2mL10SESP.   
 
 β2mL21SESP β2mL15SESP β2mL10SESP β2mL21DMSP β2mL21NOSP PVAX 
Mice with 6,7,8,9 3,4,8,9 2,4,7,9 2,3,6,9 1,4,6,9 1,3,7,9 
Mice w/o 1,2,3,4 1,2,6,7 1,3,6,8 1,4,7,8 2,3,7,8 2,4,6,8 
positive 27.1 20.3 24.3 15.8 19.6 19.9 













110 41.5 81.5 -4.0 35 37.5 
Table 6.5 Analysis of the effect each variable contributed in the DNA vaccine ‘designed’ 
experiment. 
Mice with and mice w/o correspond to the group numbers that contained or did 
not have the variable, respectively.  Positive and negative are the sum of the 
number of spots with or with out the variable, respectively.  The effect is the 
result of subtracting the negative from the positive.  
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A more sophisticated method of interpreting the data would be to develop a 
model.  Using the Design Ease 6.0.9 "designed experiment" software package the data 
was modeled with all the variables to give the following equation: 
. 
IFN-γ producing cells = -14.0 + 4.2x1011*(β2mL21SESP) + 1.6 x1011*(β2mL15SESP) 
  + 3.1 x1011*(β2mL10SESP) - 1.4 x1010*(β2mL21DMSP) 
  + 1.3 x1011*(β2mL21NOSP) + 1.4 x1011*(pVAX) 
 
The variables are given in moles and the standard error for each coefficient is 1.0 x1011.  
The model had a Model F-value of 5.01, which implies the model is significant and that 
there is only a 0.13% chance that a "Model F-Value" this large could occur due to noise. 
The F distribution compares the ratio of the model mean square to the error mean square, 
thus the higher the F-value the better the model fits the data.  The coefficients represent 
the relative effect of each of the variables.  Although the model itself lacks noise, there 
appears to be great variability between animals as shown by the intercept of –14.0 and the 
standard error in the coefficient.  Even considering these factors, at higher than 68% 
confidence level the β2mL21SESP vaccine has a greater effect in the model than the 
β2mL15SESP vaccine and the controls β2mL21DMSP, β2mL21NOSP and the pVAX1 
vector.  At the 68% confidence level there is no significant difference between 























Figure 6.25 The model coefficients for the DNA vaccine designed experiment.  
The experimental procedure is described table 6.4.  The error bars are set at one 
standard error, representing the 68% confidence level. 
Traditional method with DNA vaccines 
A very positive result from the experiment described above was the observation 
of INF-γ producing cells, which clearly demonstrated that the vaccines generated a viral 
specific immune response.  Because of the variability shown in the model and the 
difficulty of publishing data from designed experiments in animals, a more traditional 
study was also performed.  In this experiment, twenty-six 7-10 week old C57BL/6 
(H-2Kb) mice (Charles River Laboratories) were divided into 4 groups of 5 and 2 groups 
of 3.  Groups of 5 mice were injected IM, as before, into the hind leg on day 0 and 14 
with 25 µg of pUMVC3-mIL12 and 92.1 pmoles (~200 µg) of either β2mL10SESP, 
β2mL15SESP, β2mL21SESP or the control β2mL21DMSP.  Groups of 3 were injected 
IM on day 0 and 14 with either 25 µg pUMVC3-mIL12 or PBS. Spleens were isolated 14 
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days after the last injection. Cells were counted and immediately assayed for the number 
of INF-γ producing cells using an ELISPOT assay (BD Pharmingen) (Figure 6.26a).  
The DNA vaccine with a 21 AA linker gave the highest number of INF-γ 
producing cells, at 304 ± 102 spots/million splenocytes, followed closely by the 15 AA 
linker at 227 ± 88 spots/million splenocytes.  The 10 AA linker vaccine gave a value of 
only 53 ± 61 spots/million splenocytes.  The dummy epitope and PBS controls gave 
values of 1 ± 1 spots/million splenocytes and 13 ± 11 spots/million splenocytes, 
respectively.  Clearly from this data the β2m-linker-Sendai epitope-signal peptide DNA 
vaccines were able to generate viral specific CTLs.   
Student t-Tests were performed to determine if the values obtained were 
significantly different from one another (Figure 6.26b).  The values given in a matrix 
format correspond to the percent confidence that the value for the vaccine at the top of 
the column was different than the value for the vaccine at the right of each row.  I can say 
with almost 100% confidence for mice vaccinated with either β2mL21SESP or 
β2mL15SESP and with 82% confidence for mice vaccinated with β2mL10SESP that 
these vaccinated mice gave a higher response than mice vaccinated with IL-12 along.  In 









































 IL-12 alone L10 L15 L21 
Dummy 
Epitope PBS 
IL-12 alone 0.00% - - - - - 
L10 81.64% 0.00% - - - - 
L15 100.00% 99.99% 0.00% - - - 
L21 100.00% 100.00% 90.72% 0.00% - - 
Dummy 
Epitope 99.91% 98.86% 100.00% 100.00% 0.00% - 
PBS 40.62% 86.67% 100.00% 100.00% 93.21% 0.00% 
Figure 6.26 Traditional determination of DNA vaccine linker size.   
There were five C57BL/6 mice used in groups L10, L15, L21, and Dummy 
Epitope, and 3 mice in the IL-12 and PBS controls.  L10, L15, and L21 
correspond to the linker size of the vaccine. A) Depicts graphically the average 
value for the ELISPOT assay for each group and the average of duplicate 
ELISPOT assays for each mouse in the group. B) List the confidence levels, 
based on Student t-Test analysis of each group's ELISPOT data, at which one can 
say the values were statistically different. 
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Dose response 
In this experiment, twenty-six 7-10 week old C57BL/6 (H-2Kb) mice (Charles 
River Laboratories) were divided into 4 groups of 5 and 2 groups of 3.  The groups of 
five were injected IM, into each hind leg as before on day 0 and 14 with 25 µg of 
pUMVC3-mIL12 and either 100 µg, 200 µg, 400µg, or 800 µg of β2mL21SESP.  The 
groups of three received either 25 µg of pUMVC3-mIL12 or just PBS on days 0 and 14.  
Spleens were isolated 14 days after the last injection.  Cells were counted and 
immediately assayed for the number of INF-γ producing cells using an ELISPOT assay 
(BD Pharmingen).  Figure 6.27 depicts the results of this experiment.  The outlier value, 
highlighted in red, of 1260 spots for mouse 2 in the 100 µg group, was excluded based on 
the results of a Q test at 90% confidence (Q = 0.668).  This value was not included in the 
average for the 100 µg group or in the Student t-Test analysis.  
Contrary to what was expected, doses over 200 µg, when given on day 0 and 
again as a boost on day 14, generated fewer viral-specific splenocytes than lower doses.  
There was little difference between the number of spots seen in mice vaccinated with 100 
µg, at 332 ± 151 spots/million splenocytes and mice vaccinated with the 200 µg, at 304 ± 
102 spots/million splenocytes.  However, when mice were vaccinated with 400 µg of 
vaccine the number of spots dropped into half to 162 ± 148 spots/million splenocytes.  
Then as the dose was doubled to 800 µg the number of spots was cut in half again to 82 ± 
40 spots/million cells.  With over 97% confidence I can say that the values for the 100 µg 
and 200 µg dose were different that the values for the 400 µg or 800 µg dose.  Also with 



































 IL-12 100 µg 200 µg 400 µg 800 µg PBS 
IL-12 0.00% - - - - - 
100 µg 99.98% 0.00% - - - - 
200 µg 100.00% 35.48% 0.00% - - - 
400 µg 96.90% 97.46% 97.86% 0.00% - - 
800 µg 99.81% 99.99% 100.00% 89.08% 0.00% - 
PBS 40.62% 99.98% 100.00% 97.37% 99.87% 0.00% 
Figure 6.27 Dose response for β2mL21SESP.  
There were five C57BL/6 mice used in groups 100 µg, 200 µg, 400 µg, and 800 
µg, and 3 mice in the IL-12 and PBS controls.  The value, highlighted in red, of 
1260 spots for mouse 2 in the 100 µg group, was thrown out based on the results 
of a Q test at 90% confidence.  This value was not included in the average for the 
100 µg group for the determination of the confidence level. A) Depicts 
graphically the average value for the ELISPOT assay for each group and the 
average of duplicate ELISPOT assays for each mouse in the group. B) Lists the 
confidence levels, based on Student t-Test analysis of each groups ELISPOT data, 
at which one can say the values were statistically different. 
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Duration of immune response 
In this experiment, twenty-five 7-10 week old C57BL/6 (H-2Kb) mice (Charles 
River Laboratories) were divided into 3 test groups of 5 and 2 control groups of 5.  The 
test groups of five were injected IM into each hind leg on days 0 and 14 with 400 µg of 
β2mL21SESP and 25 µg of pUMVC3-mIL12.  The control groups received either 25 µg 
of pUMVC3-mIL12 and PBS or just PBS on days 0 and 14.  Test mice were sacrificed 7, 
14, and 28 days after the boost, corresponding to days 21, 28, and 42, respectively.  One 
mouse from each control group was sacrificed on day 21; three from each group were 
sacrificed on day 28; and one from each group was sacrificed on day 42.  Spleens were 
isolated; cells were counted and immediately assayed for the number of INF-γ producing 
cells using an ELISPOT assay.  Figure 6.28 shows that the number of IFN-γ producing 
cells decreased as the time from boost increased.  But even at the furthest day from the 
boost examined, 28 days, the splenocytes from vaccinated mice showed significantly 
more INF-γ producing cells, 70 ± 36 spots/million splenocytes, than either the IL-12 







































7 Days After 
Boost 
14 Days After 
Boost 
28 Days After 
Boost 
7 Days After Boost 0.00%   
14 Days After Boost 67.62% 0.00%  
28 Days After Boost 99.90% 93.50% 0.00% 
Figure 6.28 Duration of the immune response after the boost. 
Results from an ELISPOT assay for INF-γ producing splenocytes in C57BL/6 
mice vaccinated on day 0 and boosted on day 14.  L21 corresponds to five mice 
dosed with 400 µg of β2mL21SESP and 25 µg of pUMVC3-mIL12.  Mice were 
sacrificed 7, 14, or 28 days after the boost.  IL-12 refers to mice primed and 
boosted only with 25 µg of pUMVC3-mIL12.  PBS refers to mice primed and 
boosted only with PBS.  For the IL-12 and PBS samples there was only 1 mouse 
on day 7 and 28 and 3 mice on day 14.  A) Depicts graphically the average value 
for the ELISPOT assay for each group and the average of duplicate ELISPOT 
assays for each mouse in the group. B) Lists the confidence levels, based on 
Student t-Test analysis of each group's ELISPOT data, at which one can say the 
values were statistically different. 
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IL-12 effect on ELISPOT 
To determine if the IL-12 adjuvant improved the vaccine's ability to generate 
viral-specific splenocytes sixteen 7-10 week old C57BL/6 (H-2Kb) mice (Charles River 
Laboratories) were divided into 2 groups of 5 and 2 groups of 3.  The groups of five were 
injected IM, into each hind leg on days 0 and 14 with 400µg of β2mL21SESP and either 
0 mg or 25 µg of pUMVC3-mIL12.  The groups of three received either 25 µg of 
pUMVC3-mIL12 or just PBS on days 0 and 14.  Figure 6.29 gives the results of this 
experiment.  With almost 98% confidence there was a difference between the number of 
spots produced by mice treated with the IL-12 plasmid in addition to the vaccine and 
those treated with only the vaccine.  Based on the average response the use of IL-12 as an 
adjuvant increases the number of viral specific spleen CTLs by 4 fold: from 42 ± 40 
spots/million splenocytes seen in vaccinations without IL-12 to 162 ± 148 spots/million 
splenocytes seen when IL-12 was added.  With only 85% confidence can it be stated that 
the mice vaccinated with the DNA vaccine without IL-12 generated more spots than the 






































 IL-12 alone With IL-12 Without IL-12 PBS 
IL-12 alone 0.00% - - - 
With IL-12 96.90% 0.00% - - 
Without IL-12 82.54% 97.93% 0.00% - 
PBS 40.62% 97.37% 88.84% 0.00% 
Figure 6.29 The effect of IL-12 on IFN-γ producing splenocytes. 
ELISPOT assay to determine the effect of IL-12 as an adjuvant on the number of 
IFN-γ producing cells generated in the spleen.  400 µg of β2mL21SESP was 
injected IM into 5 mice on days 0 and 14 either with 25 µg of pUMVC3-mIL12 
or without pUMVC3-mIL12.  There where 3 mice in the control groups IL-12 
alone and PBS.  A) Depicts graphically the average value for the ELISPOT assay 
for each group and the average of duplicate ELISPOT assays for each mouse in 
the group. B) Lists the confidence levels, based on Student t-Test analysis of each 




Protein vaccine as a boost 
Other labs have shown that DNA vaccination followed by a boost with the 
recombinant protein could increase the specific immune response (Letvin, Montefiori et 
al. 1997; Habel, Chanel et al. 2000; Hammond, Jansen et al. 2001; Hevey, Negley et al. 
2001).  To test this idea with our vaccination strategy, sixteen 7-10 week old C57BL/6 
(H-2Kb) mice (Charles River Laboratories) were divided into 2 test groups of 5 and 2 
control groups of 3.  The tests groups were injected IM into each hind leg on day 0 with 
400µg of β2mL21SESP and 25 µg of pUMVC3-mIL12.  On day 14 one test group 
received 400 µg of β2mL21SESP and 25 µg of pUMVC3-mIL12 administered IM and 
the other receive 400 µg of pβ2mL21SE and 25 µg of pUMVC3-mIL12 administered SQ.  
The groups of three received IM either 25 µg of pUMVC3-mIL12 or just PBS on day 0 
and 14.  Figure 6.30 gives the results of this experiment.  At only a 74% confidence level 
was there a difference between the average number of spots produced by mice treated 
with the booster of recombinant fusion protein on day 14, 226 ± 92 spots/million 
splenocytes, compared to a boost with the DNA construct, 162 ± 148 spots/million 





































 IL-12 alone DNA Boost Peptide Boost PBS 
IL-12 alone 0.00% - - - 
DNA Boost 96.90% 0.00% - - 
Peptide Boost 99.98% 73.76% 0.00% - 
PBS 40.62% 97.37% 99.98% 0.00% 
Figure 6.30 The effect of the peptide vaccine as a boost on IFN-γ producing splenocytes. 
On day zero 400 µg of β2mL21SESP with 25 µg of pUMVC3-mIL12 was 
injected IM into 10 C57BL/6 mice. On day 14 five of the mice received 400 
µg of β2mL21SESP and 25 µg of pUMVC3-mIL12 administered IM, termed 
the DNA Boost.  The other five receive 400 µg of pβ2ML21SE and 25 µg of 
pUMVC3-mIL12 administered SQ, termed the Peptide Boost.  There where 3 
mice in the control groups IL-12 alone and PBS received only 25 µg of 
pUMVC3-mIL12 or PBS administered IM, respectively.  A) Depicts 
graphically the average value for the ELISPOT as assay for each group and 
the average of duplicate ELISPOT assays for each mouse in the group. B) 
List the confidence levels, based on Student t-Test analysis of each group's 
ELISPOT data, at which one can say the values were statistically different. 
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Boost schedule 
In this experiment, twenty-five 7-10 week old C57BL/6 (H-2Kb) mice (Charles River 
Laboratories) were divided into 3 test groups of 5 and 2 control groups of 5.  The test 
groups were injected IM, into each hind leg, on day 0 with 400 µg of β2mL21SESP with 
25 µg of pUMVC3-mIL12 and then boosted with the same thing on either day 7, 14 or 
28.  The control groups received either 25 µg of pUMVC3-mIL12 or just PBS on days 0 
and 14.  For the test group spleens were isolated 14 days after the boost, corresponding to 
days 21, 28, and 42, respectively.  One mouse from each control group was sacrificed on 
day 21, three from each group were sacrificed on day 28, and one from each group on 
day 42. Cells were counted and immediately assayed via an ELISPOT for the number of 
INF-γ producing splenocytes (Figure 6.31).  The data shows that with over 95% 
confidence a boost 14 days after the primary immunization generates more IFN-γ 
producing viral-specific splenocytes at an average of 162 ± 148 spots/million splenocytes 
compared to when boost were given on day 7 (51 ± 17 spots/million splenocytes), or on 


































Boost on day 14Boost on day 7 Boost on day 28 
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 L21 Boost Day 7 L21 Boost Day 14 L21 Boost Day 28
L21 Boost Day 7 0.00% - - 
L21 Boost Day 14 95.25% 0.00% - 
L21 Boost Day 28 60.86% 96.26% 0.00% 
Figure 6.31 The effect of boost time point on the number of IFN-γ producing splenocytes. 
C57bBL/6 mice vaccinated on day 0 and boosted on either day 7, day 14, or day 
28.  L21 corresponds to five mice primed and boosted with 400 µg of 
β2mL21SESP and 25 µg of pUMVC3-mIL12.  IL-12 refers to mice primed and 
boosted only with 25 µg of pUMVC3-mIL12.  PBS refers to mice primed and 
boosted only with PBS.  For the IL-12 and PBS samples there was only 1 mouse 
on day 7 and 28 and 3 mice on day 14.  The value of 365 spots/million 
splenocytes for mouse 3 L21 day 7 and the value of 200 spots/million splenocytes 
for mouse 3 L21 day 28, highlighted in red, was thrown out based on a standard Q 
test at 90% confidence. A) Depicts graphically the average value for the 
ELISPOT assay for each group and the average of duplicate ELISPOT assays for 
each mouse in the group. B) List the confidence levels, based on Student t-Test 
analysis of each group's ELISPOT data, at which one can say the values were 
statistically different. 
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STUDIES WITH LIVE SENDAI VIRUS 
The next three studies were performed at the Trudeau Institute in Saranac Lake, 
New York under the guidance of Dr. David Woodland.  A protection study was 
conducted to see if mice vaccinated with the DNA vaccine, β2mL21SESP, would survive 
a lethal dose of Sendai virus.  Tetramer staining was performed on days 4, 7, 10, and 14 
to determine the relative amounts of viral specific CTLs in vaccinated and dummy 
vaccinated mice challenged with a sub-lethal dose.  The viral titer in the lungs was 
determined on days 7 and 10 to determine if the vaccinated mice were clearing virus 
quicker than dummy vaccinated mice after a sub-lethal challenge.  These studies were 
carried out concurrently with the dose and boost studies described above, which is why a 
400 µg dose of β2mL21SESP was used. 
 
Protection study 
This study was designed to determine if the vaccine could protect mice from a 
lethal challenge of Sendai virus. Thirty-five 10-11 week-old mice C57BL/6 (H-2Kb) mice 
(Jackson Laboratory) were divided into seven groups.  Ten mice received injections of 
400 µg of β2mL21SESP IM divided equally into each hind leg on day 0 and again on day 
14 and were classified as L21 DNA/ L21 DNA.  Ten mice received 400 µg of 
β2mL21SESP IM divided equally into the hind legs on day 0 and then 400 µg of 
pβ2mL21SE SQ into the stomach area; these mice were called L21 DNA/ L21 Protein.  
Five mice received 400 µg of β2mL21DMSP IM divided equally into the hind legs on 
day 0 and again on day 14 and were termed Dummy DNA/ Dummy DNA.  Five mice 
received 400 µg of β2mL21DMSP IM divided equally into the hind legs on day 0 and 
then 400 µg of pβ2mL21SE SQ into the stomach area; these mice were referred to as 
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Dummy DNA/ L21 Protein.  All injections in the first four groups included 25 µg of 
pUMVC3-mIL12.  The final 5 mice were not injected with anything and thus were called 
Nothing.   
On day 28, 14 days after the boost, mice were anesthetized with 250-300 µl of 
Avertin (Tribromoethanol, Appendix 1) administered intraperitoneally (IP) and were then 
administered what was believed to be a lethal dose of Sendai virus (2500 EID50) 
intranasally. The survival of the mice was monitored for three weeks (Figure 6.32).  Mice 
that looked dyspneic and adopted a hunched appearance at any time during the 
experiment were euthanized with 600 µl of Avertin.        
It is obvious from the survival rate seen in the Nothing control that the chosen 
dose of 2500 EID50 was too small to be lethal.  Although the difference in survival cannot 
be considered significant it is difficult not to notice that the only group in which all the 
mice survived was the Nothing group.  In addition to the survival rates, mouse weight 
loss was monitored over the three week time period (Figure 6.33).  Weight loss is 
generally an indicator that the animal’s immune system is active and can provide a 
measure of the virus-induced morbidity (Ulmer, Donnelly et al. 1993).  In immunized 
mice one would expect to see less weight loss and a more rapid return to their 
pre-infection weight as compared to controls.  However, this was not observed in this 
experiment; as a whole, non-vaccinated mice showed less weight loss than the group of 
vaccinated mice as a whole. 
A summary of peak weight loss given for each group is presented in Table 6.6.  
Weight loss in the L21 DNA/L21 DNA group is associated with dehydration when, on 
day 13, a water bottle was found broken and emptied in one of the cages, and was not 
included.  When looking at the data in this fashion, there appears to be two distinct 























l L21 DNA / L21 DNA
L21 DNA / L21 Protein
Dummy DNA/Dummy DNA
Dummy DNA/ L21 Protein
Nothing
 
Figure 6.32 Results from protection study, percentage of mice that survived. 
C57BL/6 were IM primed with 400 µg of β2mL21SESP and 25 µg of 
pUMVC3-mIL12 or 400 µg of β2mL21DMSP and 25 µg of pUMVC3-mIL12.  
On day 14 mice were boost IM 400 µg of β2mL21SESP and 25 µg of 
pUMVC3-mIL12 or 400 µg of β2mL21DMSP and 25 µg of pUMVC3-mIL12 or 
SQ with 400 µg of the recombinant protein β2mL21SE and 25 µg of 
pUMVC3-mIL12.  14 days after the boost mice were given intranasally a 2500 
EID50 dose of Sendai virus.  Their protection from the virus was observed for 21 
days. There were 10 mice in the L21 DNA/L21 DNA and the L21 DNA/ L21 
Protein groups and only 5 mice in the other groups. 
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with the other group displaying moderate or no weight loses.  For the L21 DNA/ L21 
Protein, the moderate to no weight loss group accounts for 60% of the mice as compared 
to only 30% of the mice in the L21 DNA/ L21 DNA and 20% of the mice in both 














L21 Protein Nothing 
0-5% 20% 30% 0% 0% 0% 
5-10% 10% 20% 20% 20% 40% 
10-15% 0% 10% 0% 0% 40% 
15-20% 0% 0% 0% 0% 20% 
20-25% 10% 0% 20% 0% 0% 
25-30% 40% 20% 40% 40% 0% 
over 30% 20% 20% 20% 40% 0% 
Table 6.6 Peak weight loss, grouped in 5% increments 
C57BL/6 were IM primed with 400 µg of β2mL21SESP and 25 µg of 
pUMVC3-mIL12 or 400 µg of β2mL21DMSP and 25 µg of pUMVC3-mIL12.  
On day 14 mice were boost IM 400 µg of β2mL21SESP and 25 µg of 
pUMVC3-mIL12 or 400 µg of β2mL21DMSP and 25 µg of pUMVC3-mIL12 or 
SQ with 400 µg of the recombinant protein β2mL21SE and 25 µg of 
pUMVC3-mIL12.  14 days after the boost mice were given intranasally a 2500 
EID50 dose of Sendai virus.  Their weight loss was observed for 21 days. There 
were 10 mice in the L21 DNA/L21 DNA and the L21 DNA/ L21 Protein groups 
and only 5 mice in the other groups. 
 
 
Figure 6.33 Mouse weight (grams) and % weight loss during protection study. 
Experimental procedure described in directly above. (Below) 
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Twenty-four 9-10 week-old mice C57BL/6 (H-2Kb) mice (Jackson Laboratory) 
were divided into two equal groups.  One group received 400 µg of β2mL21SESP and 25 
µg of pUMVC3-mIL12 IM administered equally into the hind legs on day 0 and again on 
day 14.  The other group IM received 400 µg of β2mL21DMSP and 25 µg of 
pUMVC3-mIL12 divided equally into the hind legs on day 0 and again on day 14.  On 
day 28, 14 days after the boost, mice were anesthetized with 250-300 µl of Avertin 
administered IP and then administered a sub-lethal dose of Sendai virus (125 EID50) 
intranasally.  Three mice in each group were sacrificed on days 4, 7, 10 and 14.   
The bronchoalveolar lavage (BAL), spleen, lungs, and mediastinal lymph node 
(MLN) were collected. (Appendix 1)  The mediastinal lymph node was the draining 
lymph node for the lung and the BAL was a sample collected by flushing the lungs.  Red 
blood cells were lysed with Gey’s solution.  Lymphocytes were isolated from the BAL 
using a Percoll gradient where the cells of interest were found between the 40% and 80% 
layers.  The B-cells and macrophages were removed from the spleens and MLNs by 
incubating the cells on a plate coated with goat anti-mouse IgG.  Macrophages were also 
removed from the BAL samples by letting the macrophages adhere to a standard tissue 
culture plate.  After the “panning” procedures non-adherent cells were collected and 
counted.   
Cells from the spleen, lungs and MLN were analyzed separately, while the three 
BAL samples for each respective time point were pooled.  Pooling of the BAL is 
necessary to obtain enough cells to assay. The cells from these collections were stained 
for viral-specific memory CD8+ cells using a PerCP anti-mouse CD8a LY-2 antibody 
(BD Pharmingen), a FITC anti-mouse C44 antibody (BD Pharmigen) and a Sendai 
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epitope specific PE H-2Kb MHC tetramer (Trudeau Institute) (Figures 6.29-6.33).  The 
samples have been gated only to show CD8+ cells.  The upper right hand quadrant 
represents high CD44 cells that were tetramer positive, (i.e. tetramer positive memory 
cells).  
 Notice by day 4, viral specific CD8+ memory cells had arrived in the lungs of 
mice vaccinated with β2mL21SESP, but not in mice injected with the dummy vaccine, 
β2mL21DMSP.  Since the Sendai virus is a respiratory infection, the early recruitment of 
memory cells to this area was noteworthy.  Viral-specific CD8+ memory cells do not 
appear in the lungs of dummy vaccinated mice until day 7.  With almost 90% confidence 
one can say that the β2mL21SESP vaccinated mice throughout the experiment 
consistently showed a higher percentage of viral-specific memory cells in the lungs. 
 It was unfortunate that the BAL sample for day four was lost, because of the 
importance of this time point to show early arrival of viral-specific memory cells.  Even 
still, relevant data can be obtained from the other time points.  Notice that percentage of 
viral specific memory cells in the pooled BAL samples from β2mL21SESP vaccinated 
mice were consistently higher than the BAL of dummy vaccinated mice.   
 The lack of viral-specific memory cells in the spleen and MLN on day 4 was 
expected because the infection was occurring in the lungs, thus initial T-cell will be  
recruited there.  As time passes increased percentages of viral-specific cells at these 
locations in protected mice would be expected.  At almost a 90% confidence level one 
state that take place in the MLN of β2mL21SESP vaccinated mice.   The same thing 
appears to be occurring in the spleen, but the confidence level that the numbers were 
distinct dropped below 90%.  Unfortunately, with only three mice variability between 
them has a large effect on the ability to find statistical relevance; even so the trend was 
that spleens from β2mL21SESP had higher percentages of viral-specific memory cells. 
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Dummy L21 Dummy L21 Dummy L21 Dummy L21

































 Dummy Day 4 Dummy Day 7 Dummy Day 10 Dummy Day 14 
L21 Day 4 94.17% - - - 
L21 Day 7 - 99.76% - - 
L21 Day 10 - - 95.45% - 
L21 Day 14 - - - 87.47% 
Figure 6.34 Tetramer staining for viral specific memory CTL in the lungs.   
C57BL/6 mice were infected intranasally with 125 EID50 Sendai virus 14 days 
after the boost and sacrificed 4, 7, 10, and 14 days post.  They were stained with 
anti-CD8, anti-CD44 and the Sendai epitope tetramer, SEV9 Kb.  The data is 
CD8+ gated with CD44 on the x-axis and SEV9 Kb on the y-axis.  Each group 
displays 3 mice per day.  The average response for L21 Day 7 only includes 2 
mice because of the unusually high number of CD8+ cell in the sample 
highlighted in red.  A) The staining results for mice vaccinated and boosted, 14 
days later, with 400 µg β2mL21SESP and 25 µg of pUMVC3-mIL12.    B) The 
staining results for mice vaccinate and boosted, 14 days later, with 400 µg 
β2mL21DMSP and 25 µg of pUMVC3-mIL12.  C) The percentage of CD8+ cells 
that were CD44 high and recognized the tetramer. D) Student t-Test analysis for 
the level of confidence that the values were statistically distinct. 
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 Dummy Day 4 Dummy Day 7 Dummy Day 10 Dummy Day 14 
L21 Day 4 96.94% - - - 
L21 Day 7 - 99.71% - - 
L21 Day 10 - - 73.45% - 
L21 Day 14 - - - 83.31% 
Figure 6.35 Tetramer staining for viral specific memory CTL from the spleen.   
C57BL/6 mice were infected intranasally with 125 EID50 Sendai virus 14 days 
after the boost and sacrificed 4, 7, 10, and 14 days post.  They were stained with 
anti-CD8, anti-CD44 and the Sendai epitope tetramer, SEV9 Kb.  The data is 
CD8+ gated with CD44 on the x-axis and SEV9 Kb on the y-axis.  Each group 
displays 3 mice per day.  A) The staining results for mice vaccinated and boosted, 
14 days later, with 400 µg β2mL21SESP and 25 µg of pUMVC3-mIL12.    B) The 
staining results for mice vaccinate and boosted, 14 days later, with 400 µg 
β2mL21DMSP and 25 µg of pUMVC3-mIL12.  C) The percentage of CD8+ cells 
that were CD44 high and recognized the tetramer. D) Student t-Test analysis for 
the level of confidence that the values were statistically distinct. 
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 Dummy Day 4 Dummy Day 7 Dummy Day 10 Dummy Day 14 
L21 Day 4 97.48% - - - 
L21 Day 7 - 2.62% - - 
L21 Day 10 - - 99.35% - 
L21 Day 14 - - - 89.28% 
Figure 6.36 Tetramer staining for viral specific memory CTL from the Mediastinal lymph 
node (MLN).  
C57BL/6 mice were infected intranasally with 125 EID50 Sendai virus 14 days 
after the boost and sacrificed 4, 7, 10, and 14 days post.  They were stained with 
anti-CD8, anti-CD44 and the Sendai epitope tetramer, SEV9 Kb.  The data is 
CD8+ gated with CD44 on the x-axis and SEV9 Kb on the y-axis. Each group 
displays 3 mice per day, except for the day 14 L21 when a sample was lost.   A) 
The staining results for mice vaccinated and boosted, 14 days later, with 400 µg 
β2mL21SESP and 25 µg of pUMVC3-mIL12.    B) The staining results for mice 
vaccinated and boosted, 14 days later, with 400 µg β2mL21DMSP and 25 µg of 
pUMVC3-mIL12.  C) The percentage of CD8+ cells that were CD44 high and 
recognized the tetramer. D) Student t-Test analysis for the level of confidence that 
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Figure 6.37 Tetramer staining for viral specific memory CTL from the pooled 
bronchoalveolar lavage (BAL).   
C57BL/6 mice were infected intranasally with 125 EID50 Sendai virus 14 days 
after the boost and sacrificed 4, 7, 10, and 14 days post.  They were stained with 
anti-CD8, anti-CD44 and the Sendai epitope tetramer, SEV9 Kb.  The data is 
CD8+ gated with CD44 on the x-axis and SEV9 Kb on the y-axis.    A) The 
staining results for mice vaccinated and boosted, 14 days later, with 400 µg 
β2mL21SESP and 25 µg of pUMVC3-mIL12.    B) The staining results for mice 
vaccinated and boosted, 14 days later, with 400 µg β2mL21DMSP and 25 µg of 
pUMVC3-mIL12.  C) The percentage of CD8+ cells that were CD44 high and 
recognized the tetramer. Each group displays the pooled BAL from 3 mice per 
day.  The sample for day 4 spilled, so there are no results.  Also, since these are 
pooled results no Student t-Test was performed. 
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Lung viral load study 
Twenty-four 9-10 week-old mice C57BL/6 (H-2Kb) mice (Jackson Laboratory) 
were divided into two equal groups.  One group received 400 µg of β2mL21SESP and 25 
µg of pUMVC3-mIL12 injected IM divided equally into the hind legs on day 0 and again 
on day 14.  The other group received 400 µg of β2mL21DMSP and 25 µg of 
pUMVC3-mIL12 injected IM divided equally into the hind legs on day 0 and again on 
day 14.  On day 28, 14 days after the boost, mice were anesthetized with 250-300 µl of 
Avidin administered intraperitoneally and then administered a sub-lethal dose of Sendai 
virus (125 EID50) intranasally.  Three mice in each group were sacrificed on days 4, 7, 10 
and 14 and the lungs were removed.  Lungs from mice sacrificed on days 7 and 10 were 
assayed for their viral load using an endpoint titration in embryonated hen eggs. 
(Appendix 1). Lungs from mice euthanized on days 4 and 14 were frozen, to be assayed 
later if deemed necessary.   Figure 6.38 gives the results of the lung viral titers as the log 
of the EID50.  Unfortunately the number of mice studied per time point was only 3, which 
presents problems when looking for significance.  With only 35% confidence, as 
calculated from using the Student t-Test, would one state that the log of the viral titer on 
Day 7 in L21 DNA/ L21 DNA vaccinated mice, 7.0 ± 1.7 log EID50, was significantly 
lower than Dummy DNA/ Dummy DNA, 7.7 ±1.5 log EID50.  On day 10 with 88% 
confidence one could state that the L21 DNA / L21 DNA vaccinated mice, 0 ± 0 log 
EID50 had a lower viral titer than the Dummy DNA/ Dummy DNA vaccinated mice, 1.3 
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Figure 6.38 Lung viral titer data presented as the log EID50.   
C57BL/6 mice were IM primed and boosted 14 days later with 400 µg of 
β2mL21SESP and 25 µg of pUMVC3-mIL12 or with 4 or with 400 µg of 
β2mL21DMSP and 25 µg of pUMVC3-mIL12.  14 days after the boost mice were 
inoculated intranasally with 125 EID50 of the Sendai virus. Lungs were collected 
on day 4, 7, 10, and 14 post infection. Each group represents the average of 3 




An important component of vaccines against many viruses, but in particular 
against HIV, will be the development of a vaccine that is able to elicit a strong CTL 
response. (Pollack, Zhan et al. 1997; Rowland-Jones, Dong et al. 1999; Kaul, Rowland-
Jones et al. 2001; Kaul, Rowland-Jones et al. 2001; Novitsky, Flores-Villanueva et al. 
2001; Rowland-Jones, Pinheiro et al. 2001).  A key step in CTL stimulation is the 
recognition of epitopes presented in the context of the MHC-I molecule.  As a means to 
simulate this, the physical coupling of a viral epitope to the N-terminus of β2m via a 
flexible linker has been explored.  Others have examined this idea in vitro.  Caras, in his 
dissertation in 1999, reported that a recombinant fusion protein with mouse β2m linked 
via 21 AA to the H-2Kb Sendai NP immunodominant epitope could stimulate viral 
specific T-cell hybridomas (Caras 1999).  Similarly, the Barber group at the University of 
Toronto, in 1998, showed that both cells pulsed with a recombinant fusion protein of 
human β2m tethered via 12 AA to a H-2Db-restricted immunodominant epitope from 
influenza virus NP and cells transfected with a plasmid encoding β2m linked via 8 AA to 
a H-2Kd-restricted influenza NP epitope could function as target cells in a chromium 
release assay with splenocytes from influenza infected mice (Uger and Barber 1998).  
However, neither Caras nor Uger examined the effect linker size has on MHC-I binding 
or TCR recognition.  But, more importantly, neither group assayed the ability of the β2m-
fusion vaccine to trigger an immune response in vivo or its ability to provide protection 
from a viral challenge.  Both the effect of linker size and the vaccine's protective qualities 
as either a recombinant protein expressed in E. coli or as part of a mammalian expression 
vector are presented in this work.  
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β2M-SENDAI EPITOPE VACCINE AS A RECOMBINANT PROTEIN 
To look at the effect of linker size on the recombinant protein version of the β2m 
viral fusion, β2m was tethered to the H-2Kb Sendai NP immunodominant epitope using 
two different linker sizes: 10 AA and 15 AA.  As a control, throughout the work, β2m 
was tethered to a dummy epitope using a 15 AA linker.  These constructs accompanied 
Caras’ fusion protein, with the 21 AA linker, which allowed the examination of three 
different linker sizes.  The proteins were engineered with extension PCR, cloned and 
expressed in E. coli, purified and then assayed in vitro and in vivo.   
 
MHC-I upregulation  
 There were two aspects of the recombinant fusion protein vaccine that were 
important to establish before choosing which linker size to test in vivo.  The first aspect 
was whether one of the linkers allowed the construct to bind the MHC heavy chain more 
efficiently.  The second aspect was whether any of the linkers prevented the TCR from 
binding.  An MHC-I upregulation experiment was performed to answer the first question 
and it was anticipated that the T-cell hybridoma stimulation experiment would answer the 
second. 
Using the distance tool in Swiss PDB Viewer to examine the crystal structure of 
the H-2Kb molecule with the Sendai epitope (Fremont, Mutsamura et al. 1992), the length 
between the N-terminus of β2m and the C-terminus of the epitope was estimated to be 
20.6 Å.  Linkers of 10 AA, 15 AA, and 21 AA were added on to the end of the 
N-terminus of β2m using the build function of Swiss PDB Viewer.  These linkers had an 
estimated size of 15.5 Å, 22.9 Å, and 32.2 Å, respectively.  The linkers could have a 
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maximum length of 32.5 Å, 48.8 Å, and 68.3 Å respectively, if they adopted an extended 
beta sheet configuration.  To provide a visual effect of the linker on the MHC-I molecule, 
using Swiss PDB Viewer, I modified the N-terminus of β2m in the Fremont structure to 
include either a 10 AA linker or a 15 AA linker (Figure 7.1).  Notice that the 10 AA 
linker in this configuration does not visually provide enough length to allow the fusion of 
the β2m to the Sendai epitope, whereas the 15 AA linker provides the necessary length. 
Consistent with the modeling, the fusion proteins with the 15 AA and 21 AA linkers 
displayed a greater ability to stabilize the MHC-I molecule on the surface of the RMA-S 
cells than did the 10 AA linker (Figure 6.10).  There was, however, no distinguishable 
difference between the 15 AA and 21 AA linkers, which would imply that the smaller 15 
AA linker provided enough flexibility to allow the epitope to bind.   
In 1999, Shields et al. showed that murine β2m could stabilize the MHC-I 
molecule on the surface of RMA-S cells (Shields, Hodgson et al. 1999). The fact that the 
construct with a 10 AA linker showed any upregulation was slightly unexpected. Thus, 
one might be tempted to suggest that the stabilizing effect was due to the binding of β2m 
and not the combination of the epitope with β2m.  If this were the case, then the same 
magnitude of stabilization would have been seen in the cells pulsed with the dummy 
epitope. However, these cells showed only a 2-fold increase stabilization of the MHC-I 
complex over the RMA-S control, whereas the cells pulsed with the recombinant 
β2-microglobulin Sendai epitope fusion protein with a 10 AA linker showed a 7-fold 
increase. 
The data from the pβ2mL10SE studies are consistent with the published work of 
Uger et. al, 1998, which used a β2m attached to a viral epitope with 12 AA acid linker (a 
maximum length of 39.0 Å) to pulse target cells in a chromium release assay (Uger and 
Barber 1998).  Although the crystal structure for the MHC-I molecule with the allele and 
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epitope combination used by Uger has not been determined, the crystal structures of 
many other MHC-I molecules have been published.  Table 7.1 summaries the minimal 







Figure 7.1 MHC-I structures modified to include the (Ser-Gly4) repeat linker.  
The original MHC-I structure was determined by Fremont. (Fremont, Mutsamura 
et al. 1992)  A) The MHC-I structure with a 10 AA linker (red) attached to the 
N-terminus of β2m (blue).  B) The MHC-I structure with a 15 AA linker attached 













Length in Å 
1BZ9 Murine H-2Db 9 P1027 20.4 
1FG2 Murine H-2Db 9 
LCMV 
GP33 22.1 
1CE6 Murine H-2Db 9 Sendai NP 18.7 
1JPG Murine H-2Db 9 
LCMV 
NP396 20.3 
1G7Q Murine H-2Kb 8 Mucin 1 21.0 
1JPF Murine H-2Kb 11 
LCMV 
GP276 21.0 
1G7P Murine H-2Kb 9 Yeast aG 22.2 
2VAB Murine H-2Kb 9 Sendai NP 20.6 
1LEG Murine H-2Kb 8 Unknown 22.2 
1NAN Murine H-2Kb 8 PBM1 20.1 
1NAM Murine H-2Kb 8 VSV 20.4 
1N59 Murine H-2Kb 9 LCMV 22.3 
1I7U Human HLA-A2 9 P1049-6v 20.4 
1I7T Human HLA-A2 9 P1049-5V 21.2 
1I7R Human HLA-A2 9 P1058 20.6 
1IM3 Human HLA-A2 9 HCMV US2 19.9 
1DUZ Human HLA-A2 9 HCMV Tax 21.2 
1JHT Human 
HLA-
A2*0201 9 Mart-1 20.9 
1JF1 Human 
HLA-
A2*0201 10 Mart-1 20.7 
1I1F Human HLA-A2.1 9 HIV RT 21.5 
1JGE Human HLA-B27 9 Unknown 22.5 
IE28 Human HLA-B5 8 HIV KM2 22.3 
IE27 Human HLA-B5 9 HIV KM1 19.8 
1MI5 Human HLA-B8 9 EBV 19.8 
1KJV Rat Rtl-A1c 9 Unknown 19.5 
 
Table 7.1 The distance from the N-terminus of β2m to the C-terminus of the Epitope. 
Using the Swiss PDB Viewer distance tool, with the N-terminus of β2m as the 
first point and the C-terminus of the peptide as the second, the minimal distance 
needed to link β2m to the viral epitope was estimated for 25 known MHC-I 
structures. 
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the C-terminus of the peptide while it sits in the MHC heavy chain groove.  This distance 
was determined using the Swiss PDB Viewer distance tool with the first point being the 
N-terminus of β2m and the second point the C-terminus of the peptide.  Though the 
minimal distance varies within each allele based on the type of epitope presented, no 
distance observed was smaller than the length of the 12 AA linker used by Uger.  Given 
that crystal structures are only snap shots of a dynamic interaction, the actual distance in 
a fluid system may be less, as the in vitro data for the shorter linker sizes suggests.  
Nevertheless, in the upregulation experiment, both the 15 AA and 21 AA linker 
constructs performed better than the 10 AA linker construct, thus providing evidence that 
the choice of linker size was important. 
 
T-cell hybridoma stimulation assay 
Unfortunately the T-cell hybridoma stimulation assay used to see if the T-cell 
receptor preferentially tolerated one of the linker sizes was not stringent enough to 
distinguish between the linkers or the dummy epitope control.  The choice of linker size 
depended on the T-cell hybridoma clone that was used.  The M1.1B3 clone preferentially 
tolerated the 21 AA linker and the M3.4D3 clone released more IL-2 in the presence of 
the 10 AA linker (Figure 6.16).  The M2.5D10 cells were unable to respond to the 
constructs with any of the linker sizes (Figure 6.14).  Note that it would be inappropriate 
to compare the amount of IL-2 released by one clone to that of another clone, because the 
maximum amount of IL-2 released is dependent on the clone as well as the clone’s ability 
to recognize the peptide being presented (Cole, Hogg et al. 1995).  The knowledge gained 
from this set of experiments was that when the recombinant fusion protein was presented 
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in the MHC-I complex, it would be able to stimulate some but not all TCR that 
recognized the peptide presented in a normal manner via the cytosolic pathway.   
 
In vivo immune response determined with a ‘traditional’ and ‘designed’ experiment  
Having established that all the β2m-Sendai fusion proteins could stimulate some 
of the viral specific hybridomas in vitro, all three were tested in vivo.  In two separate 
experiments, using two different injection methods, intramuscularly (IM) and 
subcutaneously (SQ), mice were vaccinated with the recombinant fusion proteins to 
determine which linker size would generate the greatest immune response.  In both 
experiments the vaccinated mice failed to generate viral- specific cells that secreted 
IFN-γ in samples from either the spleen or Peyer’s patches.   The failure of the vaccines 
to stimulate the immune response in vivo was unexpected.  As described in the Results 
section the use of the adjuvant, TiterMax Gold, might well explain the inability of the 
vaccines to generate a measurable cellular immune response during the first experiment.  
However, it was not used in the ‘matrix designed’ experiment, which showed similar 
negative results.  At this point some might be tempted to discount the results from the 
‘designed’ experiment because of a lack of familiarity with the technique.  Although the 
technique has not gained popularity in academic settings, many pharmokinetic studies use 
similar approaches to determine the effect of drug combinations (Merle and Mentre 1995; 
Boza, De la Cruz et al. 2000; Siepmann, Kranz et al. 2000; Duffull, Mentre et al. 2001; 
Duffull, Retout et al. 2002).  Furthermore, as discussed below, a ‘designed’ experiment 
identified the three major contributors for generating the production of IFN-γ secreting 
splenocytes with the DNA vaccine.  Taking these observations into account led me to 
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believe that the recombinant fusion protein vaccine failed as a primary stimulator of the 
immune system. 
The most likely explanation for the poor vaccination results would be the failure 
of the recombinant protein to exchange with β2m in vivo.  Our lab had previously shown 
that pβ2mL21SE could exchange with β2m on the surface of H-2Kb expressing cells in 
vitro, with a maximal exchange rate occurring at a concentration of 2 µg/ml (Caras 
1999).  However, these experiments were performed in a serum-free media without 
exogenous β2m to compete for the binding site.  Although I could not find the reported 
value for normal β2m levels in mouse blood or lymph fluid, in humans the concentration 
of β2m in the blood is approximately 2 µg/ml (Thakar, Rodrigues et al. 1992; Rodriguez, 
Cortes et al. 2000).  A similar concentration likely exists in the mice and thus our vaccine 
would have to out-compete native exogenous β2m. Therefore, before proceeding further 
with recombinant protein vaccine design, a better understanding of exchange rate in the 
presence of competing murine β2m is necessary to predict the likelihood that the vaccine 
could exchange in vivo.  Furthermore, because ultimately this vaccine would be used in 
human subjects, it would therefore be vital to understand the ability of the β2m fusion 
protein to exchange on the surface of cells expressing human MHC-I molecules while in 
the presence of human β2m.  It has been reported that human β2m has a higher affinity for 
both human and mouse MHC-I molecules than murine β2m (Karlsson, Groth et al. 1980).  
Since the murine β2m was used in the present work it may be prudent to switch to human 
β2m for future studies with this type of vaccine construct. 
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β2M-SENDAI EPITOPE VACCINE AS A MAMMALIAN EXPRESSION VECTOR  
To look at the effect of linker size on the mammalian expression version of the 
β2m viral fusion vaccine, β2m was tethered to the H-2Kb Sendai NP immunodominant 
epitope using three different linkers of sizes: 10 AA, 15 AA, and 21 AA.  Two additional 
controls were engineered to accompany the DNA vaccines, one control had a dummy 
(nonsense) epitope with a 21 AA linker and the other had only the 21 AA linker with no 
epitope at all.  The constructs were engineered with extension PCR, ligated into the 
pVAX1 minimal mammalian expression vector, cloned in E. coli, purified and then 
assayed in vitro and in vivo.   
 
T-cell hybridoma stimulation assay 
Regrettably, little information was gained from the in vitro T-cell hybridoma 
stimulation assays on transfected cell lines, as exemplified by the data shown in Figure 
6.24.  The likely problem with these experiments was very low transfection efficiencies.  
The transfection efficiency into the RMA-S cells of a plasmid expressing the green 
fluorescence protein (GFP) was estimated at less than one in a thousand cells (data not 
presented).  While the transfection efficiency into the NOR-10 cells was better, even then 
it was only between 6-9% for the GFP plasmid (data not presented).  If it were 
determined to be desirable to repeat these experiments, then the construct should be cut 
out of the pVAX1 vector and ligated into an alternate vector, such as pCDNA3.1 
(Invitrogen), that provides a mammalian selection marker.  The selection marker would 
allow one to eliminate untransfected cells and generate a stable clone line.  Uger et. al, 
1998, employed a similar method to generate stably-transfected RMA-S cells that 
expressed their β2m influenza epitope protein (Uger and Barber 1998).   
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For a few reasons the generation of stable clones was not conducted in this work.  
First, the T-cell hybridoma stimulation experiment with the recombinant proteins 
established that this assay would not be able to identify whether one of the linker sizes 
was optimal.  Second, the pVAX1 vector meets the requirements established by the Food 
and Drug Administration for uses as a DNA vaccine in humans, whereas vectors such as 
pCDNA3.1 do not (FDA 1996,).  Finally, since there are differences between the in vitro 
and in vivo environments, it was more prudent to test the DNA vaccines in vivo. 
 
In vivo immune response determined with a ‘traditional’ and ‘designed’ experiment  
Two in vivo experiments were conducted to establish the best linker sizes to use; 
one following a ‘traditional’ experimental design where several animals were given only 
one vaccine and assayed for the number of IFN-γ producing splenocytes.  The other 
followed a ‘matrix designed’ experimental approach where animals where given multiple 
vaccines at various doses to determine the effect of any one vaccine.  In both experiments 
the β2m-Sendai epitope construct with the 21 AA linker performed best.  As for the 
construct that performed second best, the data was inconsistent.  The 10 AA linker out 
performed the 15 AA linker construct in the ‘designed’ experiment by a small margin of 
40 spots/million splenocytes in the ELISPOT assay.  In the traditional method, however, 
the 15 AA linker out performed the 10 AA linker construct by 174 spots/million 
splenocytes.   
The 1/8th 2 level factorial center cube design used in the ‘designed’ experiment 
was the minimum required to determine the effect of each variable assuming that each 
variable acted independently.  To take into consideration all the possible interactions 
between the 6 variables a larger full 2 level factorial design with 64 experimental groups 
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would have been needed. Originally it was believed that the vaccine would act 
independently in such a fashion that increasing the dose of one of the vaccines would not 
affect the response of others.  This may not have been the case, as is discussed later, 
when looking at the effect of high doses of the DNA vaccine.  Therefore, the results from 
the ‘traditional’ method were probably a more accurate picture of the order of 
performance.  Nevertheless the both the ‘designed’ experiment and the ‘traditional’ 
experiment collectively showed that the 21 AA linker outperformed the 10 AA and 15 
AA linkers and that all three vaccines outperformed the controls.  Also, the decreased 
response seen in the mice vaccinated with β2mL10SESP further highlights the 
importance of choosing an appropriate linker size. 
There might be some concern as to whether the protein expressed on the cell 
surface is in fact the β2m-21 AA linker- Sendai epitope fusion protein or if it is only the 
Sendai epitope, after cleavage from the fusion protein by a cellular protease.  Although 
not to be offered as a definitive answer, the observed difference between the vaccines 
with the 10 AA, 15 AA, and 21 AA linkers to stimulate viral specific splenocytes, as 
shown in Figure 6.26, suggests that unless the small changes in linker sizes have dramatic 
effects on the ability of cellular proteases to cleave the epitope, then one could assume 
that the fusion protein would be intact on the surface of the cell.  The following 
experiments could provide additional support to the idea that in vivo an intact fusion 
protein was being surface expressed. 
Unfortunately we do not have the tools to assess surface expression in vivo.  As an 
alternative one could alter the β2m molecule in a manner that does not allow it to 
associate with the MHC-I heavy chain.  Point mutations in β2m have been shown to 
decrease the ability of the molecule to associate with the MHC-I heavy chain (Shields, 
Hodgson et al. 1999).  Presumably mutations could prevent the expressed fusion protein 
 178
from associating with the MHC heavy chain and becoming part of the MHC-I complex.  
If mice vaccinated with a plasmid containing β2m point mutations were able to generate a 
viral specific immune response similar to mice vaccinated with the β2mL21SESP 
vaccine, then this would provide evidence that the Sendai epitope was being cleaved.  If 
mice were not able to generate the immune response, then one could deduce that the 
intact fusion protein was surface expressed. 
A less direct method would be to remove the signal peptide from the vaccine 
design.  Proteins expressed from this plasmid would be directed to the cytosol, thus 
exposing the protein to the standard protein processing via the cytosolic pathway.  
Presumably, mice vaccinated with this plasmid might generate a small viral specific 
immune response, but most likely one would see a noticeable reduction in the number of 
viral specific splenocytes when compared to the original vaccine. 
As additional evidence that intact fusion protein was most likely being surface 
expressed one could look at the studies performed by Uger et al., 1998 (Uger and Barber 
1998).  They showed that if the surface peptides were stripped from cells transfected with 
their β2m-influenza epitope, these peptides could not precondition potential target cells in 
a chromium release assay.  Alternatively, peptides stripped from cells pulsed with the 
influenza epitope were able to condition cells as targets.  From these experiments they 
concluded that the β2m-influenza epitope was surface expressed.  Unfortunately due to 
the low transfection efficiencies in vitro this would not be an option with our construct, 
when expressed by the pVAX1 vector.  However, this specific issue of surface expression 
could potentially be addressed with an alternate vector such as pCDNA3.1 
The failure of the plasmid vaccine to generate a mucosal response as measured by 
the number of IFN-γ producing cells in the Peyer’s patches was probably due to the IM 
route chosen to deliver the vaccine and the choice of mucosal systems to analyze.  The 
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IM injection is traditionally known for its ability to create a systemic immune response 
(Yokoyama, Hassett et al. 1997; Fu, Guan et al. 1999; Ledwith, Manam et al. 2000).  For 
inducing a generalized mucosal immune response other routes such as oral or intranasal 
administration function better.  Although IM DNA vaccines often fail to generate a 
widespread mucosal immune response they are known to produce a local mucosal 
immune response in the draining lymph node (Wolff, Malone et al. 1990; Bohm, Mertens 
et al. 1998).  For the hind leg injection site used in these experiments the draining lymph 
node would be the popliteal node.  The Peyer’s patches were chosen instead because of 
their ability to offer data concerning a desired widespread mucosal response. 
 
Dose response 
The most fascinating observation presented in this work was the unusual dose 
response seen in the studies with the various amounts of β2mL21SESP DNA vaccines 
and 25 µg of pUMVC3-mIL12.   The data suggests that as the amount of a DNA vaccine, 
known to stimulate the production of IFN-γ producing splenocytes, was increased, the 
number of IFN-γ producing cells decreased.  The doses of plasmid DNA used in this 
work were higher than those reported by others who have examined dose responses on 
DNA vaccinations (Bohm, Mertens et al. 1998; Fu, Guan et al. 1999; Johnson, Conway et 
al. 2000; Lee, Yoon et al. 2001).   Fu et al., 1999, showed that as the amount of a DNA 
vector expressing the NP gene from influenza increased from 30 ng – 30 µg the number 
of CTL-specific splenocytes also increased (Fu, Guan et al. 1999).  Bohm et al., 1998, 
Johnson et al., 2000, and Lee et al., 2001, showed that as the dose of their respective 
DNA vaccines increased to 100 µg the measured viral specific immune response also 
increased (Bohm, Mertens et al. 1998; Johnson, Conway et al. 2000; Lee, Yoon et al. 
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2001). To the best of my knowledge we have conducted the only known experiments 
with DNA vaccines up to 800 µg, with our starting dose of 100 µg as the highest 
previously reported value in a dose response study.  These values have been reported as 
µg of plasmid and not moles of plasmid; thus one might want to suggest that molar 
values would have been more equivalent to the doses used in other works.  On this note, 
since pVAX1 is a minimal mammalian expression vector, whereas the vectors used by 
the other groups were not, it would be likely that when comparing µg to µg, mice 
vaccinated in this work received high molar doses.   
Our data suggests that doses over 200 µg begin to have a negative effect on the 
measured immune response with reductions occurring in an almost linear fashion (Figure 
6.27). At first I was tempted to believe that this might be a general rule for all DNA 
vaccines.  I began developing the idea that the effect of the increased dose was due  to 
tissue damage that interfered with uptake of the vaccine.  But I doubt that this was the 
case, because tissue damage results in the activation of the immune system, which would 
presumably benefit the development of the viral specific response (Goldsby, Kindt et al. 
2000).   
Another possibility was that with increased initial doses of DNA, the mice 
developed a specific immune response to the DNA itself.  Thus when the boost was given 
the mouse was primed to prevent the uptake of the boost DNA.  An interesting idea, but 
again I doubt this would be the case because I could not find published work 
demonstrating a specific immune response against naked DNA.  Perhaps the increased 
DNA triggered an increased non-specific immune response.  Outside of CpG motifs 
found in bacterial DNA being used as adjuvants, I could find no published work to 
confirm or disprove this idea.   Since the DNA constructs in this work did not contain any 
known CpG motifs this type of effect was considered negligible.  
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If total DNA was an issue in defining a response it could easily be tested by 
supplementing the smaller doses of β2mL21SESP with the pVAX1 vector, which would 
result in all doses having an equal amount of total DNA.  If repeating the experiment in 
this fashion gave the same results, then there might be something to the idea that 
increased total DNA was a problem in DNA vaccinations.  More work would then be 
needed to determine if the problem with total DNA was due to an idea I have proposed 
above or to a completely different reason altogether.   
Perhaps the decrease in the generation of viral specific IFN-γ producing 
splenocytes with increasing doses of DNA is not a general feature of DNA vaccines, but 
instead is specific for this particular vaccine.  There was a potential, due to the type of 
vaccine used, that the orientation of the viral epitope being displayed might be slightly 
different when presented by two different H-2Kb alleles on the surface of the same cell.  
A number of reports have shown that small variations in the peptide presentation on the 
same cell can cause partial or complete inhibition of T-cell activation (Sloan-Lancaster 
and Allen 1996; Preckel, Grimm et al. 1997; Stotz, Bolliger et al. 1999; Preckel, Hellwig 
et al. 2001).  Thus one could imagine that, since the epitope was physically attached to a 
flexible linker, there exists the possibility that the epitope could be presented by different 
H-2Kb alleles in a similar but slightly different fashion, causing T-cell anergy.  However, 
if this were the case one would expect this to occur regardless of the dose; and this was 
not what the data showed. 
Another concern specific for our DNA vaccine has recently been exposed.  For 
years the level of β2m in the blood has been correlated with diseases such as HIV, 
rheumatoid arthritis, multiple myeloma and chronic myelogenous leukemia (Revillard, 
Vincent et al. 1982; Lifson, Hessol et al. 1992; Thakar, Rodrigues et al. 1992; Mocroft, 
Johnson et al. 1997; Rodriguez, Cortes et al. 2000; Moreau, Misbahi et al. 2002).  In the 
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past it was believe that the high level of β2m was a side effect of the disease and not a 
potential contributor to it.  However, two very recent works, one by Bodnar et al., 2003, 
and the other by Xie et al., 2003, provide evidence that high levels of β2m have negative 
effects on the activation of cytotoxic T-lymphocytes.  Bodnar et al. have shown that a B 
cell line pulsed with 5 µM (60 µg/ml) β2m showed significantly weaker CTL activation 
than cells that were not pulsed with β2m (Bodnar, Bacso et al. 2003).  Similarly, Xie et al. 
showed that in a dose-dependent manner concentration of β2m greater than 10 µg/ml 
caused a down regulation of MHC-I and co-stimulatory molecules expressed on the 
surface of monocyte-derived dendritic cells (Xie, Wang et al. 2003).  In the presence of 
β2m these cells produced more of the immuno-suppressant cytokines: IL-6, IL-8, and 
IL-10 (Xie, Wang et al. 2003).  Additionally, Xie et al showed that in the presence of β2m 
the dendritic cells were less able to stimulate T-cells, as measured by lower IL-2 and 
IFN-γ release (Xie, Wang et al. 2003). 
It has been established that the expression of naked DNA injected 
intramuscularly, as done in this experiment, is localized to the muscle it was injected into 
and the draining lymph node associated with that muscle (Wolff, Malone et al. 1990; 
Yokoyama, Hassett et al. 1997; Bohm, Mertens et al. 1998; Martin, Parker et al. 1999; 
Ledwith, Manam et al. 2000).    Though, as mentioned earlier, no study has looked at 
doses in the range where this work showed a decreased response, it has been shown that 
expression levels of the encoded protein increase with increased DNA dosages (Fu, Guan 
et al. 1999).  Therefore, I postulate that the decrease of IFN-γ producing splenocytes seen 
with the higher doses was due to a high localized concentration of β2m.   
Our vaccine construct was being driven by the enhancer-promoter sequences from 
the immediate early gene of the human cytomegalovirus (CMV), thus higher expression 
levels of β2m would be expected than under normal conditions. Furthermore, β2m 
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naturally presented itself on the outside of the cell in a non-covalent manner bound to the 
MHC heavy chain in an interaction known to be tenuous (Karlsson, Groth et al. 1980).  
This combination makes it relatively easy to imagine the existence of high localized 
concentration in the area where the Sendai epitope was being presented.  This high 
localized concentrations of β2m would have also been seen in the ‘matrix design’ 
experiment, especially with groups 4, 6, and 9 where more than 300 µg of a β2m- 
expressing vaccine was injected.  
This theory that high localized concentrations of β2m were a problem could easily 
be tested.  An experiment similar to the one proposed to determine if high doses of DNA 
were an issue could be performed.  However, instead of supplementing the doses of 
β2mL21SESP with the pVAX 1 vector, one could simply use the β2mL21DMSP vector, 
since this vector also produces β2m.  This experiment could provide evidence towards 
making the case that high-localized concentrations of β2m were a legitimate concern.  Of 
course the experiment with the pVAX 1 vector would have to be performed as a control 
to rule out the potential effect of the high doses of DNA. 
If high localized concentrations of β2m were established as a problem with this 
vaccine, then changing the route of delivery from IM to intranasal (IN) would be 
advisable.  IM administration provided a convenient initial route to test the vaccines; it 
was fairly easy to perform without having to anesthetize the mice and has been proven to 
elicit systemic immune responses.  Although mice would need to be anesthetized, the IN 
route has been shown to elicit both systemic and generalized mucosal immune responses 
(Oh, Kim et al. 2001; Tadokoro, Koizumi et al. 2001; Iqbal, Lin et al. 2003).  Following 
DNA vaccination via the IN route Oh et al, 2001, showed mRNA corresponding to the 
DNA vaccine could be found in the lung, spleen, brain, and lymph nodes (Oh, Kim et al. 
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2001). The widespread distribution of the vaccine might overcome high localized β2m 
concentrations.   
 
STUDIES WITH LIVE SENDAI VIRUS 
Given that a 400 µg dose of DNA was used for both the priming and boosting in 
the protection studies, high localized concentrations of β2m possibly existed in these 
animals.  While β2m concentrations in the hind leg muscle and associated draining lymph 
node might prevent priming of the immune system, it should have little effect on the 
generation of an immune response in the lungs.   Therefore, it might be hard to argue that 
the concentration of β2m had a negative effect in the protection study.   Furthermore, if 
the vaccines were unable to prime the CTL response ahead of the infection then these 
mice should have responded similarly to the unprimed mice.  Another concern for this 
vaccine might be that the β2mL21SESP vaccine inappropriately activated the clonal 
expansion of a viral specific CTL population that recognized the Sendai epitope but was 
unable to respond effectively.  In this situation, the mice in this group would have faired 
poorly while the mice in the dummy vaccinated group would have responded in the same 
manner as the unvaccinated group.  However, in this study all vaccinated mice, including 
the dummy vaccinated ones, faired worse than the unvaccinated control mice.  As a group 
they showed an increased weight loss and decreased survival numbers. 
Aside from the injection of a plasmid expressing β2m, all vaccinated mice 
received 25 µg of a plasmid expressing the IL-12 cytokine.  IL-12 was included because 
it is known to shift the immune response to favor the secretion of TH1 cytokines, such as 
IFN-γ (Kim, Ayyavoo et al. 1997; Scott and Trinchieri 1997; Park and Scott 2001; 
Trinchieri 2003).  Since CTLs respond better in a TH1 cytokine environment, directing 
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the immune system in this direction was believed to be a desirable end result.  Clear 
evidence of the ability of IL-12 to increase the number of splenocytes secreting IFN-γ can 
be seen by the difference observed when mice were given β2mL21SESP plasmid alone as 
compared to those that also received the IL-12 plasmid (Figure 6.29).  However, unless 
the high β2m concentrations were not just a localized event but instead had widespread 
consequences then the only other possibility consistent with the data available was that 
the IL-12 was having a negative effect.    
The co-administration of IL-12 as an adjuvant with a DNA vaccine has shown 
mixed results that depend on the virus the vaccine is trying to protect against. 
Co-administration of IL-12 has been shown to increase the protective characteristics of 
vaccines generated against pseudorabies virus, Mycobacterium tuberculosis, herpes 
simplex virus-2, hepatitis B, and the parasites Leishmania major and Trypanosoma cruzi 
(Kim, Ayyavoo et al. 1997; Chow, Chiang et al. 1998; Mendez, Gurunathan et al. 2001; 
Katae, Miyahira et al. 2002; Triccas, Sun et al. 2002; van Rooij, Glansbeek et al. 2002).   
The use of IL-12 as an adjuvant had no effect on DNA vaccines against influenza 
(Iwasaki, Stiernholm et al. 1997; Lee, Youn et al. 1999).  Finally, IL-12 as an adjuvant 
has been shown to have negative effects on vaccines designed to protect against Japanese 
encephalitis virus JAV, SIV when a cDNA library was used as the vaccine, and Feline 
infectious peritonitis (FIP) (Chen, Pan et al. 2001; Glansbeek, Haagmans et al. 2002; 
Sykes, Lewis et al. 2002).  While, JAV generally requires the production of neutralizing 
Ab for protection, which would not be favored by a shift towards an TH1 response, SIV 
and FIP rely on a cellular immune response to help provide protection.   Also, Romani, 
Puccetti, and Bistoni, in a review, have stated that “in acute viral or fungal infections, the 
immuno-toxicity of relatively low doses of IL-12 was associated with the uncontrolled 
production of pro-inflammatory cytokines, such as TNFα and IFN-γ, thus resulting in 
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septic shock-like pathology or excessive sensitization to microbial stimuli” (Romani, 
Puccetti et al. 1997). 
  As far as I know the present work has been the first study using IL-12 as an 
adjuvant with a DNA vaccine against the Sendai virus.  Therefore, there exists a 
possibility that IL-12 might have a negative effect on the protection against the Sendai 
virus. Unfortunately, prior to performing the protection study, it was not anticipated that 
IL-12 or high concentrations of β2m might present a problem, thus no independent 
controls were incorporated into our experiment.  For this reason the negative effect seen 
in the vaccinated group cannot be attributed to one or the other possibilities without 
performing additional experiments. 
When comparing the groups in the protection study that were given IL-12, the 
group that faired best was the mice vaccinated IM with β2mL21SESP and boosted SC 
with pβ2mL21SE.  The vaccination strategy of using a DNA vaccine to prime the system 
and a protein vaccine to boost has shown promise by others (Letvin, Montefiori et al. 
1997; Habel, Chanel et al. 2000; Hammond, Jansen et al. 2001; Hevey, Negley et al. 
2001).  Letvin et al., 1997, showed that rhesus monkeys vaccinated with a vector 
encoding for the HIV Env protein and boosted with the recombinant Env protein were 
protected from a chimeric SIV challenge (Letvin, Montefiori et al. 1997).  It would, 
however, be premature to claim that this vaccination strategy was the reason for 
decreased weight loss seen in mice from this group in the protection study or for that 
matter the increased number of IFN-γ producing splenocytes seen in mice boosted with 
the peptide vaccine (Figure 6.30).  The reason it would be premature is that the effect of 
only having an initial priming with the DNA vaccine and no boost whether it be protein 
or DNA has not been investigated.  The combination of high localized concentrations of 
β2m plus a subcutaneous injection of the recombinant β2m-Sendai epitope fusion protein, 
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which should not increase the localized concentration of β2m in the muscle tissue or 
popliteal node, provides a way for the peptide boost to show a false positive effect. 
The protection study will need to be repeated with and without IL-12.  Before 
conducting the experiment it would be prudent to investigate administering the vaccine 
intranasally (IN).  Also, it would be advisable to determine the cause for the decreased 
response observed with higher doses of DNA and then make the necessary adjustments to 
the protection study to account for it.  Additionally it will be necessary to determine a 
dose of Sendai virus that is lethal to unprotected mice. 
In the tetramer staining and viral titer studies, performed with sub-lethal doses of 
Sendai virus, the only controls were mice vaccinated with the dummy epitope and with 
the IL-12 plasmid.  Therefore no information concerning the negative effects of the IL-12 
plasmid or high β2m can be gained from these experiments.  However, in these 
experiments, along with the comparative results in the protection study, the β2mL21SESP 
vaccinated mice mounted a better viral specific immune response than did the dummy 
vaccinated group.  The β2mL21SESP vaccinated group mounted a viral specific immune 
response in the lungs by day 4, whereas this response was not seen in dummy-vaccinated 
mice until day 7 (Figure 6.34).  Throughout the study the β2mL21SESP group showed 
higher percentages of CD8+ viral specific memory cells in the lungs than did the controls.  
Increased percentages of CD8+ viral specific memory cells were also observed in the 
spleen, MLN, and BAL of β2mL21SESP vaccinated mice compared to the dummy 
vaccinated group (Figures 6.35-6.37).  Additionally, based on viral titers, by day 10 all 
three mice in the β2mL21SESP vaccinated group had cleared the infection from the lungs 
while only one of the three mice in the β2mL21DMSP group tested negative for virus 




Unfortunately questions still exist as to the protective ability of this vaccine, 
therefore it would be premature to suggest that the vaccine could one day be used as 
either a prophylactic or therapeutic treatment for HIV.  Assuming the problems with the 
protection study were due to the co-administration of IL-12, modification would still be 
required to make it effective against HIV.  First, when designing an HIV version of this 
vaccine the murine β2m will need to be exchanged for the human version of this 
molecule.  Second, an appropriate HIV epitope will need to be identified.  HIV epitopes 
should be chosen based on their ability to be presented in different MHC-I alleles along 
with their likelihood of being broadly cross-reactive against the different stains of HIV.  
Many epitopes have been identified that show these characteristics: for example the Gag 
– p17, residues 77-85,  Pol, residues 313-321, and Nef, residues 71-80 (Ferrari, Kostyu et 
al. 2000).  The basic design allowing for the easy exchange of epitopes should be kept to 
make it straightforward to design multiple vaccines covering a spectrum of HIV CTL 
epitopes. 
Overall this work has made a novel contribution to the understanding of β2m viral 
epitope fusion vaccines.  The choice of linker size has been shown to be an important 
consideration when tethering the β2m to the viral epitope.  The ability of a DNA vaccine 
to generate a viral specific immune response has been established.  Though the protective 
ability of the vaccine has not been established, the early arrival of viral specific memory 
cells gives credence to the vaccine's potential to provide protection. 
 






  Appendix I: Materials and Methods 
PROTEIN VACCINE PROTOCOLS 
Extension PCR 
This protocol uses the Expand High Fidelity PCR System (Roche) to create the 
PCR products that code for the β2m-Sendai epitope fusion proteins.  For the 
pβ2mL10SEHT and pβ2mL15SEHT constructs, the first template was the pSK-β2m 
plasmid and the second was the purified PCR product from the reaction with the first 
template.  For the pβ2mL15DMHT the only template used was the pβ2mL15SEHT 
pCRT7/NT plasmid.  The primers can be found in the section Appendix: Primers. 
 
___1. Prepare the PCR cocktail below 
  MM1 µl  MM2    µl 
dNTPs (Roche) 10mm 2 Expand buffer 2 10X 10 
T7 primer  15µm  2 dH2O  39 
Upstream Primer 15µm  2      
Template    2 
dH2O   42  
 
___2. Make 2 sample mixtures of MM1 and MM2 by mixing 25µl of MM1 with 24.5 µl 
of MM2 in a small PCR tube then add 0.5 µl of Expand PCR enzyme (taq + pfu). 
Samples now have a total volume of 50 µl.   
___3. Run PCR program danny β2m on the Perkin Elmer GeneAmp PCR System 2400 
(Figure A.1) 
___4. Run a 1% agarose TAE gel at ~75 V for 1 hr on PCR product to verify 
amplification. 





Figure A.1 PCR program danny β2m 
 
 
TOPO cloning for the pβ2mL10SEHT, pβ2mL15SEHT and pβ2mL15DMHT 
This protocol was use to transform a clone bacteria with the vectors expressing 
pβ2mL10SEHT, pβ2mL15SEHT and pβ2mL15DMHT, respectively. 
___1. The purified PCR product was then ligated into the pCRT7/NT-TOPO vector 
following the directions provided in the pCRT7 TOPO TA Cloning kit version E 
(Invitrogen) page 11 (Invitogen 2000). (See below) 
___2. The cells were allowed to recover in 200 µl of SOC (below) in the 37°C New 
Brunswick Scientific C25 Incubator Shaker at 37°C for 30-45 minutes at 230 
RPM. Avoid incubating the cells in SOC for longer than 60 minutes; since the 
SOC media does not contain a selection antibiotic longer incubation times may 
cause the bacteria to reject the plasmid. 
___3. While waiting on the cells to recover, LB plates containing 60 µg/ml ampicillin 
should be placed into the 37°C oven to warm. 
 191
___4. Using two different amounts (one small ~ 50 µl, one large ~ 180 µl), plate the 
SOC/cell sample on to the two LB plates.  Spread the samples evenly and then let 
them set face up for 10 minutes in the 37°oven. 
___5. After 10 minutes flip the plates and let incubate overnight. 
 
For SOC media: dissolve 20 g bacto-tryptone, 5 g bacto-yeast extract, 0.5 g NaCl, 
950 ml of dH2O, add 10 ml of 250 mM KCl and pH to 7.0 and fill to 1 L with dH2O, 
autoclave then add 20 ml of a 1 M glucose solution that had been passed through a 0.22 
micron filter.  Aliquot into 200 µl samples and store at -80°C) 
 
pCRT7 TOPO TA Cloning kit version E (Invitrogen) page 11 (Invitogen 2000) 
This protocol was used to ligate the PCR products into the pCRT7/NT TOPO 
vector. 
___1. Turn on water bath to 42ºC and thaw of SOC (above) to room temperature. 
___2. Prepare the reaction below 
 Fresh PCR product 0.5-4µl 
 Salt Solution 1µl 
 Sterile Water add to final volume of 5µl 
 TOPO Vector 1µl 
 Total   6µl 
___3. Mix reaction gently and incubate for 5 minutes at room temperature, then place 
mixture on ice. 
___4. Add 2µl of TOPO reaction from above into a vial of One Shot Chemically 
Competent E. coli and mix gently. DO NOT mix by pipetting up and down. 
___5. Incubate on ice for 5-30 minutes. 
___6.  Heat-shock the cells for 30 seconds in a 42ºC water bath without shaking. 
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___7. Immediately transfer the tubes to ice. 
 
Master plate for all constructs 
This protocol was used to create a plate of isolated colonies. 
___1. Draw a 4x4 grid on the back of a clean LB plate containing 60 µg/ml ampicillin. 
___2. Using a platinum wire tool, pick a colony off the original plate and place it down 
in one of the squares created on the fresh plate.  Repeat this process until all 
squares are occupied.  16 colonies were transplanted. 
___3. Then place the new plate face up for 10 minutes in the 37°oven, after 10 minutes 
flip the plates and let incubate overnight 
 
Colony PCR screening for all constructs 
This protocol was used to determine if transformed bacteria cells had a plasmid 
with the desired length for the inserted construct.  The primers can be found in Appendix: 
Primers. 
___1. Prepare the PCR cocktail below to screen 10 colonies. 
 µl 
dNTPs 10mm 6 
Forward primer 15µm 6 
Reverse primer  15µm  6  
Taq Buffer (Roche) 10X 22 
dH2O   180 
total  220 
 
___2. Mix well then, divide the cocktail into 10 labeled tubes, 20 µl per tube. 
___3. Take a swipe of a colony with a toothpick, and swirl it in the PCR cocktail. 
___4. Boil the cocktail for 5 minutes. 
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___5. Transfer the cocktail to PCR tubes. 
___6. Add 0.5 µl of Taq polymerase (Roche) 
___7. Run the Danny β2m program on the Perkin Elmer GeneAmp PCR System 2400 
___8. Add 4 µl of 6X DNA loading buffer (0.25% bromophenol blue, 0.25% xylene 
cyanol FF, and 30% glycerol in dH2O) to each tube and run a 1% agarose TAE 
gel at 75V for ~1.5 hrs to see if the amplified band is present.  Running buffer is 
40 mM Tris-acetate, pH 8.0, 1 mM EDTA. 
 
 
Protein expression and purification 
This protocol was used to obtain large amounts of pure pβ2mL21SE, 
pβ2mL15SE, pβ2mL10SE, or pβ2mL15DM. 
Heat shock transformation 
___1. Turn on water bath to 42°C 
___2. Combine 1 µl of pure plasmid with 20 µl of BL21(DE3) cells 
___3. For a negative control combine 1 µl of dH20 with 20 µl of cells 
___4. Store cells on ice for 20-30 min 
___5. Thaw out one 200 µl vial of SOC for every transformation 
___6. Incubate cells in 42°C bath for 30-60 sec. 
___7. Put cells back on ice for 2 minutes 
___8. Add 200 µl of SOC to each vial of cells 
___9. Place vials in the incubator shaker at 37°C for 45-60 minutes at 230 RPM.  
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 Growth, Induction, and Harvesting 
___10. With the SOC/cell solution inoculate 10 ml of LB with 60 µg/ml ampicillin, do 
the same for the negative control.  To ensure proper oxygen delivery, choose a 
tube where the total volume of liquid is no more than 30% of the total volume of 
the container. 
___11. Place in the 37°C incubator shaker overnight at 230 RPM 
___12. With 3 ml of the overnight culture of cells inoculate two 6L flask containing 1400 
ml of LB with 60 µg/ml ampicillin.  
___13. Let cells grow to an OD600= 0.5-0.8 in the incubator shaker at 37°C and 230 
RPM. 
___14. Induce the expression of the insert with 1 mM final concentration Isopropylthio-
β-D-galactoside (IPTG) 
___15. Allow protein expression for 2-3 hours in the incubator shaker at 37°C and 230 
RPM. 
___16. Harvest cells at 4500g for 15-20 min at 4°C with Sorvall GSA rotor in the Sorvall 
RC-5B Refrigerated Superspeed Centrifuge. 
___17. Collect and weigh cell pellet 
___18. Store cell pellet at  -80°C until needed.   
Cell Lysis and Ni NTA Column 
___19. Thaw out cell pellet 
___20. Lyse cells in 5 times volume/pellet weight (ml/g) with Lysis Buffer B (8M urea, 
100 mM NaH2PO4, 10 mM Tris•Cl (pH=8.0)). 
___21. Mix solution on a stir plate for 1-1.5 hrs 
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___22. Equilibrate a charged Ni-NTA agarose column (QIAGEN) with Lysis Buffer B, 
the column size should be 1 ml column per 20 g of cell pellet. 
___23. To remove cell debris spin the lysed cell solution at 27000g, 4°C for 20 min in the 
Sorvall SS-34 rotor in the Sorvall RC-5B Refrigerated Superspeed Centrifuge. 
___24. Load supernatant onto the Ni-NTA column and discard pellet 
___25. Washed with Lysis Buffer B, pH=6.3, equal to the amount loaded. 
___26. Eluted with the Lysis Buffer B, pH=4.5 equal to ~15% of the load volume 
___27. Adjust pH of eluate to ~ 8 to reduce problems associated with lower pHs. 
___28. Run a 15% Tris-Glycine SDS-PAGE gel at 200 V for ~ 40 min to check the purity 
of the eluted protein 
Refolding 
The protein was refolded in a two-step dialysis process similar to that described in 
the Current Protocols in Protein Science page 6.5.3-4 (Coligan, et al., 2002).  
___29. Tie a double knot into one end of wet 6,000-8,000 dialysis tubing (Spectrum) 
___30. Transfer the eluted protein into the dialysis tubing and double knot the other end 
___31. On a stir plate dialysize against 4 liters BHG buffer A (50 mM glycine, 10% (w/v) 
sucrose, 1 mM EDTA, 4 M Urea, 1 mM reduced glutathione, 0.1 mM oxidized 
glutathione, pH 9.6) overnight at 4°C. 
___32. Remove the tubing from BHG buffer A and dialyze against BGH buffer B (60 
mM ethanolamine, pH 9.6, 10% (w/v) sucrose, 1 mM EDTA, 0.1 mM reduced 
glutathione, 0.01 mM oxidized glutathione) for 6-8 hrs on the stir plate at 4°C 
___33. Perform BCA Protein Assay (Pierce) according to the manufacturer’s instructions 
to determine the concentration of the protein 
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Poly-histidine tag removal and protein concentration. 
___34. Incubate up to 10 mg of protein, as determined from a BCA Protein Assay, with 
50 U recombinant Enterokinase (Novagen) for 16 hours in BGH buffer B.   
___35. Concentrate the cut protein using a YM-3 Centriprep (Amicon) spun at 3000g, 
4°C in a GSA rotor. 
___36. To exchange the BGH buffer B with PBS; when the protein sample volume in the 
previous step reaches 1 ml add 14 ml of PBS and concentrate again, repeat.  This 
is equivalent to dialyzing 30 ml against 6.75 liters. 
___37.  Perform BCA Protein Assay according to the manufactures instructions to 
determine the concentration of the protein 
 
Upregulation of MHC I expression 
The upregulation experiment was used to determine if the β2m-Sendai epitope 
fusion proteins could bind to the MHC heavy chain and stabilize the MHC-I complex on 
the outside of RMA-S cells. 
___1. Grow RMA-S cells in RMA-S Growth Media ((RPMI 1640 with L-Glutamine 
containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin) termed 
RGM) at 37ºC in a 5% CO2 humidified incubator. 
___2. Take twice as much protein as the total to be used in the incubation with RMA-S 
cell. For example, for five 100 µl 50µM samples, use the equivalent of 10 
samples. (later half the sample will be lost)  Exchange the PBS that the proteins 
are in with RGM, using a Centricon 3 or Microcon 3 by combining 20x the 
volume of protein with the media. Spin time is ~3 hours at 1315g and 4°C in the 
Adams Compact II Centrifuge (Becton Dickinson) (Dr. Kramers cold room).  
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Concentrate the samples to below twice the total volume need for incubation. For 
example that would be below 1000 µl. (Note it is likely that the antibiotics got 
filtered out, so be sure to use sterile techniques) 
Perform steps 3-7 and 9-11 under the laminar flow hood with sterile techniques 
___3. Bring the sample volume to twice that used need for incubation with media. For 
our example that would be 1000 µl.  So you should have 1000 µl of a 50 µM 
sample. 
___4. Pass the samples through a .22 µm syringe filter, collect all the sample you can.  
(this is where you will lose about half the sample) 
___5. Combine 990 µl of RGM with 10 µl of 5mM peptide (FAPGNYPAL, synthesized 
from the University of Texas Protein Facility) to make a 50 µM solution and pass 
this through a .22 µm syringe filter. 
___6. Count the RMA-S cells using a hemocytometer 
___7. Take 3x105 cells per sample per protein and combine the sample for the same 
protein together in a 2.0 ml microfuge tube.  
___8. Spin the cells at 510g for 5 min in the Eppendorf Centrifuge 5412c in the 4°C 
cold room  
___9. Carefully remove the supernatant using a pipette 
___10. Add the RGM containing the protein or peptide control to the cells and mix by 
pipetting up and down a couple of times. 
___11. Put 100 µl of cells per well into a 96 well plate.  
___12. Place the plate into a 30°C incubator with 5% CO2 for one hour 
___13. Seal in the CO2 using Parafilm and place the plate at 26°C for 18-22 hrs 
___14. Remove the Parafilm and place the plate in a 37°C incubator with 5% CO2 for 
2 hr 
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From this point on keep everything on ice. 
___15. Remove the plate and transfer the cells to labeled 0.6 ml microfuge tubes 
___16. Pellet the cells at 510g for 5 minutes in the Eppendorf Centrifuge 5412c in the 
4°C cold room  
___17. Remove the supernatant using a pipette. 
___18. Add 200 µl of PBS with 0.1 % sodium azide and flick the tube several times to 
resuspend the cell pellet 
___19. Pellet the cells at 510g for 5 minutes at 4°C. 
___20. Remove the supernatant using a pipette. 
___21. Add 200 µl of PBS with 0.1 % Sodium Azide and 2.0 µg/ml of R-PE Anti-mouse 
H-2Kb Ab and then flick the tube several times to resuspend the cell pellet 
___22. Let the sample incubate on ice for 30 min 
___23. Pellet cells at 510g for 5 minutes at 4°C. 
___24. *** Wash twice with 200 µl of PBS with 0.1% Sodium Azide by pelleting and 
removing the supernatant. 
___25. After both washes resuspend the pellet in 200 µl of PBS with 0.1% Sodium Azide 
and store on ice until Flow cytometry, (can be stored without fixing for no more 
than a few hours) 
___26. Run the flow cytometer (BD FACSCalibur) in a log scale for collecting the PE 
fluorescence, because it will max out the linear scale. Report the mean 
fluorescence data. (note dead cells will have higher side scatters and lower 
forward scatters, thus try to gate them out)  
 
 *** Using a dye such as 7-Aminoactinomycin D (7AAD) or To-Pro3 to stain for dead 
cells is recommended and should be done after step 23, but this was only done in one of 
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the upregulation experiments.  Simply, remove the cells from the ice, add 2 µl of 7AAD 
solution (BD Pharmingen) per 100 µl of sample, incubate at room temperature in the dark 
for 10 min, run FACS. 
 
Tumor cocktail and complete tumor media (CTM) preparation 
This media was used with the T-cell hybridoma clones. 
___1. In a large sterile flask mix 
MEM Gibco 320-1380AJ  630 ml 
Dextrose Gibco 15023-021 7.5 g 
Essential Amino Acids (50x) Gibco 11130-051 75ml 
Non-Essential Amino Acids (100x)  Gibco 12383-014 140 ml 
Sodium Pyruvate (100x) Gibco 11360-070 100ml  
Penicillin/Streptomycin/Glutamine (100x) Gibco 10378-016 100 ml 
___2. Adjust pH to 7.0 with 10 N NaOH 
___3. Then add: 
Sodium bicarbonate Gibco 11810-025 8.5 g 
β-mercaptoethanol Gibco 21985-023  34 µl 
___4. Filter the solution through a 500 ml .22µm filter PES vacuum flask 
___5. Aliquot 43ml into sterile 50 ml tubes and freeze. 
___6. Add 43 ml to 500 ml of S-MEM + 10% FBS to make tumor media 
In the original protocol from David Woodland’s lab 500 mg of Gentamycin 
sulfate was used, however I have omitted this antibiotic because we did not have it. Also 
I felt like it was overkill because there are already two antibiotics, Penicillin and 
Streptomycin, in the mix. 
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T-cell hybridoma stimulation assay for peptide vaccines 
This protocol was intended to determine if any of the linkers interfered with 
T-cell receptor recognition.  However, the T-cell hybridoma stimulation assay proved to 
be inappropriate for this task, thus eventually all peptide vaccines were tested in vivo.  
___1. Grow RMA-S cells in RGM in a 5% CO2 humidified incubator. 
___2. Exchange the PBS that the proteins are in with RGM, using a centricon 3 or 
microcon 3. Described above in “Upregulation of MHC I Expression”. Final 
concentration of the vaccine should be 50 µM 
___3. Prepare a 50 µM solution of Sendai peptide as described in “Upregulation of 
MHC I Expression” 
___4. Count the RMA-S cells and put 4.5 samples of 3x105 cells per well into a 15ml 
falcon tube and spin down at 400g in the ThermoIEC Centra CL2 clinical 
centrifuge for 5 min. 
___5. Resuspend in the appropriate media containing the vaccine or peptide  
___6. Plate 4 wells of 3x105 cells per well in a 96 well plate 
___7. Place the plate into a 30°C incubator with 5% CO2 for one hour 
___8. Seal the CO2 in using Parafilm and place the plate a 26°C for 18-20 hours 
___9. After the incubation, pellet the cells at 4°C for 5 minutes at 400g in the Beckman 
CS-15R centrifuge with the S2096 Rotor.  
___10. Carefully remove supernatant. 
___11. Added 200 µl of the T-cell hybridomas in CTM at a total of 4.5x105 hybridoma 
cells per well.  This can be individual hybridoma clones or a combination of 
clones. 
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___12. Pipette cells up and down several times 
___13. Incubate at 37°C and 5% CO2 for 18-24 hours.  
___14. Perform IL-2 ELISA. 
 
IL-2 ELISA 
This protocol follows the procedure outlined by the manufacturer for the OptEIA 
Mouse IL-2 Set (BD Pharmingen). The recombinant IL-2 and antibodies used were from 
this set.  This experiment was used to determine the amount of IL-2 released during 
T-cell hybridoma stimulation assays. 
___1. Coat microwells with 100 µl per well of Capture Antibody (Anti-mouse IL-2 
monoclonal antibody) diluted 1:500 in coating buffer (0.1M Carbonate, pH 9.5 
made by dissolving 0.84g NaHCO3 and 0.356 g Na2CO3 adjusting the pH to 9.5 
and filling to 100 ml). 
___2. Seal plate and incubate overnight at 4°C. 
___3. Discard coating solution and wash 3 times with ~300 µl of wash buffer (PBS, pH 
7, with 0.05% Tween-20) 
___4. Block Plates with ~200 µl of assay diluent (PBS, pH 7, with 10% FBS) for 1 hour 
at room temp.  
___5. While the plate is blocking transfer samples to 0.6 ml microfuge tubes 
___6. Pellet cells at 510g for 5 minutes in the Eppendorf Centrifuge 5412c in the 4°C 
cold room  
___7. The supernatant will be assayed for IL-2. 
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___8. Prepare IL-2 200 pg/ml standard by following instructions on Instruction/Analysis 
Certificate, which were; add 10 µl of recombinant mouse IL-2 to 6.44 ml of assay 
diluent and mix. 
___9. Prepare 300µl of the other standards (100, 50, 25, 12.5, 6.3, 3.1 pg/ml) by serial 
dilutions of the 200 pg/ml sample supplementing with assay diluent.  Use assay 
diluent as the zero standard. 
___10. Discard blocking solution and wash wells 3 times with ~300 µl wash buffer. 
___11. Pipette 100 µl of each sample supernatant or standard into the appropriate wells. 
___12. Seal plate and incubate for 2 hrs at room temperature. 
___13. Discard sample and standard solutions and wash wells 5 times with ~300 µl wash 
buffer. 
___14. Add 100 µl of working detector (1:2000 dilution of detection antibody, 
biotinylated anti-mouse IL-2 in assay diluent plus avidin-horseradish peroxidase 
conjugate at a 1:500 dilution) 
___15. Seal plate and incubate for 1 hr at room temperature. 
___16. Discard the working detector solution and wash wells 7 times with ~300 µl wash 
buffer. Allow the wash to soak for at least 30 seconds during each wash. 
___17. Add 100 µl of 1-Step Ultra TMB substrate solution (Pierce)  
___18. Incubate plate in the dark until desired color is achieved, usually 30 min to 1 hour. 
___19. Add 50 µl of stop solution (0.5M oxalic acid) 
___20. Read absorbance with the EL340 Microplate Bio Kinetics Reader (Bio-Tek 
Instruments) at A 450 nm within 30 minutes of stopping reactions.  (You may 




ELISPOT assay   
This protocol follows the procedure outlined in the manufacturer’s instructions for 
the Mouse IFN-γ ELISPOT Set (BD Pharmingen) and was used for all ELISPOT to 
determine the number of INF-γ secreting cells. 
Under the Laminar Flow Hood 
___1. Dilute capture antibody, purified anti-mouse IFN-γ (BD Pharmingen), 1:200 in 
coating buffer (PBS, pH 7.2, sterile filtered) 
___2. Add 100 µl of dilute antibody solution to each well of an ImmunoSpot Elispot 
plate (BD Pharmingen).  (These plates contain a special membrane necessary to 
perform the assay.  Take care not to puncture the membrane when adding reagents 
to the plate.) 
___3. Seal plate and store at 4°C overnight in the tissue culture refrigerator  
___4. Aspirate off coating buffer and wash wells once with blocking solution (RPMI 
1640 with L-Glutamine containing 10% FBS, 100 U/ml penicillin and  100 
µg/mL streptomycin (i.e. RGM) 
___5. Add 200 µl of blocking solution to each well and incubate at room temperature 
for 2 hr. 
___6. During the blocking time, count the cells you want to add. 
___7. Make the necessary dilutions to give a final cell count of 2x106 cells/ml. 
___8. Perform serial dilutions to give cells concentrations of 2x106 cells/ml, 1x106 
cells/ml, 5x105 cells/ml and 2.5x105 cells/ml. 
___9. Aspirate off blocking solution  
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___10. Added 100 µl of 100 µM Sendai Peptide in growth media to each well, final 
concentration 50 µM (except Sendai peptide minus negative controls) 
___11. Added 100 µl of cells to each well following the 96 well format below. 
___12. Replace lid and incubate plates at 37°C in 5% CO2 for between 18-24 hr. 
Sterile conditions no longer required 
___13. Discard cells and wash wells 2x with deionized water. Allowing each wash to 
soak for 3-5 minutes. 
___14. Wash wells 3x with wash buffer I (PBS, pH 7.2, with 0.05% Tween-20) letting 
buffer soak for 2 min 
___15. Dilute detection antibody, biotinylated anti-mouse IFN-γ (BD Pharmingen), 1:250 
in dilution buffer (PBS, pH 7.2, with 10% FBS) 
___16. Add 100 µl to each well. 
___17. Replace lid and incubate at room temperature of 2 hrs. 
___18. Discard detection antibody solution and wash wells 3x with wash buffer I letting 
buffer soak for 2 min 
___19. Dilute avidin-horseradish peroxidase 1:100 in dilution buffer. 
___20. Add 100 µl to each well. 
___21. Replace lid and incubate at room temperature for 1 hr. 
___22. Discard avidin-HRP solution and wash wells 4x with wash buffer I letting buffer 
soak for 2 min. 
___23. Wash well 2x with PBS letting buffer soak for 2 min 
___24. Add 100 µl of final substrate solution (see below) 
___25. Monitor spot development from 5~60 minutes. Usually closer to 60 minutes. 
___26. Stop substrate reaction by washing wells with DI water. 
___27. Air dry plates for at least 2hrs (overnight okay) in the dark.  
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___28. Store plates in the dark until analysis. 
___29. Count spots under a Olympus SZX12 microscope (located in Dr. Tesmer’s cold 
room). 
Final substrate solution preparation. 
___30. Prepare AEC (3-amino-9-ethyl-carbazole; Sigma A-5754) stock solution by 
dissolving 100 mg of AEC in 10 ml of DMF (N,N-dimethylformanide; Sigma 
D-4551)  ** Prepare solution in glassware under the fume hood because it will 
react with plastics. 
___31. Prepare 0.1 M acetate solution by combining 14.8 ml of 0.2 M acetic acid/glacial 
acid with 35.2 ml of 0.2 M sodium acetate, adjust pH to 5.0 and fill to 100 ml. 
___32. Now combine 333.3 µl of AEC stock solution with 10 ml of 0.1 M acetate 
solution and filter through a 0.45 µm filter.  Add 5 µl of H2O2 (30%) and use 
immediately. 
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DNA VACCINE PROTOCOLS 
Extension PCR for DNA constructs 
See PROTEIN VACCINE PROTOCOLS.  This experiment was used to create the 
DNA constructs β2mL10SESP and β2mL15SESP.  For both the first template was the 
pSK-β2m vector; the second template was a purified first PCR product with added the 
linker; the third template was a purified second PCR product which added the Sendai 
epitope and a portion of the Signal peptide.  The primers for these reactions can be found 
in the section, Appendix: Primers. 
  
Restriction digestion of DNA construct (PCR product) and pVAX1 plasmid 
This protocol was used to create the appropriate overhangs in the pVAX1 plasmid 
and final DNA PCR products for the β2mL10SESP and β2mL15SESP.  The overhangs 
will facilitate in the ligation process. 
Ethanol precipitation 
If the DNA is in a solution other than water then ethanol precipitate the DNA 
prior to digestion. 
___1. Transfer DNA to a container where it fills no more than one fourth the total 
volume. For example, a 2000 µL tube should have no more than 500 µL of DNA 
solution.  
___2. Add one tenth volume of sodium acetate buffer to equalize ion concentrations  
___3. Add at least two volumes of cold 100% ethanol; let stand in -20°C freezer for at 
least one hour (okay to go overnight) 
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___4. Centrifuge sample for 15 minutes at >18,000g on the Eppendorf Centrifuge 5412c 
in the 4°C cold room  
___5. Remove as much supernatant as possible with a 1 ml micropipet; recentrifuge for 
1 min, then remove the rest with a 200 µL pipet  
___6. Add 200 µL of cold 70% ethanol; centrifuge for 5 minutes in the centrifuge at 4 
°C  
___7. Remove supernatant with a 200 µL pipet; evaporate remaining ethanol in a 37 °C 
water bath or at room temperature. 
___8. Resuspend pellet in desired volume of water. 
Sequential digestion  
___9. Turn on the water bath and set it at 37°C. 
___10. Pipette the following amounts into vials, all values are µl. 
 
 
 pVAX1 PCR3 Xho I* Nhe I No Cut  
Buffer M 4 4 1 1 1 
pVAX1 Vector (0.33 µg/µl) 3 0 1 1 1 
PCR product 0 33 0 0 0 
Sterile dH2O 30 0 7 7 8 
Xho I  ** (New England Biolabs) 0 0 1 0 0 
Nhe I ** (New England Biolabs) 3 3 0 1 0  
 Total 40 40 10 10 10 
 
* Prepare Xho I at step 13 
** Add the enzymes last, right before your are ready to incubate the reaction.  Always try 
to minimize the time the enzymes are out of the -20°C freezer. 
 
___11. Let digest 1.5 hrs. 
___12. Inactivate the enzymes by heating to 65ºC for 20 min 
___13. Prepare the Xho I control, after the Nhe I digestion.  
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___14. Add 2 µmoles Tris-HCl (pH 7.5) to the pVAX1 and PCR sample to bring the final 
concentration (fc) to about 50 mM.  So add 2 µl of 1 M Tris-HCl pH 7.5. 
___15. Add 2.6 µmoles NaCl to the pVAX1 and PCR sample to bring the fc  ~100 mM.  
So add 2.6 µl of 1 M NaCl. 
___16. Add 3 µl of Xho I to the pVAX1 and PCR. 
___17. Incubate the reactions for 1.5 hrs in the water bath at 37°C. 
___18. Run the entire pVAX1 and PCR product on a 1% agarose TAE gel with the 
following lanes assignments, instead of adding 6X loading dye to the PCR use 
30% glycerol as a 6X loading buffer. 
___19. Cut the pVAX 1 and PCR product out and purify using the QIAEX II gel 
extraction kit.  Eluded with dH2O for sequencing or 10 mM Tris·Cl, pH 8.5 for 
storage. 
___20. Run a 1% agarose TAE gel to determine the concentration of each. 
 
 
Restriction digestion of pVAX1 β2mL15SESP to cut out Sendai epitope. 
This protocol was followed to cut out the Sendai epitope form pVAX1 
β2mL15SESP so that the β2mL21SESP, β2mL21DMSP, and β2mL21NESP plasmids 
could be created.  Start by Ethanol Precipitate the pVAX1 β2mL15SESP, if needed. See 
Restriction digestion of DNA construct (PCR product) and pVAX1 plasmid. 
Sequential restriction digestion 
___1. Turn on the water bath and set it at 37°C. 
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___2. Pipette the following amounts into vials, all values are µl. 
 
  pVAX1 AGE I BAMH I No Cut  
NEBuffer 1 5 5 5 5  
pVAX L15 Vector (0.85µg/µl) 0.59 0.59 0.59 0.59 
Sterile dH2O 40.41 40.41 44.41 44.41 
Age I (New England Biolabs) 4 4 0 0 
BAMH I (New England Biolabs) 0 0 0 0  
 Total 50 50 50 50 
 
___3. Mix the reaction by pipetting up and down (do not vortex), then centrifuge to 
bring solution to the bottom of the tube. 
___4. Let digest 1.5 hours at 37ºC. 
___5. Inactivate the enzymes by heating to 65ºC for 20 min 
___6. Add 2µl of 4M NaCl (final concentration ~ 150mM), 0.53µl of BSA (final 
concentration = 100 µg/ml), 1µl of BAMH I or 1µl of dH2O 
___7. Let digest 1.5 hour at 37ºC. 
___8. Inactivate the enzymes by heating to 80ºC for 20 min 
___9. Run a 1% agarose TAE gel at 75V for ~1.5 hrs to determine if the DNA was 
properly cut. 
 
Oligonucleotide annealing  
This protocol was used to anneal complementary oligonucleotides that either 
encode for L21SE, L21DM, or L21NE.  The annealed oligonucleotides will be used to 
create β2mL21SESP, β2mL21DMSP, and β2mL21NESP.  The oligos used can be found 




___1. Prepare the following mixture in a PCR tube. 
 µL 
Oligo 1   10 µM 30 (complementary to oligo 2) 
Oligo 2   10 µM 30 (complementary to oligo 1) 
Expand 10X PCR buffer (Roche) 10 
dH2O 30 
Total  100 
 
___2. In the Perkin Elmer GeneAmp PCR System 2400 heat the sample to 94°C for 5 
minutes to separate strands, anneal together at a temperature between 52-56°C for 
1 hour 
 
Ligation with Rapid DNA Ligation Kit (Roche)   
This protocol was used to ligate the cut final PCR constructs for β2mL10SESP 
and β2mL15SESP into the cut pVAX1 vector.  The protocol was also used to ligate the 
annealed oligonucleotide for the 21 AA linker, the dummy epitope and the no epitope 
into cut pVAX1 β2mL15SESP.  The concentrations of the insert (cut PCR product or 
annealed oligos) and the concentration of the cut plasmid are needed to proceed.  
 
___1. In a small vial combine plasmid and insert at a 1 to 3 molar ratio and a 1 to 4 
molar ratio plasmid to insert.  Make sure the total amount of DNA is less than 200 
µg and the total volume less than 8 µl. 
___2. For a self ligation control combine plasmid with dH2O. 
___3. Bring volume in above to 8 µl with dH20. 
___4. Add 2 µl of DNA diluting buffer 5x  (Vial 2) 
___5. Add 10 µl of T4 DNA ligation buffer (Vial 1) 
___6. Mix thoroughly 
___7. Add 1 µl T4 DNA ligase 5 units/µl (Vial 3) 
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___8. Mix thoroughly  
___9. Incubate at room temp for 20 min 
___10. Turn the water bath on to 42°C. 
___11. Remove, from the -80°C freezer and thaw on ice, enough DH5-α cells or 
TOP10F’ cells for the reactions, including a negative control. 
___12. Remove, from the -80°C freezer and thaw on ice ,1 vial of SOC (200 µl) for each 
reaction. So for this example that would be 4 reactions: 1/3, 1/4, self ligation 
control, and negative control. 
___13. Add 1.5 µl of the ligation reaction to the chemically-competent 25 µl of bacteria 
cells and mix gently. For the negative control use 1 µl of dH2O. Do not pipette up 
and down. (the negative control verifies that the selection antibiotic works. 
___14. Incubate on ice for 20 minutes. 
___15. Heat shock the mixture for 30-45 seconds at 42°C. 
___16. Immediately put on ice. 
___17. Add 200 µl of SOC, and let shake for 1 hr at 37°C. 
___18. While you are waiting for the cells to recover, place to LB plates containing 60 
µg/ml ampicillin into the 37°C oven to warm them. 
___19. Using two different amounts (one small ~ 50 µl, one large ~ 150 µl), plate the 
SOC/cell sample on to the two LB plates containing 60 µg/ml ampicillin.  Spread 
the samples evenly and then let them set face up for 10 minutes in the 37°oven. 
___20. After 10 minutes flip the plates and let incubate overnight. 
 
 
Colony PCR screening for DNA constructs 




This protocol was used to obtain large quantities of β2mL21SESP, β2mL15SESP, 
β2mL10SESP, β2mL21DMSP, β2mL21NESP, and pVAX1. 
___1. In the morning, dip a sterile toothpick into the frozen glycerol stock of the 
bacteria vector with the plasmid of interest and drop it into a starter culture of 10 
ml LB with 50 µg/ml kanamycin.  (Bacteria glycerol stocks are kept in the -80°C 
freezer and should never be thawed.  Also, always have a primary stock of the 
isolated plasmid for long term storage).  For all bacterial growth samples pick a 
container where the total volume of solution is less than 30% of the total container 
volume. 
___2. Grow starter culture for 8 hr in the New Brunswick Scientific C25 Incubator 
Shaker at 37°C and 230 RPM. 
___3. Take 3ml of the starter culture and use that to inoculate two 6 L flasks containing 
1.2 liters of LB with 50 µg/ml kanamycin. (This is a 1/400 dilution)  
___4. Grow bacteria overnight for 12-16 hr in the incubator shaker at 37°C and 230 
RPM 
___5. Harvest cells at 3000g for 15-20 minutes at 4°C using the Sorvall GSA rotor in 
the Sorvall RC-5B Refrigerated Superspeed Centrifuge. 
___6. Remove the supernatant by inverting the tube and keep the cell pellet.  Cell pellets 
can be frozen at -20°C overnight if need be or at –80 for longer time periods. 
___7. Follow directions for steps 4 through 15 in the QIAGEN QIAfilter Handbook for 
a QIAfilter Giga prep of a high copy plasmid (QIAGEN 2000).  A 2000 ml 
graduated cylinder is convenient container to place the QIAGEN-Tip.  For the 
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pelleting the DNA out of the isopropanol (step 15) the screw top SS-34 tubes 
work well and can withstand the high g-force. 
___8. Add 10 ml of 70% ETOH to the DNA pellet from the isopropanol wash (step 15) 
___9. Transfer the ETOH/DNA solution into 2 ml microfuge tubes. 
___10. Pellet the DNA at >15,000 g in the Eppendorf Centrifuge 5412c in the 4°C cold 
room for 10 min. 
___11. Remove the supernatant with a pipette 
___12. Air dry the pellet for 10-15 min at room temperature. 
___13. Add 100-150 µl of PBS to each microfuge tube and resuspend the DNA pellet by 
votexing 
___14. Combine the resuspended DNA into one tube 
___15. Determine the DNA concentration using absorbance at 260 nm as measured by 
the Beckman DU530 Life Science UV/Vis Spectrophotometer. Take 2 µl of DNA 
and dilute it to 1 ml with PBS then find the A260.  DNA concentration equals 
DNA µg/ml = A260 x dilution factor (500 in this example)x50 (µg/ml)/A260.  I like 
reporting as µg/µl so I divided the above value by 1000. Pure DNA solutions will 
have an A260/A280 ratio about 1.8 or higher. 
 
QIAGEN QIAfilter Handbook steps 4-15 (QIAGEN 2000) 
Taken from the QIAGEN QIAfilter Handbook 
___4. Screw the QIAfilter Mega-Giga Cartridge onto a 45 mm-neck glass bottle and 
connect it to a vacuum source. 
___5. Resuspend the bacterial pellet in 125 ml Buffer P1. 
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___6. Add 125 ml Buffer P2, mix gently but thoroughly by inverting 4–6 times, and 
incubate at room temperature for 5 min. 
___7. Add 125 ml chilled Buffer P3, and mix immediately and thoroughly by inverting 
4–6 times. Mix well until white, fluffy material has formed and the lysate is no 
longer viscous. Proceed directly to step 8. Do not incubate on ice. 
___8. Pour the lysate into the QIAfilter Mega-Giga Cartridge and incubate at room 
temperature for 10 min. 
___9. Switch on the vacuum source. After all liquid has been pulled through, switch off 
the vacuum source. Leave the QIAfilter Cartridge attached. 
___10. Add 50 ml Buffer FWB2 to the QIAfilter Cartridge and gently stir the precipitate 
using a sterile spatula. Switch on the vacuum source until the liquid has been 
pulled through completely. 
___11. Equilibrate a QIAGEN-tip 2500 or QIAGEN-tip 10000 by applying 75 ml Buffer 
QBT and allow the column to empty by gravity flow. 
___12. Apply the filtered lysate from step 10 onto the QIAGEN-tip and allow it to enter 
the resin by gravity flow. 
___13. Wash the QIAGEN-tip with a total of 600 ml Buffer QC. 
___14. Elute DNA with 75 ml Buffer QF. 
___15. Precipitate DNA by adding 52.5 ml room-temperature isopropanol (0.7 volumes) 
to the eluted DNA. Mix, and centrifuge immediately at 15,000 x g for 30 min at 





T-cell hybridoma stimulation assay for DNA vaccines 
This experiment was intended to determine if the T-cell receptor tolerated 
preferentially tolerated one of the linker sizes.  The DNA vaccine first had to be 
transfected into the NOR-10 cell line before the cells could be used as targets in the 
stimulation assay.  However, the T-cell hybridoma stimulation assay proved to be 
inappropriate for this task, thus all DNA vaccines were tested in vivo.  
Day 1 
___1. Aspirate NOR-10 growth media (NGM) (DMEM 20% FBS and 1% Penicillin-
Streptomycin) from NOR-10 cells growing in a T75 flask 
___2. Add 5 ml of Trypsin EDTA and incubate for 10 min at 37°C and 5% CO2 
___3. Add 20 ml of NGM to neutralize the trypsin 
___4. Pellet cells at setting one in the clinical centrifuge for 10 min 
___5. Resuspend the pellet in 10 ml NGM 
___6. Count cells using the hemocytometer 
___7. Seed 2.5 x 106 NOR-10 cells into a T25 flask and fill to 10 NOR-10 growth media 
___8. Incubate overnight at 37°C and 5% CO2 
Day 2 
___9. Dilute 12 µg of DNA (9 µg Vaccine and 3µg of peGFP-N2 (CloneTech)) with 
500 µl of DMEM no serum; mix well 
___10. Add 75 µl of SuperFect Transfection Reagent (Qiagen) and mix well 
___11. Incubate at R1 for 5-10 min to allow complex formation 
___12. While complex formation takes place, gently aspirate of media for the NOR-10 
cells passed yesterday and wash with serum free DMEM or PBS 
___13. Add 4.5 ml of DMEM 20% FBS (no antibiotics) to the DNA/SuperFect complex 
___14. Transfer 5 ml of the DNA/Superfect media to the NOR-10 cells 
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___15. Incubate for 3 hrs at 37°C and 5% CO2  
___16. Aspirate off media and rinse 3 times with serum free DMEM or PBS 
___17. Add 10 ml of NGM and incubate overnight 
Day 3 
___18. Aspirate media from NOR-10 cells growing in a T25 flask 
___19. Add 2 ml of Trypsin EDTA and incubate for 10 min at 37°C and 5% CO2 
___20. Add 20 ml NGM to neutralize the trypsin 
___21. Pellet cells at setting one in the clinical centrifuge for 10 min 
___22. Resuspend the pellet in 10 ml NGM 
___23. Count cells using the hemocytometer 
___24. Seed 3 x 105 NOR-10 cells into a each well of a 12 well plate and fill to 2 ml with 
NGM. 
___25. Incubate overnight at 37°C and 5% CO2  
Day 4 
___26. Add Sendai Epitope to a final concentration of 2µM to the NOR-10 cells to be 
used as positive control. 
___27. Incubate peptide NOR-10 cells for 2 hrs at 37°C and 5%CO2 
___28. In the mean time count T-cell hybridoma cells 
___29. Dilute hybridoma cells to a final concentration of 1*106 cells/ml 
___30. Aspirate media off all NOR-10 cells including peptide pulsed cells  
___31. Wash all NOR-10 cells twice with CTM (above) 
___32. Add 2 ml of Tumor cells or Tumor media to the appropriate wells 
___33. To the positive control add peptide to a final concentration of 2 µM 
___34. Incubate cells at 37°C and 5%CO2 for 18-24 hrs. 
___35. Perform IL-2 ELISA (see PROTEIN VACCINE PROTOCOLS) 
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PROTOCOLS TAKEN FROM DR. WOODLAND’S LAB PROTOCOL BOOK AND 
PRESENTED IN A FORMAT SIMILAR TO THE OTHER PROTOCOLS IN THIS APPENDIX. 
Lymphocyte processing and SEV9 Kb tetramer staining protocols 
This protocol was used to assay if mice vaccinated with the β2mL21SESP vaccine 
and the pUMVC3-mIL12 could mount an earlier immune response with a higher 
magnitude of CD8+ viral specific memory cells than mice vaccinated with the 
β2mL21SESP and the pUMVC3-mIL12. 
Collection of organs 
___1. Mice are euthanized via the injection of 0.5 ml of Tribromoethanol via the intra-
peritoneal route. 
___2. When the mice are under the anesthetic effect of the Tribromoethanol they are cut 
in the auxiliary area with sharp scissors to nick the major auxiliary blood vessels. 
This allows for the bleeding out of the animal to minimize contamination of 
sampled organs by peripheral blood.  The blood is allowed to drain from the 
animal for a minute or two. 
___3. The mouse is then placed on its back with its head toward the technician and the 
skin gently removed over the neck and throat area.  The trachea is then exposed 
by gently pulling back on the fat, muscle, and salivary glands located in the area 
from the top of the sternum to the lower portion of the mandible. 
___4. The trachea is elevated using some curved forceps and a small cut is made on the 
upper surface of the trachea, taking care not to cut through the entire diameter of 
the trachea.  This should provide a small hole in which the catheter for the 
collection of lymphocytes in the bronchiole and alveolar spaces can be inserted.  
The fluid removed in this manner is termed BAL for Bronchiole Alveolar Lavage. 
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___5. A 1cc syringe fitted with a plastic catheter and containing 1.0 ml of ice cold 
Hank’s Balanced Salts Solution (HBSS) is gently threaded into the trachea toward 
the lungs.  The 1.0 ml of HBSS is then injected into the lungs and then washed 
back and forth.  A volume of approximately 0.75 to 0.9 ml should be recovered 
from the lung.  This lavage of the lungs should be repeated 3 additional times to 
adequately remove all of the resident bronchiole and alveolar lymphocytes.  
Routinely, the BAL harvested from individual mice in a group is pooled for 
analysis.  ( Note: For the SEV9 Kb Tetramer Time Course Experiments, all mice 
were lavaged 4 times with 1.0 ml and samples from individual animals were 
pooled within groups.) 
___6. The spleens of the mice are then removed by placing them in their right side and 
then carefully removing the skin on the left and making a small hole through the 
peritoneal wall above the spleen.  The spleen is then exteriorized with forceps and 
cut free from associated blood vessels and connective tissues and placed in a tube 
containing 10 ml of HBSS on ice.  Spleens from individual mice within a group 
are  pooled for analysis. 
___7. The Mediastinal Lymph Nodes (MLN) and Lungs are then harvested from the 
mice by placing them on their backs and removing the skin above the rib cage.  A 
cut through the rib cage removing the sternum exposes the thoracic cavity.  The 
ribs on the right side of the mouse are further trimmed to allow the better 
visualization of the MLN which can be found behind the right lung, medially and 
slightly anterior, along the back of the thoracic cavity.  The MLN are grasped 
with forceps and gently cut to remove them and placed in 10 ml of cold HBSS.  
The MLN of individual mice are pooled within an experimental group.  The 
Lungs are gently cut free and likewise pooled in 10 ml of cold HBSS. 
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Processing of tissues –  single cell isolation, Gey’s lysis & 40%-80% percoll of lung, & 
IgG primaria flask panning. 
 
___8. The spleens, MLN’s, and Lungs are gently pressed through a fine nylon mesh to 
achieve single cell suspensions.  Briefly, the harvested organs are placed in 100 
mm sterile petri dishes with the 10 ml of HBSS.  With sterile forceps the organs 
are placed into nylon mesh bags, which are gently pressed with the plunger of a 
5-10 ml syringe against the bottom of the petri dish.  A single cell suspension 
should result in the surrounding HBSS, which can be harvested to a sterile 
centrifuge tube (Sp & MLN use 15 ml tube, Lung use 50 ml tube).  The 
suspension from the lungs should be passed through a nylon mesh cells strainer to 
remove large pieces of tissue.  The nylon mesh bags are rinsed with 5 ml of HBSS 
for Sp and MLN and 30 ml of HBSS for Lungs to recover as many lymphocytes 
as possible. 
___9. The single cell suspensions (Sp, MLN, Lg, and BAL) are then centrifuged at 1200 
rpm for 10 minutes at 4C (Program 2). 
___10. The supernatant is then removed from the cell pellet via aspiration or gently 
tipping the tube.  The cell pellets are gently flicked to resuspend and break up 
clumps. 
___11. 2.0 ml of Gey’s (below) solution is added to the Spleen and Lung cells, while 1.0 
ml of Gey’s is added to the MLN and BAL cells with gentle mixing.  The cells are 
incubated at room temperature for 5 minutes and then topped off with HBSS to 
achieve a final volume of 15 ml per tube. 
___12. The Gey’s treated cell suspensions (Sp, MLN, Lg, and BAL) are then centrifuged 
at 1200 rpm for 10 minutes at 4C (Program 2). 
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___13. After centrifugation the supernatants are removed from the cell pellets as above 
and the Sp cells are resuspended in 10.0 ml of Complete Tumor Medium (CTM) 
and placed on ice.  The MLN and BAL cells are resuspended with 1.0 ml of CTM 
and likewise placed on ice.   
___14. The lung cells are resuspended with 1.0 ml of 80% Percoll per set of mouse lungs.  
Therefore, if 4 mice were harvested per pooled group, you need to suspend the 
lung cell pellet with 4.0 ml of 80% Percoll.  The lung cell/80% Percoll solution is 
then added to 15 ml centrifuge tubes in 2.0 ml volumes. 
___15. A 40% Percoll layer is then gently “floated” onto the surface of the lung cell/80% 
Percoll suspension.  The best method to do this is to angle the 15 ml conical 
centrifuge tube to an angel of approximately 30 degrees and slowly pipette the 2.0 
ml of 40% Percoll down the side of the tube.  Once the 40% Percoll has been 
layered the tube can slowly be brought to the vertical position and you should see 
a sharp interface between the 40% and 80% layers.  Be very gentle in handling the 
tubes so that you don’t cause mixing to occur. 
___16. The 40/80 Percoll gradients are then centrifuged for 25 minutes at 1650 rpm and 
18C (Program 7 or 14) 
___17. While the lung cells are spinning the Sp, MLN and BAL cells can be counted via 
the hemacytometer to determine cell numbers. 
___18. The depletion of B-cells and Macrophages from the Spleen and MLN samples is 
accomplished via “panning” approximately 2.0E+07 cells onto T-75 Primaria 
flask which have been coated with anti-mouse IgG (Refer to W/B Protocol: B 
Cell Depletion by Panning: Goat Anti-Mouse IgG Coated Flasks).  Briefly, a 10 
ml suspension of 2.0x107 cells in CTM is incubated in the coated Primaria flasks 
at 37°C, 10% CO2, for one hour.  The non-adherent cells are then gently 
 221
resuspended by rocking the flask and then washing with an additional 10 ml of 
CTM.  The non-adherent cells are then centrifuged at 1200 rpm for 10 minutes at 
4°C (Program 2).  The cells are then resuspended in 1.0 ml of CTM and counted 
via the hemacytometer. 
___19. After centrifugation of the lung cell Percoll gradients there should be a layer of 
lymphocytes at the interface of the 40% and 80% layers.  These cells are gently 
removed using a Pasteur pipette and placing them into a 50 ml centrifuge tube.   
___20. The Percoll enriched lymphocytes are washed with 25-30 ml of HBSS to remove 
the excess Percoll and centrifuged at 1200 rpm for 10 minutes at 4°C (Program 2).  
The supernatant is removed and the lung cells resuspended in 1.0 ml of CTM, 
placed on ice, and counted via the hemacytometer. 
___21. When cell counts have been determined for all the tissues (Sp, MLN, Lg, and 
BAL), aliquots containing 5.0x105 cells are added to replicate wells (1 well for 
each stain combination for each sample) of a U-bottom 96 well plate for NP/PA 
tetramer flow Cytometry staining. The maximum number of cells/well is 1x106. 
Tetramer (NP Db & PA Db) flow cytometry staining. 
 
Staining Wash Buffer (SWB) (50 ml 10X PBS, 5 ml 10% Sodium Azide, 10 ml 
fetal calf serum, 435 ml ddH2O) 
 
___22. Add a volume of cells to achieve the appropriate number cells and wells in a 
96-well round bottom plate (See Step #21). 
___23. Spin the plate @ 1500 rpm for 3 minutes and 4°C (Program 3).  Flick the plate. 
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___24. Resuspend the cell pellets in 50 µl of a 1:100 dilution of Fc Block (BD 
Pharmingen anti-mouse CD16/Cd32 Fc II/III) diluted in staining wash buffer 
(SWB). 
___25. Incubate the plate on ice for 20 minutes. 
___26. Add 150 µl of SWB to each well.  Spin plate as above and flick. 
___27. Add 100 µl / well of the appropriate dilution of SEV9 Kb tetramer (PE) stain 
which has been diluted in SWB.  Incubate for 1 hour at room temperature in the 
dark. 
___28. Add 100 µl / well of SWB to each well. Spin plate and flick. 
___29. Add 200 µl / well of SWB to each well. Spin plate and flick. 
___30. Add 100 µl / well of the appropriate dilution of secondary antibodies in SWB 
(FITC and TC/PC labeled). Incubate 20 minutes on ice in the dark. 
___31. Add 100 µl / well staining wash buffer.  Spin plate and flick. 
___32. Wash 2 additional times with 200 µl /well of SWB. 
___33. Resuspend the pellets in 125 µl staining wash buffer.  The 125 µl will be 
transferred into microtubes prior to analysis. 




Viral titer  
This protocol was used to assay if mice vaccinated with the β2mL21SESP vaccine 
and the pUMVC3-mIL12 could clear virus quicker than mice vaccinated with the 
β2mL21SESP and the pUMVC3-mIL12. Since you will be working with the Sendai virus 
all parts of this experiment except the initial 10 day egg incubation will need to be 
conducted in a bio-safety level 3 facility. Egg preparation 
Fertile eggs can be stored between 50-60°F with ~ 72% relative humidity for up 
to 5 days before use; they must be turned daily. 
___1. 10 days prior to use, place 216 eggs non-incubated but fertile (Charles River 
SpaFas, Inc.) into the incubator at 37.5°C with a relative humidity of 63%. (eggs 
can be used from day 9-11, but at no other time) 
___2. In a dark room candle eggs.  Put each egg against candle light and check for 
embryo status look for alive/dead and for live embryos mark the location of the 
air sack; discard dead eggs. 
Chicken red blood cell preparation (maintain sterile conditions) 
___3. Centrifuge chicken blood (Colorado Serum Co. CS 1131) at 1500 rpm for 5 
minutes at 4°C. Remove plasma and white blood cell layer.  Save RBC layer. 
___4. Add 9ml of 0.85% saline for each ml of RBC and wash by centrifuging and 
discarding supernatant.  Do this three times 
___5. Pellet cells by centrifugation at 1500 rpm for 10 minutes at 4°C. 
___6. You can store the blood for 5-7 days at this point. 
___7. Create a 1% working solution before use. 
 224
Lung preparation 
___8. Obtain fresh lung or frozen lung tissue 
___9. Homogenize in 1 ml of antibiotic solution (2x105 units/ ml Penicillin G potassium 
(embryo tested) (Sigma P4687), 40mg/ml Streptomycin sulfate (Sigma S9137) 
and 2x104 units/ml Polymyxin B sulfate (Sigma P4932)), using the tissue 
homogenizer 
___10. Make 12 serial dilutions of each lung sample starting with undiluted 
___11. Save any undiluted sample in case protocol needs to be repeated. 
Egg injection 
___12. Make a small hole with a hand Dremel tool in the egg at the location of the air 
sack. 
___13. With the 25 gauge needle inject 100 µl of one of the sample dilutions. 
___14. Seal the hole with melted paraffin. 
Viral egg incubation   
___15. Incubate eggs at 37°C for 48 hours. 
___16. Transfer eggs to cold room for 24 hours 
Haemagglutination assay 
___17. Added 25 µl of PBS to each well, 2 wells per egg + 4 wells for positive control 
and 4 well for negative control that gives 440 well which is 4.6 plates. 
___18. Draw out allantoic fluid with a glass Pasteur pipette through the small hole in the 
egg. 
___19. Place 2 drops into each well for that sample. Use dilute Sendai virus for positive 
control and PBS for the negative control. 
___20. Add 50 µl of the 1% chicken RBC solution. 
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___21. Incubate at RT for 30 minutes. 
___22. Record results as positive if you see lattice formation (agglutination) or as 
negative if you see button formation (no agglutination) 
The egg infectious dose (EID50) is the highest dilution of virus that showed 
agglutination in 50% of the eggs. 
 
Tribromoethanol 20 mg/ml  
The protocol was used to prepare Tribromoethanol (Avertin), which was used to 
anesthetize and euthanize mice. 
___1. In a graduated cylinder or glass bottle add 20 ml tert-amyl-OH (Fisher A730-1) 
___2. Add 20 g 2,2,2-tribromoethanol (Aldrich T4840-2) to the alcohol. 
___3. Swirl until the solid goes into solution at ambient temperature (this may take 
awhile). 
___4. Slowly add 500 ml ddH2O to flask on a hot plate while stirring (hot plate on low). 
___5. Make sure that salts stay in solution before you add more H2O. 
___6. Bring water to 1 L. 
___7. Turn the hot plate off when all of the solid has gone into solution. 
___8. Stir O/N. 
___9. Check that the 2,2,2-tribromoethanol has not precipitated out of solution.  If 
necessary, turn the hot plate back on until the solid has gone back into solution.    
___10. Bottle-top filter (0.22 µm) to remove eluate. 
___11. Aliquot into glass bottles and label the  bottles with the date made and your 
initials. 
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___12. Store the Avertin in the refrigerator in the bottom drawer to minimize the amount 
of light contacting the solution. 
___13. For each batch of Tribromoethanol made, test 5 C57Bl/6 mice with 0.20cc, 
0.25cc, 0.30cc of solution (also called Avertin).  Note how lightly the mice are 
asleep by squeezing the hind feet.  Also note if any of the mice do not wake up. 
 
 
Lysis of red blood cells 
This protocol was used to lyse red blood cells in collected tissues. 
___1. Allow an appropriate aliquot of Gey’s Solution (below) to warm to room 
temperature from 4°C and, if necessary, equilibrate the pH to ~7.0 by incubation 
in a 10% CO2 incubator.   
___2. Prepare a single cell suspension of spleen cells and spin down 400g for 10 min. 
___3. Dry resuspend the pellet and add Gey’s Solution (1-2 ml/spleen).   
___4. Incubate 5 minutes at room temperature and add 20 ml of HBSS to wash the cells. 
 
 
Gey’s solution (buffered ammonium chloride) 
This protocol was used to prepare Gey’s solution, which was used to lyse red 
blood cells. 
___1. Combine 8.0 g NH4Cl (Fisher 42328-0010), 0.5 g KHCO3 (Sigma P-9144), 0.5 
ml 0.5% Phenol Red (Sigma P-0290) 
___2. Added ddH2O  to a final volume of 500 ml 




Appendix II:  Primers  
 
 
Primer Name:  _21INSERT5____________________ 
 
Manufacturer:  _SIGMA________________________ 
 
Who ordered it: _Danny Piper____________________ 
 
Length (nt):  ___69__________________________ 
 
Molecular Weight: ___21544.4______________________ 
 
Melting Temp (ºC): ___90.4_________________________ 
 
Concentration: __stock 100 µM, working 10 µM_____ 
 
Sequence:   
 
5’CCGGT TTATA TGCTT TTGCG CCAGG AAATT ATCCC GCTTT AGGAG 





21INSERT5 was ordered along with 21insert3 to allow one to increase the 
pVAX1 β2mL15SESP to a 21 AA linker.  There are AGE1 and BAMH I overhangs when 
the two anneal together 
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Primer Name: 21Insert3  
 
Manufacturer: Sigma  
 
Who ordered it: Danny   
 
Length (nt): 69  
 
Molecular Weight: 20966.3  
 
Melting Temp (ºC): 89.3  
 
Concentration: Stock 100 µM, Working 10 µM_____ 
 
Sequence:   
 
5’ GATCC TCCTC CACCA CTACC TCCAC CACCT CCTAA AGCGG GATAA 




21INSERT3 was ordered along with 21insert5 to allow one to increase the pVAX1 
β2mL15SESP to a 21 AA linker.  There are AGE 1 and BAMH I overhangs when the two 
anneal together. 
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Primer Name: ForPVAX  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 18  
 
Molecular Weight: 5493.6  
 
Melting Temp (ºC): 62.1  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 





Forward primer for sequencing pVAX1 vector constructs 
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Primer Name: RevPVAX  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 18  
 
Molecular Weight: 5564.6  
 
Melting Temp (ºC): 64.5  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 





Reverse primer for sequencing pVAX1 vector constructs. 
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Primer Name: ForPCT7  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 18  
 
Molecular Weight: 5589  
 
Melting Temp (ºC): 59.8  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 





Forward primer for sequencing pCRT7/NT vector constructs. 
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Primer Name: EKDEP  
 
Manufacturer: Sigma  
 
Who ordered it: Jamie Caras  
 
Length (nt): 48  
 
Molecular Weight: 24901  
 
Melting Temp (ºC): 99.8  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 
 
5’– AGCAG CGAGC TCATC GACGA CGACG ACAAG TTCGC TCCGG GTAAC 





Second primer in Protein PCR scheme, anneals to the linker and adds the epitope and 




Primer Name: HISTAG  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Jamie Caras  
 
Length (nt): 65  
 
Molecular Weight: 18863  
 
Melting Temp(ºC): 94.5  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 
 
5’– ATCTG GCCCA GCCGG CCCAG CATAT GGGCC ATCAT CATCA TCATC 









Primer Name: T7PRIMER  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 22  
 
Molecular Weight: 6743  
 
Melting Temp(ºC): 56.0  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 




Standard primer for many vectors and the down stream primer in the PCR reactions 
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Primer Name: β2MLINK  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Jamie  
 
Length (nt): 84  
 
Molecular Weight: 26292  
 
Melting Temp (ºC): 101.7  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 
5’– GGAGG TGGCG GATCC GGTGG CGGAG GAAGC GGCGG AGGTG GCAGC 





Binds to the 5′ prime end of β2m and adds the sequence that codes for a 21AA linker 
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Primer Name: β2MLINK15  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Ralphie  
 
Length (nt): 66  
 
Molecular Weight: 20552  
 
Melting Temp (ºC): 98.5  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 
5’-- GGAGG TGGCG GATCC GGTGG CGGAG GAAGC GGCGG AGGTG GCAGC 




Binds to β2m  and adds a 15 AA linker. 
 
 237
Primer Name: Link10  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Ralphie  
 
Length (nt): 48  
 
Molecular Weight: 14880  
 
Melting Temp (ºC): 94  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 





Binds to β2m and adds the code for a 10 AA linker to the 5′ end. 
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Primer Name: DNAVACCINESANDIMEPITOPESIGNALPEPTIDE  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 73  
 
Molecular Weight: 22565  
 
Melting Temp (ºC): 85.8  
 
Concentration: Stock 150 µM, working 15 µM  
 
 
Sequence:   
 
5` -- TTTAG TAAGT TTAAC CGGTT TATAT GCTTT TGCTC CTGGT AATTA 




Adhere to the 5` end of any of the linkers and add the Sendai epitope and part of the 
signal epitope.  May form dimers.  
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Primer Name: DNAVACCINESIGNALPEPTIDEPVAX  
 
Manufacturer: Sigma Genosys  
 
Who ordered it: Danny Piper  
 
Length (nt): 75  
 
Molecular Weight: 23137  
 
Melting Temp (ºC): 77.4  
 
Concentration: Stock 150 µM, working 15 µM  
 
Sequence:   
 
5` -- AATAT AATAA CTTAA GCTAG CTAAC ATGGC GAGAT CAGTA ACTCT 




Attaches to the part of signal peptide and add the remaining part of signal peptide and 
necessary  Nhe I endonuclease site to ligate into pVAX1 vector 
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Primer Name:  CONTROL3____________________ 
 
Manufacturer:  _SIGMA________________________ 
 
Who ordered it: _Larisa Watson____________________ 
 
Length (nt):  ___69__________________________ 
 
Molecular Weight: ___20984.3_____________________ 
 
Melting Temp (ºC): ___88.0________________________ 
 
Concentration: __stock 100 µM, working 10 µM_____ 
 
Sequence:   
 
5’GATCCTCCTCCACCACTACCTCCACCACCTCCTAAAGCAAGGGCTCGTATA





CONTROL3 was ordered along with CONTROL5 to allow one to test the specificity of 
the T cell hybridoma for the Sendai epitope in the DNA vaccines. The epitope will be 
used as a control.  The epitope expressed will be FASIRALAL, in place of the Sendai 
epitope.  There are AGE1 and BAMH I overhangs when the two anneal together. 
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Primer Name:  CONTROL5      ____________________ 
 
Manufacturer:  _SIGMA  _________________________ 
 
Who ordered it: _Larisa Watson  ____________________ 
 
Length (nt):  ___69 ____________________________ 
 
Molecular Weight: ___21526.3  ____      ________________ 
 
Melting Temp (ºC): ___89.1      ________________________ 
 
Concentration: __Stock 100 µM, Working 10 µM_______ 
 
Sequence:   
 
5’CCGGTTTATATGCTTTTGCGTCTATACGAGCCCTTGCTTTAGGAGGTGGTGG





CONTROL5 was ordered along with CONTROL3 to allow one to test the specificity of 
the T cell hybridoma for the Sendai epitope in the DNA vaccines.  The epitope will be 
used as a control.  The epitope expressed will be FASIRALAL, in place of the Sendai 
epitope.  There are AGE1 and BAMH I overhangs when the two anneal together. 
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Primer Name:  NO Epitope3____________________ 
 
Manufacturer:  _SIGMA_______________________ 
 
Who ordered it: _Larisa Watson__________________ 
 
Length (nt):  ___42__________________________ 
 
Molecular Weight: ___12572_____________________  _ 
 
Melting Temp (ºC): ___82.1________________________ 
 
Concentration: _Stock 100 µM, Working 10 µM_____ 
 
Sequence:   
 





No Epitope 3 was ordered along with No Epitope 5 to allow one to test if the linker alone 
could elicit a Sendai specific immune response in the DNA vaccines.  The no epitope will 
be used as a negative control in T-cell stimulation experiments.  There are AGE1 and 





Primer Name:  NO Epitope5____________________ 
 
Manufacturer:  SIGMA________________________ 
 
Who ordered it: Larisa Watson___________________ 
 
Length (nt):  __42___________________________ 
 
Molecular Weight: __13257.2______________________ 
 
Melting Temp (ºC): __84.1_________________________ 
 
Concentration: Stock 100 µM, Working 10 µM_____ 
 
Sequence:   
 





No Epitope 5 was ordered along with No Epitope 3 to allow one to test if the linker alone 
could elicit a Sendai specific immune response in the DNA vaccine.  The no epitope will 
be used as a negative control in T-cell stimulation experiments.  There are AGE1 and 




Primer Name:  _ForLARISA___________________ 
 
Manufacturer:  _SIGMA________________________ 
 
Who ordered it: _Larisa Watson____________________ 
 
Length (nt):  ___56__________________________ 
 
Molecular Weight: ___17310.8_____________________ 
 
Melting Temp (ºC): ___89.4________________________ 
 
Concentration: ___100 µM______________________ 
 
Sequence:   
 
5’CATTGACGACGACGATAAGTTCGCATCTATACGCGCCCTTGCTTTAGGAGG





ForLARISA was ordered along with RevLARISA  and when combined will form Sal1 
and BAMH I overhangs.  The annealed product can be put into the pCRT7/NT 
β2mL15SEHT cut with Sal I and BAMH I to replace the Sendai Epitope with a dummy 
epitope with a linker size of 21 AA.  The dummy epitope will be used as a negative 
control in T-cell stimulation experiments.   The procedure did not work. 
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Primer Name:  _RevLARISA___________________ 
 
Manufacturer:  _SIGMA________________________ 
 
Who ordered it: _Larisa Watson____________________ 
 
Length (nt):  ___64__________________________ 
 
Molecular Weight: ___19640.3_____________________ 
 
Melting Temp (ºC): ___90.8________________________ 
 
Concentration: ___100 µM______________________ 
 
Sequence:   
 
5’GATCCCCCAC CTCCTAAAGC AAGGGCGCGT ATAGATGCGA ACTTATCGTC 





RevLARISA was ordered along with ForLARISA and when combined will form Sal1 
and BAMH I overhangs.  The annealed product can be put into the pCRT7/NT 
β2mL15SEHT cut with Sal I and BAMH I to replace the Sendai Epitope with a dummy 
epitope with a linker size of 15 AA.  The dummy epitope will be used as a negative 
control in T-cell stimulation experiments.  This procedure did not work. 
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Primer Name:  _PCRLAR15_____________________ 
 
Manufacturer:  _SIGMA________________________ 
 
Who ordered it: _Danny Piper____________________ 
 
Length (nt):  ___61__________________________ 
 
Molecular Weight: ___19640.3_____________________ 
 
Melting Temp (ºC): ___90.8________________________ 
 
Concentration: ___100 µM______________________ 
 
Sequence:   
 
5’ATTGACGACGACGATAAGTTCGCATCTATACGTGCCCTTGCTCTGGGAGGT





PCRLAR 15 encodes for the Enterokinase site and the Dummy epitope FASIRALAL.  
During a one step PCR with pCRT7/NT β2mL15SEHT as a template and the T7 primer 
as the down stream primer, it one can exchange the Sendai epitope with the dummy 
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